drug_name,drug_name_en,indication,indication_en,company_clean,therapeutic_area_norm,therapeutic_area_norm_en,highest_phase_indication_standard,highest_phase_standard_sort_val,drug_synonyms,targets,mechanism_of_action,global_highest_phase_all_indication_standard,global_highest_phase_all_indication_sort_val,global_highest_phase_all_indication_date,global_highest_phase_indication,global_highest_phase_indication_start_date,global_development_status,drug_category_1,drug_category_2,drug_category_3,drug_tag,pharmacological_type,is_top20_mnc,is_cyclic_peptide,is_rare_disease,is_originator_indication_drug,is_top20mnc_indication_drug,research_institution,research_institution_count
杆菌肽,bacitracin,细菌感染,bacterial infection,Columbia University,感染领域,Infectious Diseases,approved,5,杆菌肽;bacitracin,not available,多肽类抗生素,approved,5,1948-07-29,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,多肽类抗生素,False,True,False,True,False,Columbia University(原研),1
缩宫素,oxytocin,催产/引产,Oxygen/induced labor,Travere Therapeutics,泌尿生殖领域,Genitourinary,approved,5,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,oxytocin,合成的oxytocin,approved,5,1954-06-30,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,合成的,False,True,False,True,False,Travere Therapeutics(原研),1
缩宫素,oxytocin,产后子宫出血,Postpartum uterine bleeding,Travere Therapeutics,泌尿生殖领域,Genitourinary,approved,5,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,oxytocin,合成的oxytocin,approved,5,1954-06-30,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,合成的,False,True,False,True,False,Travere Therapeutics(原研),1
缩宫素,oxytocin,孤独症谱系障碍,autism spectrum disorder,Travere Therapeutics,精神领域,Psychiatry,phase 3,3,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,oxytocin,合成的oxytocin,approved,5,1954-06-30,III期临床,,Active,创新药,化药,多肽,环肽;First-in-Class,合成的,False,True,False,True,False,Travere Therapeutics(原研),1
多粘菌素B,polymyxin B,细菌性肺炎,bacterial pneumonia,,感染领域,Infectious Diseases,approved,5,多粘菌素B;polymyxin B,not available,多粘菌素类抗生素,approved,5,1956-08-06,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,False,True,False,False,False,--,0
多粘菌素B,polymyxin B,菌血症,bacteremia,,感染领域,Infectious Diseases,approved,5,多粘菌素B;polymyxin B,not available,多粘菌素类抗生素,approved,5,1956-08-06,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,False,True,False,False,False,--,0
多粘菌素B,polymyxin B,细菌性心内膜炎,bacterial endocarditis,,感染领域,Infectious Diseases,approved,5,多粘菌素B;polymyxin B,not available,多粘菌素类抗生素,approved,5,1956-08-06,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,False,True,False,False,False,--,0
放线菌素D,dactinomycin,肾母细胞瘤,nephroblastoma,Recordati Rare Diseases,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,True,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,肾母细胞瘤,nephroblastoma,Tiziana Life Sciences,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,肾母细胞瘤,nephroblastoma,Rasna,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,横纹肌肉瘤,rhabdomyosarcoma,Recordati Rare Diseases,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,True,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,横纹肌肉瘤,rhabdomyosarcoma,Tiziana Life Sciences,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,横纹肌肉瘤,rhabdomyosarcoma,Rasna,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,睾丸癌,testicular cancer,Recordati Rare Diseases,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,True,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,睾丸癌,testicular cancer,Tiziana Life Sciences,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,睾丸癌,testicular cancer,Rasna,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,尤文氏肉瘤,Ewing's sarcoma,Recordati Rare Diseases,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,True,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,尤文氏肉瘤,Ewing's sarcoma,Tiziana Life Sciences,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,尤文氏肉瘤,Ewing's sarcoma,Rasna,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,妊娠滋养细胞肿瘤,gestational trophoblastic tumor,Recordati Rare Diseases,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,True,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,妊娠滋养细胞肿瘤,gestational trophoblastic tumor,Tiziana Life Sciences,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
放线菌素D,dactinomycin,妊娠滋养细胞肿瘤,gestational trophoblastic tumor,Rasna,肿瘤领域,Oncology,approved,5,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,DNA,放线菌素抗生素,approved,5,1964-12-10,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,False,True,True,False,False,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),3
卷曲霉素,capreomycin,肺结核,tuberculosis,Eli Lilly,感染领域,Infectious Diseases,approved,5,卷曲霉素;capreomycin;卷须霉素;结核霉素;Capastat,not available,多肽类抗生素,approved,5,1971-06-02,批准上市,,Active,创新药,化药,小分子,环肽;差异化疾病,多肽类抗生素,True,True,False,True,True,Eli Lilly(Top20 MNC)(原研),1
杆菌肽+多粘菌素B,bacitracin+polymyxin B,细菌感染,bacterial infection,,感染领域,Infectious Diseases,approved,5,杆菌肽+多粘菌素B;bacitracin+polymyxin B,not available,多粘菌素类抗生素;多肽类抗生素,approved,5,1974-04-16,批准上市,,Active,创新药,化药,复方;多肽,环肽,多粘菌素类抗生素;多肽类抗生素,False,True,False,False,False,--,0
去氨加压素,desmopressin,肾盂肾炎,Pyelonephritis,Ferring Pharmaceuticals,感染领域,Infectious Diseases,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,肾盂肾炎,Pyelonephritis,维健医药,感染领域,Infectious Diseases,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,A型血友病,Hemophilia A,Ferring Pharmaceuticals,血液领域,Hematology,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,2023-04-10,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,A型血友病,Hemophilia A,维健医药,血液领域,Hematology,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,2023-04-10,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,血管性血友病,von Willebrand disease,Ferring Pharmaceuticals,血液领域,Hematology,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,2023-04-10,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,血管性血友病,von Willebrand disease,维健医药,血液领域,Hematology,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,2023-04-10,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,血小板减少症,Thrombocytopenia,Ferring Pharmaceuticals,血液领域,Hematology,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,血小板减少症,Thrombocytopenia,维健医药,血液领域,Hematology,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,中枢性尿崩症,central diabetes insipidus,Ferring Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,中枢性尿崩症,central diabetes insipidus,维健医药,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,遗尿症,enuresis,Ferring Pharmaceuticals,精神领域,Psychiatry,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,1995-06-01,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,遗尿症,enuresis,维健医药,精神领域,Psychiatry,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,1995-06-01,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,肝硬化,Cirrhosis,Ferring Pharmaceuticals,消化领域,Digestive System,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,肝硬化,Cirrhosis,维健医药,消化领域,Digestive System,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,膀胱炎,Cystitis,Ferring Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,膀胱炎,Cystitis,维健医药,泌尿生殖领域,Genitourinary,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,尿频,Frequent urination,Ferring Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,尿频,Frequent urination,维健医药,泌尿生殖领域,Genitourinary,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,出血,Bleeding,Ferring Pharmaceuticals,其他领域,Others,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,2023-04-10,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,出血,Bleeding,维健医药,其他领域,Others,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,2023-04-10,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,夜尿症,Nocturia,Ferring Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,夜尿症,Nocturia,维健医药,泌尿生殖领域,Genitourinary,approved,5,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,低钠血症,Hyponatremia,Ferring Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,III期临床,2023-08-31,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,低钠血症,Hyponatremia,维健医药,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,III期临床,2023-08-31,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,维生素D缺乏,Vitamin D deficiency,Ferring Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,I期临床,2025-12-18,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,维生素D缺乏,Vitamin D deficiency,维健医药,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,I期临床,2025-12-18,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,低血压,hypotension,Ferring Pharmaceuticals,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,I期临床,2025-10-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);维健医药,2
去氨加压素,desmopressin,低血压,hypotension,维健医药,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,vasopressin,vasopressin类似物,approved,5,1978-02-21,I期临床,2025-10-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);维健医药,2
粘菌素,colistin,志贺杆菌病,shigellosis,Par Pharmaceutical(Endo International),感染领域,Infectious Diseases,approved,5,粘菌素;colistin;抗敌素;COL,not available,多粘菌素类抗生素,approved,5,1982-01-01,批准上市,,Active,创新药,化药,其他,环肽;差异化疾病,多粘菌素类抗生素,False,True,False,True,False,Par Pharmaceutical(Endo International)(原研),1
紫霉素,viomycin,结核病,tuberculosis,Pfizer,感染领域,Infectious Diseases,approved,5,紫霉素;viomycin,not available,多肽类抗生素,approved,5,1982-01-01,批准上市,,Active,创新药,化药,小分子,环肽,多肽类抗生素,True,True,False,True,True,Pfizer(Top20 MNC)(原研),1
血管加压素,vasopressin,中枢性尿崩症,central diabetes insipidus,Par Sterile Products,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,血管加压素;vasopressin;arginine vasopressin;精氨酸加压素;抗利尿激素;Vasostrict;Vasopressins;argipressin,vasopressin,vasopressin,approved,5,1982-01-01,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,False,True,False,True,False,Par Sterile Products(原研),1
血管加压素,vasopressin,血管扩张性休克,vasodilatory shock,Par Sterile Products,其他领域,Others,approved,5,血管加压素;vasopressin;arginine vasopressin;精氨酸加压素;抗利尿激素;Vasostrict;Vasopressins;argipressin,vasopressin,vasopressin,approved,5,1982-01-01,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,False,True,False,True,False,Par Sterile Products(原研),1
环孢素,cyclosporine,再生障碍性贫血,aplastic anemia,Sandoz,血液领域,Hematology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,True,True,False,Sandoz(原研),1
环孢素,cyclosporine,类风湿性关节炎,rheumatoid arthritis,Sandoz,骨骼肌肉领域,Musculoskeletal,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,银屑病,psoriasis,Sandoz,免疫领域,Immunology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,器官移植排斥,organ transplant rejection,Sandoz,免疫领域,Immunology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,True,True,False,Sandoz(原研),1
环孢素,cyclosporine,移植物抗宿主病,graft versus host disease,Sandoz,免疫领域,Immunology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,True,True,False,Sandoz(原研),1
环孢素,cyclosporine,特应性皮炎,atopic dermatitis,Sandoz,免疫领域,Immunology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,狼疮性肾炎,lupus nephritis,Sandoz,免疫领域,Immunology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,肾病综合征,nephrotic syndrome,Sandoz,泌尿生殖领域,Genitourinary,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,干眼病,dry eye disease,Sandoz,眼科领域,Ophthalmology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,角结膜炎,keratoconjunctivitis,Sandoz,眼科领域,Ophthalmology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,非感染性葡萄膜炎,noninfectious uveitis,Sandoz,眼科领域,Ophthalmology,approved,5,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,批准上市,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,溃疡性结肠炎,ulcerative colitis,Sandoz,消化领域,Digestive System,phase 3,3,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,III期临床,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sandoz(原研),1
环孢素,cyclosporine,章鱼壶心肌症,Takotsubo cardiomyopathy,Sandoz,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,1983-11-14,II期临床,,Active,创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,False,True,True,True,False,Sandoz(原研),1
奥曲肽,octreotide,类癌,carcinoid,Novartis,肿瘤领域,Oncology,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,1988-10-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,类癌综合征,carcinoid syndrome,Novartis,肿瘤领域,Oncology,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,2003-07-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,低血糖症,hypoglycemia,Novartis,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,2024-06-03,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,肢端肥大症,acromegaly,Novartis,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,1988-10-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,甲状腺肿,goiter,Novartis,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,消化性溃疡,peptic ulcer,Novartis,消化领域,Digestive System,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,肝硬化,Cirrhosis,Novartis,消化领域,Digestive System,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,出血,Bleeding,Novartis,其他领域,Others,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,2023-01-29,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,胃泌素瘤,gastrinoma,Novartis,肿瘤领域,Oncology,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,2003-07-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,食管静脉曲张出血,Esophageal variceal bleeding,Novartis,消化领域,Digestive System,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,2023-01-05,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,消化性溃疡出血,peptic ulcer bleeding,Novartis,消化领域,Digestive System,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,十二指肠溃疡出血,duodenal ulcer bleeding,Novartis,消化领域,Digestive System,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,胰瘘,pancreatic fistula,Novartis,消化领域,Digestive System,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,胰岛细胞瘤,islet cell tumor,Novartis,肿瘤领域,Oncology,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,2003-07-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Novartis,肿瘤领域,Oncology,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,1988-10-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,食管静脉曲张,Esophageal varices,Novartis,消化领域,Digestive System,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,2023-01-29,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,急性胰腺炎,acute pancreatitis,Novartis,消化领域,Digestive System,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,血管活性肠肽瘤,vasoactive intestinal peptide tumor,Novartis,肿瘤领域,Oncology,approved,5,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,批准上市,2003-07-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,神经内分泌肿瘤,neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 3,3,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,III期临床,2005-09-15,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,消化道出血,gastrointestinal bleeding,Novartis,消化领域,Digestive System,phase 3,3,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,III期临床,2015-03-10,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,增殖性糖尿病视网膜病变,proliferative diabetic retinopathy,Novartis,眼科领域,Ophthalmology,phase 3,3,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,III期临床,2005-08-16,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,多囊肝病,polycystic liver disease,Novartis,消化领域,Digestive System,phase 3,3,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,II/III期临床,2007-01-24,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,肿瘤,tumor,Novartis,肿瘤领域,Oncology,phase 2,2,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,II期临床,2023-09-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 2,2,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,II期临床,2005-06-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 2,2,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,II期临床,2005-09-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,脑膜瘤,Meningioma,Novartis,肿瘤领域,Oncology,phase 2,2,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,II期临床,2015-01-07,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,十二指肠疾病,duodenal disease,Novartis,消化领域,Digestive System,phase 2,2,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,II期临床,2023-09-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,脑膜血管外皮细胞瘤,Meningeal hemangiopericytoma,Novartis,肿瘤领域,Oncology,phase 2,2,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,II期临床,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,2型糖尿病,type 2 diabetes,Novartis,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,I期临床,2024-06-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,代谢相关脂肪性肝病,metabolic related fatty liver disease,Novartis,消化领域,Digestive System,phase 1,1,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,I期临床,2023-11-13,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,糖尿病黄斑水肿,diabetic macular edema,Novartis,眼科领域,Ophthalmology,phase 1,1,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,I期临床,2025-03-18,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,腹泻,diarrhea,Novartis,消化领域,Digestive System,phase 1,1,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,I期临床,2001-08-31,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
奥曲肽,octreotide,原发性神经外胚层肿瘤,primary neuroectodermal tumor,Novartis,肿瘤领域,Oncology,phase 1,1,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,somatostatin,somatostatin类似物,approved,5,1988-10-21,I期临床,2023-10-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
铟[111In]喷曲肽,indium In-111 pentetreotide,放射性核素显像,radionuclide imaging,Keenova Therapeutics,诊断试剂领域,Diagnostic Reagents,approved,5,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,approved,5,1994-06-02,批准上市,2015-09-28,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,False,True,False,True,False,Keenova Therapeutics(原研),1
铟[111In]喷曲肽,indium In-111 pentetreotide,神经内分泌肿瘤,neuroendocrine tumors,Keenova Therapeutics,肿瘤领域,Oncology,approved,5,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,approved,5,1994-06-02,批准上市,2015-09-28,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,False,True,True,True,False,Keenova Therapeutics(原研),1
卡培立肽,carperitide,急性心力衰竭,acute heart failure,Astellas Pharma,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide,ANP,重组ANP,approved,5,1995-01-20,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class,重组,True,True,False,False,True,Astellas Pharma(Top20 MNC);Daiichi Sankyo(原研),2
卡培立肽,carperitide,急性心力衰竭,acute heart failure,Daiichi Sankyo,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide,ANP,重组ANP,approved,5,1995-01-20,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class,重组,True,True,False,True,False,Astellas Pharma(Top20 MNC);Daiichi Sankyo(原研),2
来匹卢定,lepirudin,肝素引起的血小板减少症,Heparin-induced thrombocytopenia,Bayer,血液领域,Hematology,approved,5,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,approved,5,1997-03-12,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,抑制剂;类似物,True,True,False,False,True,Bayer(Top20 MNC);Hoechst(Sanofi)(Top20 MNC)(原研)(无权益),2
来匹卢定,lepirudin,肝素引起的血小板减少症,Heparin-induced thrombocytopenia,Hoechst(Sanofi),血液领域,Hematology,approved,5,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,approved,5,1997-03-12,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,抑制剂;类似物,True,True,False,True,True,Bayer(Top20 MNC);Hoechst(Sanofi)(Top20 MNC)(原研)(无权益),2
地西卢定,desirudin,深静脉血栓,deep vein thrombosis,Novartis,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,approved,5,1997-07-08,批准上市,2003-04-04,Active,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研);Kacefa,2
地西卢定,desirudin,深静脉血栓,deep vein thrombosis,Kacefa,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,approved,5,1997-07-08,批准上市,2003-04-04,Active,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,True,True,False,False,False,Novartis(Top20 MNC)(原研);Kacefa,2
地西卢定,desirudin,肺栓塞,pulmonary embolism,Novartis,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,approved,5,1997-07-08,批准上市,,Active,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研);Kacefa,2
地西卢定,desirudin,肺栓塞,pulmonary embolism,Kacefa,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,approved,5,1997-07-08,批准上市,,Active,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,True,True,False,False,False,Novartis(Top20 MNC)(原研);Kacefa,2
地西卢定,desirudin,髋关节置换术,hip replacement,Novartis,骨骼肌肉领域,Musculoskeletal,approved,5,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,approved,5,1997-07-08,批准上市,,Active,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,True,True,False,True,True,Novartis(Top20 MNC)(原研);Kacefa,2
地西卢定,desirudin,髋关节置换术,hip replacement,Kacefa,骨骼肌肉领域,Musculoskeletal,approved,5,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,thrombin;hirudin,hirudin类似物;thrombin抑制剂,approved,5,1997-07-08,批准上市,,Active,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,True,True,False,False,False,Novartis(Top20 MNC)(原研);Kacefa,2
依替巴肽,eptifibatide,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),Millennium Pharmaceuticals(Takeda Pharmaceuticals),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,True,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),Schering-Plough(Merck & Co.),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,经皮冠状动脉介入治疗,percutaneous coronary intervention,Millennium Pharmaceuticals(Takeda Pharmaceuticals),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,批准上市,2020-11-19,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,True,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,经皮冠状动脉介入治疗,percutaneous coronary intervention,Schering-Plough(Merck & Co.),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,批准上市,2020-11-19,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,急性冠脉综合征,acute coronary syndrome,Millennium Pharmaceuticals(Takeda Pharmaceuticals),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,批准上市,2020-11-19,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,True,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,急性冠脉综合征,acute coronary syndrome,Schering-Plough(Merck & Co.),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,批准上市,2020-11-19,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,心肌梗塞,myocardial infarction,Millennium Pharmaceuticals(Takeda Pharmaceuticals),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,批准上市,2021-04-23,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,True,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,心肌梗塞,myocardial infarction,Schering-Plough(Merck & Co.),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,批准上市,2021-04-23,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,缺血性卒中,ischemic stroke,Millennium Pharmaceuticals(Takeda Pharmaceuticals),心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,III期临床,2018-11-08,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,True,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,缺血性卒中,ischemic stroke,Schering-Plough(Merck & Co.),心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,III期临床,2018-11-08,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,不稳定性心绞痛,unstable angina,Millennium Pharmaceuticals(Takeda Pharmaceuticals),心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,III期临床,2010-02-26,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,True,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
依替巴肽,eptifibatide,不稳定性心绞痛,unstable angina,Schering-Plough(Merck & Co.),心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,GPIIb/IIIa,GPIIb/IIIa抑制剂,approved,5,1998-05-18,III期临床,2010-02-26,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,True,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),2
锝[99mTc]地普奥肽,technetium Tc-99m depreotide,癌症,cancer,Bayer,肿瘤领域,Oncology,approved,5,锝[99mTc]地普奥肽;technetium Tc-99m depreotide;NeoSpect;depreotide;地普奥肽,SSTR,anti-SSTR多肽偶联核素;含锝放射性示踪剂,approved,5,1999-08-03,批准上市,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,True,True,False,True,True,Bayer(Top20 MNC)(原研),1
阿托西班,atosiban,推迟早产,postpone premature birth,Johnson & Johnson,泌尿生殖领域,Genitourinary,approved,5,阿托西班;atosiban;Tractocile;依保;dTVT;RWJ-22164,OXTR;AVPR,AVPR拮抗剂;OXTR拮抗剂,approved,5,2000-01-19,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;G蛋白偶联受体,拮抗剂,True,True,False,False,True,Johnson & Johnson(Top20 MNC);Ferring Pharmaceuticals(原研),2
阿托西班,atosiban,推迟早产,postpone premature birth,Ferring Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,阿托西班;atosiban;Tractocile;依保;dTVT;RWJ-22164,OXTR;AVPR,AVPR拮抗剂;OXTR拮抗剂,approved,5,2000-01-19,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;G蛋白偶联受体,拮抗剂,True,True,False,True,False,Johnson & Johnson(Top20 MNC);Ferring Pharmaceuticals(原研),2
特利加压素,terlipressin,肝肾综合征,Hepatorenal syndrome,Ferring Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,肝肾综合征,Hepatorenal syndrome,Ikaria(Keenova Therapeutics),泌尿生殖领域,Genitourinary,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,肝肾综合征,Hepatorenal syndrome,Orphan Therapeutics,泌尿生殖领域,Genitourinary,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,肝肾综合征,Hepatorenal syndrome,ESP Pharma(PDL BioPharma),泌尿生殖领域,Genitourinary,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,产后子宫出血,Postpartum uterine bleeding,Ferring Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,产后子宫出血,Postpartum uterine bleeding,Ikaria(Keenova Therapeutics),泌尿生殖领域,Genitourinary,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,产后子宫出血,Postpartum uterine bleeding,Orphan Therapeutics,泌尿生殖领域,Genitourinary,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,产后子宫出血,Postpartum uterine bleeding,ESP Pharma(PDL BioPharma),泌尿生殖领域,Genitourinary,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,休克,shock,Ferring Pharmaceuticals,其他领域,Others,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,休克,shock,Ikaria(Keenova Therapeutics),其他领域,Others,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,休克,shock,Orphan Therapeutics,其他领域,Others,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,休克,shock,ESP Pharma(PDL BioPharma),其他领域,Others,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,食管静脉曲张出血,Esophageal variceal bleeding,Ferring Pharmaceuticals,消化领域,Digestive System,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,食管静脉曲张出血,Esophageal variceal bleeding,Ikaria(Keenova Therapeutics),消化领域,Digestive System,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,食管静脉曲张出血,Esophageal variceal bleeding,Orphan Therapeutics,消化领域,Digestive System,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,食管静脉曲张出血,Esophageal variceal bleeding,ESP Pharma(PDL BioPharma),消化领域,Digestive System,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,消化性溃疡出血,peptic ulcer bleeding,Ferring Pharmaceuticals,消化领域,Digestive System,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,消化性溃疡出血,peptic ulcer bleeding,Ikaria(Keenova Therapeutics),消化领域,Digestive System,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,消化性溃疡出血,peptic ulcer bleeding,Orphan Therapeutics,消化领域,Digestive System,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,消化性溃疡出血,peptic ulcer bleeding,ESP Pharma(PDL BioPharma),消化领域,Digestive System,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,术后出血,postoperative bleeding,Ferring Pharmaceuticals,其他领域,Others,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,术后出血,postoperative bleeding,Ikaria(Keenova Therapeutics),其他领域,Others,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,术后出血,postoperative bleeding,Orphan Therapeutics,其他领域,Others,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
特利加压素,terlipressin,术后出血,postoperative bleeding,ESP Pharma(PDL BioPharma),其他领域,Others,approved,5,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,vasopressin,vasopressin类似物,approved,5,2001-01-22,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,False,False,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),4
卡泊芬净,caspofungin,真菌感染,fungal infection,Merck & Co.,感染领域,Infectious Diseases,approved,5,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2001-01-26,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
卡泊芬净,caspofungin,曲霉病,Aspergillosis,Merck & Co.,感染领域,Infectious Diseases,approved,5,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2001-01-26,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
卡泊芬净,caspofungin,念珠菌病,candidiasis,Merck & Co.,感染领域,Infectious Diseases,approved,5,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2001-01-26,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
卡泊芬净,caspofungin,念珠菌血症,candidemia,Merck & Co.,感染领域,Infectious Diseases,approved,5,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2001-01-26,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
卡泊芬净,caspofungin,侵袭性念珠菌病,Invasive candidiasis,Merck & Co.,感染领域,Infectious Diseases,approved,5,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2001-01-26,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
卡泊芬净,caspofungin,侵袭性曲霉病,Invasive aspergillosis,Merck & Co.,感染领域,Infectious Diseases,approved,5,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2001-01-26,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
卡泊芬净,caspofungin,食管念珠菌感染,Esophageal Candida Infection,Merck & Co.,感染领域,Infectious Diseases,approved,5,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2001-01-26,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
生长抑素,somatostatin,食管静脉曲张出血,Esophageal variceal bleeding,Merck KGaA,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,True,True,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,食管静脉曲张出血,Esophageal variceal bleeding,海森生物,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,False,False,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,消化性溃疡出血,peptic ulcer bleeding,Merck KGaA,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,True,True,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,消化性溃疡出血,peptic ulcer bleeding,海森生物,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,False,False,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,十二指肠溃疡出血,duodenal ulcer bleeding,Merck KGaA,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,True,True,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,十二指肠溃疡出血,duodenal ulcer bleeding,海森生物,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,False,False,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,胰瘘,pancreatic fistula,Merck KGaA,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,True,True,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,胰瘘,pancreatic fistula,海森生物,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,False,False,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,胆瘘,bile fistula,Merck KGaA,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,True,True,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,胆瘘,bile fistula,海森生物,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,False,False,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,肠瘘,intestinal fistula,Merck KGaA,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,True,True,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,肠瘘,intestinal fistula,海森生物,消化领域,Digestive System,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,False,False,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,糖尿病酮症酸中毒,diabetic ketoacidosis,Merck KGaA,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,True,True,Merck KGaA(Top20 MNC)(原研);海森生物,2
生长抑素,somatostatin,糖尿病酮症酸中毒,diabetic ketoacidosis,海森生物,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,somatostatin,somatostatin,approved,5,2002-03-06,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,原形,True,True,False,False,False,Merck KGaA(Top20 MNC)(原研);海森生物,2
兰瑞肽,lanreotide,类癌,carcinoid,Ipsen,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,类癌,carcinoid,Teijin,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,类癌,carcinoid,Biomeasure,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,类癌,carcinoid,Tulane University,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,True,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,类癌综合征,carcinoid syndrome,Ipsen,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2002-03-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,类癌综合征,carcinoid syndrome,Teijin,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2002-03-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,类癌综合征,carcinoid syndrome,Biomeasure,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2002-03-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,类癌综合征,carcinoid syndrome,Tulane University,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2002-03-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,True,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,肢端肥大症,acromegaly,Ipsen,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2002-03-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,肢端肥大症,acromegaly,Teijin,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2002-03-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,肢端肥大症,acromegaly,Biomeasure,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2002-03-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,肢端肥大症,acromegaly,Tulane University,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2002-03-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,True,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,垂体瘤,Pituitary tumor,Ipsen,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,垂体瘤,Pituitary tumor,Teijin,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,垂体瘤,Pituitary tumor,Biomeasure,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,垂体瘤,Pituitary tumor,Tulane University,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,True,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Ipsen,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2014-12-16,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Teijin,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2014-12-16,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Biomeasure,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2014-12-16,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Tulane University,肿瘤领域,Oncology,approved,5,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,批准上市,2014-12-16,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,True,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,神经内分泌肿瘤,neuroendocrine tumors,Ipsen,肿瘤领域,Oncology,phase 3,3,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,III期临床,2016-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,神经内分泌肿瘤,neuroendocrine tumors,Teijin,肿瘤领域,Oncology,phase 3,3,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,III期临床,2016-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,神经内分泌肿瘤,neuroendocrine tumors,Biomeasure,肿瘤领域,Oncology,phase 3,3,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,III期临床,2016-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,神经内分泌肿瘤,neuroendocrine tumors,Tulane University,肿瘤领域,Oncology,phase 3,3,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,III期临床,2016-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,True,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,Ipsen,肿瘤领域,Oncology,phase 3,3,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,III期临床,2025-03-17,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,Teijin,肿瘤领域,Oncology,phase 3,3,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,III期临床,2025-03-17,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,Biomeasure,肿瘤领域,Oncology,phase 3,3,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,III期临床,2025-03-17,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
兰瑞肽,lanreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,Tulane University,肿瘤领域,Oncology,phase 3,3,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,somatostatin,somatostatin类似物,approved,5,2002-03-14,III期临床,2025-03-17,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,True,False,Ipsen;Teijin;Biomeasure;Tulane University(原研),4
米卡芬净,micafungin,曲霉病,Aspergillosis,Sandoz,感染领域,Infectious Diseases,approved,5,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2002-10-08,批准上市,,Active,创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,False,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),2
米卡芬净,micafungin,曲霉病,Aspergillosis,Astellas Pharma,感染领域,Infectious Diseases,approved,5,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2002-10-08,批准上市,,Active,创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),2
米卡芬净,micafungin,念珠菌病,candidiasis,Sandoz,感染领域,Infectious Diseases,approved,5,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2002-10-08,批准上市,,Active,创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,False,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),2
米卡芬净,micafungin,念珠菌病,candidiasis,Astellas Pharma,感染领域,Infectious Diseases,approved,5,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2002-10-08,批准上市,,Active,创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),2
米卡芬净,micafungin,侵袭性念珠菌病,Invasive candidiasis,Sandoz,感染领域,Infectious Diseases,approved,5,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2002-10-08,批准上市,,Active,创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,False,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),2
米卡芬净,micafungin,侵袭性念珠菌病,Invasive candidiasis,Astellas Pharma,感染领域,Infectious Diseases,approved,5,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2002-10-08,批准上市,,Active,创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),2
米卡芬净,micafungin,食管念珠菌感染,Esophageal Candida Infection,Sandoz,感染领域,Infectious Diseases,approved,5,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2002-10-08,批准上市,,Active,创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,False,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),2
米卡芬净,micafungin,食管念珠菌感染,Esophageal Candida Infection,Astellas Pharma,感染领域,Infectious Diseases,approved,5,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2002-10-08,批准上市,,Active,创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),2
Restasis,Restasis (cyclosporine A),干眼病,dry eye disease,Allergan(AbbVie),眼科领域,Ophthalmology,approved,5,Restasis;Restasis (环孢素);Restasis (cyclosporine A),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2002-12-23,批准上市,2002-12-23,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,True,True,False,True,True,Allergan(AbbVie)(Top20 MNC)(原研),1
Restasis,Restasis (cyclosporine A),流泪,shed tears,Allergan(AbbVie),其他领域,Others,phase 3,3,Restasis;Restasis (环孢素);Restasis (cyclosporine A),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2002-12-23,II/III期临床,2020-11-20,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,True,True,False,True,True,Allergan(AbbVie)(Top20 MNC)(原研),1
Restasis,Restasis (cyclosporine A),眼科疾病,Eye diseases,Allergan(AbbVie),眼科领域,Ophthalmology,phase 1,1,Restasis;Restasis (环孢素);Restasis (cyclosporine A),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2002-12-23,I期临床,2024-10-03,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,True,True,False,True,True,Allergan(AbbVie)(Top20 MNC)(原研),1
达托霉素,daptomycin,皮肤/皮肤结构感染,Skin/skin structure infection,Gilead Sciences,感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,False,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
达托霉素,daptomycin,皮肤/皮肤结构感染,Skin/skin structure infection,Eli Lilly,感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,True,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
达托霉素,daptomycin,皮肤/皮肤结构感染,Skin/skin structure infection,Cubist Pharmaceuticals(Merck & Co.),感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,False,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
达托霉素,daptomycin,菌血症,bacteremia,Gilead Sciences,感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,False,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
达托霉素,daptomycin,菌血症,bacteremia,Eli Lilly,感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,True,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
达托霉素,daptomycin,菌血症,bacteremia,Cubist Pharmaceuticals(Merck & Co.),感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,False,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
达托霉素,daptomycin,细菌性心内膜炎,bacterial endocarditis,Gilead Sciences,感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,False,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
达托霉素,daptomycin,细菌性心内膜炎,bacterial endocarditis,Eli Lilly,感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,True,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
达托霉素,daptomycin,细菌性心内膜炎,bacterial endocarditis,Cubist Pharmaceuticals(Merck & Co.),感染领域,Infectious Diseases,approved,5,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,not available,脂肽类抗生素,approved,5,2003-09-12,批准上市,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,True,True,False,False,True,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),3
卡贝缩宫素,carbetocin,产后子宫收缩乏力,Postpartum uterine atony,Ferring Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,卡贝缩宫素;carbetocin;卡比托辛;Duratocin;巧特欣,oxytocin,oxytocin类似物,approved,5,2004-10-20,批准上市,,Active,创新药,化药,小分子,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研),1
卡贝缩宫素,carbetocin,产后子宫出血,Postpartum uterine bleeding,Ferring Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,卡贝缩宫素;carbetocin;卡比托辛;Duratocin;巧特欣,oxytocin,oxytocin类似物,approved,5,2004-10-20,批准上市,,Active,创新药,化药,小分子,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研),1
齐考诺肽,ziconotide,慢性疼痛,chronic pain,Tersera,麻醉镇痛领域,Anesthesia & Analgesia,approved,5,齐考诺肽;ziconotide;Prialt;SNX-111,N-type calcium channel,N-type calcium channel阻断剂,approved,5,2004-12-28,批准上市,2004-12-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,阻断剂,False,True,False,False,False,Tersera;Neurex(Perrigo)(原研);Jazz Pharmaceuticals(无权益),3
齐考诺肽,ziconotide,慢性疼痛,chronic pain,Neurex(Perrigo),麻醉镇痛领域,Anesthesia & Analgesia,approved,5,齐考诺肽;ziconotide;Prialt;SNX-111,N-type calcium channel,N-type calcium channel阻断剂,approved,5,2004-12-28,批准上市,2004-12-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,阻断剂,False,True,False,True,False,Tersera;Neurex(Perrigo)(原研);Jazz Pharmaceuticals(无权益),3
齐考诺肽,ziconotide,慢性疼痛,chronic pain,Jazz Pharmaceuticals,麻醉镇痛领域,Anesthesia & Analgesia,approved,5,齐考诺肽;ziconotide;Prialt;SNX-111,N-type calcium channel,N-type calcium channel阻断剂,approved,5,2004-12-28,批准上市,2004-12-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,阻断剂,False,True,False,False,False,Tersera;Neurex(Perrigo)(原研);Jazz Pharmaceuticals(无权益),3
普兰林肽,pramlintide,1型糖尿病,type 1 diabetes,Bristol-Myers Squibb,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,普兰林肽;pramlintide;Symlin;AC137,amylin,amylin类似物,approved,5,2005-03-16,批准上市,2005-03-16,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,False,True,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2
普兰林肽,pramlintide,1型糖尿病,type 1 diabetes,Amylin Pharmaceuticals(AstraZeneca),内分泌及代谢领域,Endocrinology & Metabolism,approved,5,普兰林肽;pramlintide;Symlin;AC137,amylin,amylin类似物,approved,5,2005-03-16,批准上市,2005-03-16,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2
普兰林肽,pramlintide,2型糖尿病,type 2 diabetes,Bristol-Myers Squibb,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,普兰林肽;pramlintide;Symlin;AC137,amylin,amylin类似物,approved,5,2005-03-16,批准上市,2005-03-16,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,False,True,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2
普兰林肽,pramlintide,2型糖尿病,type 2 diabetes,Amylin Pharmaceuticals(AstraZeneca),内分泌及代谢领域,Endocrinology & Metabolism,approved,5,普兰林肽;pramlintide;Symlin;AC137,amylin,amylin类似物,approved,5,2005-03-16,批准上市,2005-03-16,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2
普兰林肽,pramlintide,糖尿病前期,prediabetes,Bristol-Myers Squibb,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,普兰林肽;pramlintide;Symlin;AC137,amylin,amylin类似物,approved,5,2005-03-16,II/III期临床,2024-10-01,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,False,True,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2
普兰林肽,pramlintide,糖尿病前期,prediabetes,Amylin Pharmaceuticals(AstraZeneca),内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,普兰林肽;pramlintide;Symlin;AC137,amylin,amylin类似物,approved,5,2005-03-16,II/III期临床,2024-10-01,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2
普兰林肽,pramlintide,代谢性骨病,metabolic bone disease,Bristol-Myers Squibb,骨骼肌肉领域,Musculoskeletal,phase 1,1,普兰林肽;pramlintide;Symlin;AC137,amylin,amylin类似物,approved,5,2005-03-16,I期临床,2023-12-29,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,False,True,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2
普兰林肽,pramlintide,代谢性骨病,metabolic bone disease,Amylin Pharmaceuticals(AstraZeneca),骨骼肌肉领域,Musculoskeletal,phase 1,1,普兰林肽;pramlintide;Symlin;AC137,amylin,amylin类似物,approved,5,2005-03-16,I期临床,2023-12-29,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),2
脑利钠肽,nesiritide biosimilar,心力衰竭,heart failure,西藏药业(康哲药业),心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,BNP,重组BNP,approved,5,2005-03-31,批准上市,,Active,生物类似药,生物,多肽,环肽;差异化疾病,重组,False,True,False,True,False,西藏药业(康哲药业)(原研),1
脑利钠肽,nesiritide biosimilar,急性心力衰竭,acute heart failure,西藏药业(康哲药业),心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,BNP,重组BNP,approved,5,2005-03-31,I期临床,2025-11-16,Active,生物类似药,生物,多肽,环肽;差异化疾病,重组,False,True,False,True,False,西藏药业(康哲药业)(原研),1
脑利钠肽,nesiritide biosimilar,慢性心力衰竭,chronic heart failure,西藏药业(康哲药业),心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,BNP,重组BNP,approved,5,2005-03-31,I期临床,2025-12-17,Active,生物类似药,生物,多肽,环肽;差异化疾病,重组,False,True,False,True,False,西藏药业(康哲药业)(原研),1
脑利钠肽,nesiritide biosimilar,心脏病,heart disease,西藏药业(康哲药业),心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,BNP,重组BNP,approved,5,2005-03-31,I期临床,2023-01-28,Active,生物类似药,生物,多肽,环肽;差异化疾病,重组,False,True,False,True,False,西藏药业(康哲药业)(原研),1
脑利钠肽,nesiritide biosimilar,急性失代偿性心力衰竭,acute decompensated heart failure,西藏药业(康哲药业),心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,BNP,重组BNP,approved,5,2005-03-31,I期临床,2025-06-11,Active,生物类似药,生物,多肽,环肽;差异化疾病,重组,False,True,False,True,False,西藏药业(康哲药业)(原研),1
脑利钠肽,nesiritide biosimilar,参考原研,Reference original research,苏兰生物,其他领域,Others,approved,5,脑利钠肽;布罗纳泰(重组人脑利钠肽);nesiritide biosimilar;布罗纳泰,BNP,重组BNP,approved,5,2005-05-10,批准上市,,Active,生物类似药,生物,多肽,环肽,重组,False,True,False,True,False,苏兰生物(原研),1
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),干眼病,dry eye disease,Novagali Pharma(Santen Pharmaceutical),眼科领域,Ophthalmology,approved,5,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2005-10-11,批准上市,,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,2
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),干眼病,dry eye disease,Harrow,眼科领域,Ophthalmology,approved,5,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2005-10-11,批准上市,,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,False,False,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,2
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),春季角结膜炎,Vernal keratoconjunctivitis,Novagali Pharma(Santen Pharmaceutical),眼科领域,Ophthalmology,approved,5,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2005-10-11,批准上市,2018-07-06,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,True,True,False,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,2
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),春季角结膜炎,Vernal keratoconjunctivitis,Harrow,眼科领域,Ophthalmology,approved,5,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2005-10-11,批准上市,2018-07-06,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,True,False,False,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,2
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),角结膜炎,keratoconjunctivitis,Novagali Pharma(Santen Pharmaceutical),眼科领域,Ophthalmology,phase 2,2,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2005-10-11,II期临床,2023-12-13,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,2
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),角结膜炎,keratoconjunctivitis,Harrow,眼科领域,Ophthalmology,phase 2,2,Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2005-10-11,II期临床,2023-12-13,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,False,False,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,2
阿尼芬净,anidulafungin,念珠菌病,candidiasis,Pfizer,感染领域,Infectious Diseases,approved,5,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,批准上市,2006-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
阿尼芬净,anidulafungin,念珠菌病,candidiasis,Eli Lilly,感染领域,Infectious Diseases,approved,5,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,批准上市,2006-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
阿尼芬净,anidulafungin,念珠菌病,candidiasis,Vicuron Pharmaceuticals(AbbVie),感染领域,Infectious Diseases,approved,5,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,批准上市,2006-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
阿尼芬净,anidulafungin,念珠菌血症,candidemia,Pfizer,感染领域,Infectious Diseases,approved,5,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,批准上市,2006-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
阿尼芬净,anidulafungin,念珠菌血症,candidemia,Eli Lilly,感染领域,Infectious Diseases,approved,5,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,批准上市,2006-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
阿尼芬净,anidulafungin,念珠菌血症,candidemia,Vicuron Pharmaceuticals(AbbVie),感染领域,Infectious Diseases,approved,5,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,批准上市,2006-02-17,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
阿尼芬净,anidulafungin,侵袭性曲霉病,Invasive aspergillosis,Pfizer,感染领域,Infectious Diseases,phase 3,3,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,III期临床,2007-09-18,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
阿尼芬净,anidulafungin,侵袭性曲霉病,Invasive aspergillosis,Eli Lilly,感染领域,Infectious Diseases,phase 3,3,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,III期临床,2007-09-18,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,True,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
阿尼芬净,anidulafungin,侵袭性曲霉病,Invasive aspergillosis,Vicuron Pharmaceuticals(AbbVie),感染领域,Infectious Diseases,phase 3,3,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,approved,5,2006-02-17,III期临床,2007-09-18,Active,创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,True,True,False,False,True,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),3
罗米地辛,romidepsin,皮肤T细胞淋巴瘤,Cutaneous T-cell lymphoma,Fujisawa Pharmaceutical(Astellas Pharma),肿瘤领域,Oncology,approved,5,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,HDAC,HDAC抑制剂,approved,5,2009-11-05,批准上市,2009-11-05,Active,创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,True,True,True,True,True,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),2
罗米地辛,romidepsin,皮肤T细胞淋巴瘤,Cutaneous T-cell lymphoma,Gloucester Pharmaceuticals(Bristol-Myers Squibb),肿瘤领域,Oncology,approved,5,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,HDAC,HDAC抑制剂,approved,5,2009-11-05,批准上市,2009-11-05,Active,创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,True,True,True,False,True,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),2
罗米地辛,romidepsin,胰腺导管癌,pancreatic ductal carcinoma,Fujisawa Pharmaceutical(Astellas Pharma),肿瘤领域,Oncology,phase 2,2,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,HDAC,HDAC抑制剂,approved,5,2009-11-05,I/II期临床,2020-02-06,Active,创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,True,True,False,True,True,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),2
罗米地辛,romidepsin,胰腺导管癌,pancreatic ductal carcinoma,Gloucester Pharmaceuticals(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 2,2,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,HDAC,HDAC抑制剂,approved,5,2009-11-05,I/II期临床,2020-02-06,Active,创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,True,True,False,False,True,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),2
罗米地辛,romidepsin,肌层浸润性膀胱癌,muscle invasive bladder cancer,Fujisawa Pharmaceutical(Astellas Pharma),肿瘤领域,Oncology,phase 1,1,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,HDAC,HDAC抑制剂,approved,5,2009-11-05,I期临床,2025-05-09,Active,创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,True,True,False,True,True,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),2
罗米地辛,romidepsin,肌层浸润性膀胱癌,muscle invasive bladder cancer,Gloucester Pharmaceuticals(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 1,1,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,HDAC,HDAC抑制剂,approved,5,2009-11-05,I期临床,2025-05-09,Active,创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,True,True,False,False,True,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),2
艾卡拉肽,ecallantide,遗传性血管性水肿,hereditary angioedema,Dyax(Takeda Pharmaceuticals),皮肤领域,Dermatology,approved,5,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,PKK,PKK抑制剂,approved,5,2009-12-01,批准上市,2009-12-01,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,True,True,True,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),3
艾卡拉肽,ecallantide,遗传性血管性水肿,hereditary angioedema,CVie Therapeutics(Windtree Therapeutics),皮肤领域,Dermatology,approved,5,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,PKK,PKK抑制剂,approved,5,2009-12-01,批准上市,2009-12-01,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,True,False,False,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),3
艾卡拉肽,ecallantide,遗传性血管性水肿,hereditary angioedema,Fovea Pharmaceuticals(Sanofi),皮肤领域,Dermatology,approved,5,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,PKK,PKK抑制剂,approved,5,2009-12-01,批准上市,2009-12-01,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,True,False,True,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),3
艾卡拉肽,ecallantide,ACE抑制剂引起的血管性水肿,Angioedema caused by ACE inhibitors,Dyax(Takeda Pharmaceuticals),心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,PKK,PKK抑制剂,approved,5,2009-12-01,II期临床,2009-12-21,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,True,True,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),3
艾卡拉肽,ecallantide,ACE抑制剂引起的血管性水肿,Angioedema caused by ACE inhibitors,CVie Therapeutics(Windtree Therapeutics),心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,PKK,PKK抑制剂,approved,5,2009-12-01,II期临床,2009-12-21,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,False,False,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),3
艾卡拉肽,ecallantide,ACE抑制剂引起的血管性水肿,Angioedema caused by ACE inhibitors,Fovea Pharmaceuticals(Sanofi),心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,PKK,PKK抑制剂,approved,5,2009-12-01,II期临床,2009-12-21,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,False,True,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),3
帕瑞肽,pasireotide,肢端肥大症,acromegaly,Recordati,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,批准上市,2014-11-24,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,肢端肥大症,acromegaly,Novartis,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,批准上市,2014-11-24,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,库欣综合征,Cushing's syndrome,Recordati,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,批准上市,2012-04-24,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,库欣综合征,Cushing's syndrome,Novartis,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,批准上市,2012-04-24,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,胰瘘,pancreatic fistula,Recordati,消化领域,Digestive System,phase 3,3,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,III期临床,2009-10-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,胰瘘,pancreatic fistula,Novartis,消化领域,Digestive System,phase 3,3,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,III期临床,2009-10-14,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,泌乳素瘤,prolactinoma,Recordati,肿瘤领域,Oncology,phase 3,3,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II/III期临床,2012-06-15,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,泌乳素瘤,prolactinoma,Novartis,肿瘤领域,Oncology,phase 3,3,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II/III期临床,2012-06-15,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,乳腺癌,breast cancer,Recordati,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2011-05-20,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,乳腺癌,breast cancer,Novartis,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2011-05-20,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,胰腺癌,pancreatic cancer,Recordati,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2009-08-13,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,胰腺癌,pancreatic cancer,Novartis,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2009-08-13,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,髓样甲状腺癌,medullary thyroid cancer,Recordati,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2011-01-05,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,髓样甲状腺癌,medullary thyroid cancer,Novartis,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2011-01-05,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,低血糖症,hypoglycemia,Recordati,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,低血糖症,hypoglycemia,Novartis,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,多囊肾病,polycystic kidney disease,Recordati,泌尿生殖领域,Genitourinary,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2012-08-21,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,多囊肾病,polycystic kidney disease,Novartis,泌尿生殖领域,Genitourinary,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2012-08-21,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,神经内分泌肿瘤,neuroendocrine tumors,Recordati,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2010-12-03,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,神经内分泌肿瘤,neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2010-12-03,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,滑膜肉瘤,synovial sarcoma,Recordati,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2024-06-13,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,滑膜肉瘤,synovial sarcoma,Novartis,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2024-06-13,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,促结缔组织增生性小圆细胞瘤,desmoplastic small round cell tumor,Recordati,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2024-06-13,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,促结缔组织增生性小圆细胞瘤,desmoplastic small round cell tumor,Novartis,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2024-06-13,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,脑膜瘤,Meningioma,Recordati,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2008-12-23,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,脑膜瘤,Meningioma,Novartis,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2008-12-23,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,肺和胸腺类癌,Lung and thymic carcinoid tumors,Recordati,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,肺和胸腺类癌,Lung and thymic carcinoid tumors,Novartis,肿瘤领域,Oncology,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,True,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,减肥术后低血糖症,Hypoglycemia after bariatric surgery,Recordati,消化领域,Digestive System,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2023-07-03,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,False,False,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
帕瑞肽,pasireotide,减肥术后低血糖症,Hypoglycemia after bariatric surgery,Novartis,消化领域,Digestive System,phase 2,2,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,somatostatin,somatostatin类似物,approved,5,2012-04-24,II期临床,2023-07-03,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,True,True,False,True,True,Recordati;Novartis(Top20 MNC)(原研)(无权益),2
利那洛肽,linaclotide,便秘型肠易激综合征,constipation irritable bowel syndrome,AstraZeneca,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2012-08-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,便秘型肠易激综合征,constipation irritable bowel syndrome,Astellas Pharma,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2012-08-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,便秘型肠易激综合征,constipation irritable bowel syndrome,Forest Laboratories(AbbVie),消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2012-08-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,便秘型肠易激综合征,constipation irritable bowel syndrome,Ironwood Pharmaceuticals,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2012-08-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,True,False,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,便秘,constipate,AstraZeneca,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2023-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,便秘,constipate,Astellas Pharma,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2023-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,便秘,constipate,Forest Laboratories(AbbVie),消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2023-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,便秘,constipate,Ironwood Pharmaceuticals,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2023-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,True,False,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,慢性特发性便秘,chronic idiopathic constipation,AstraZeneca,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2012-08-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,慢性特发性便秘,chronic idiopathic constipation,Astellas Pharma,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2012-08-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,慢性特发性便秘,chronic idiopathic constipation,Forest Laboratories(AbbVie),消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2012-08-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,慢性特发性便秘,chronic idiopathic constipation,Ironwood Pharmaceuticals,消化领域,Digestive System,approved,5,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,批准上市,2012-08-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,True,False,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,结直肠癌,colorectal cancer,AstraZeneca,肿瘤领域,Oncology,phase 2,2,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,II期临床,2019-01-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,结直肠癌,colorectal cancer,Astellas Pharma,肿瘤领域,Oncology,phase 2,2,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,II期临床,2019-01-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,结直肠癌,colorectal cancer,Forest Laboratories(AbbVie),肿瘤领域,Oncology,phase 2,2,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,II期临床,2019-01-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,结直肠癌,colorectal cancer,Ironwood Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,II期临床,2019-01-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,True,False,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,肠易激综合征,irritable bowel syndrome,AstraZeneca,消化领域,Digestive System,phase 2,2,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I/II期临床,2024-11-18,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,肠易激综合征,irritable bowel syndrome,Astellas Pharma,消化领域,Digestive System,phase 2,2,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I/II期临床,2024-11-18,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,肠易激综合征,irritable bowel syndrome,Forest Laboratories(AbbVie),消化领域,Digestive System,phase 2,2,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I/II期临床,2024-11-18,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,肠易激综合征,irritable bowel syndrome,Ironwood Pharmaceuticals,消化领域,Digestive System,phase 2,2,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I/II期临床,2024-11-18,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,True,False,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,肠道清洗,bowel cleansing,AstraZeneca,消化领域,Digestive System,phase 1,1,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I期临床,2021-11-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,肠道清洗,bowel cleansing,Astellas Pharma,消化领域,Digestive System,phase 1,1,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I期临床,2021-11-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,肠道清洗,bowel cleansing,Forest Laboratories(AbbVie),消化领域,Digestive System,phase 1,1,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I期临床,2021-11-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,肠道清洗,bowel cleansing,Ironwood Pharmaceuticals,消化领域,Digestive System,phase 1,1,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I期临床,2021-11-30,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,True,False,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,急性胰腺炎,acute pancreatitis,AstraZeneca,消化领域,Digestive System,phase 1,1,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I期临床,2024-01-26,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,急性胰腺炎,acute pancreatitis,Astellas Pharma,消化领域,Digestive System,phase 1,1,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I期临床,2024-01-26,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,急性胰腺炎,acute pancreatitis,Forest Laboratories(AbbVie),消化领域,Digestive System,phase 1,1,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I期临床,2024-01-26,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
利那洛肽,linaclotide,急性胰腺炎,acute pancreatitis,Ironwood Pharmaceuticals,消化领域,Digestive System,phase 1,1,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,GC-C,GC-C激动剂,approved,5,2012-08-30,I期临床,2024-01-26,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,True,True,False,True,False,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),4
gallium Ga-68 dotatate,gallium Ga-68 dotatate,PET显像,PET imaging,Advanced Accelerator Applications(Siemens Healthineers),诊断试剂领域,Diagnostic Reagents,approved,5,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-06-01,批准上市,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),1
gallium Ga-68 dotatate,gallium Ga-68 dotatate,神经内分泌肿瘤,neuroendocrine tumors,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,approved,5,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-06-01,批准上市,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),1
gallium Ga-68 dotatate,gallium Ga-68 dotatate,HR阳性乳腺癌,HR positive breast cancer,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 2,2,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-06-01,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),1
gallium Ga-68 dotatate,gallium Ga-68 dotatate,鼻咽癌,Nasopharyngeal cancer,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 2,2,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-06-01,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),1
gallium Ga-68 dotatate,gallium Ga-68 dotatate,小细胞肺癌,small cell lung cancer,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 1,1,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-06-01,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),1
镓[68Ga]伊索曲肽,68Ga-edotreotide,PET显像,PET imaging,Advanced Accelerator Applications(Siemens Healthineers),诊断试剂领域,Diagnostic Reagents,approved,5,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,批准上市,2019-08-21,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,PET显像,PET imaging,ITM Isotope,诊断试剂领域,Diagnostic Reagents,approved,5,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,批准上市,2019-08-21,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,PET显像,PET imaging,远大医药,诊断试剂领域,Diagnostic Reagents,approved,5,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,批准上市,2019-08-21,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,PET显像,PET imaging,IASON(Curium Austria),诊断试剂领域,Diagnostic Reagents,approved,5,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,批准上市,2019-08-21,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,神经内分泌肿瘤,neuroendocrine tumors,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,approved,5,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,批准上市,2016-12-08,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,神经内分泌肿瘤,neuroendocrine tumors,ITM Isotope,肿瘤领域,Oncology,approved,5,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,批准上市,2016-12-08,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,神经内分泌肿瘤,neuroendocrine tumors,远大医药,肿瘤领域,Oncology,approved,5,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,批准上市,2016-12-08,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,神经内分泌肿瘤,neuroendocrine tumors,IASON(Curium Austria),肿瘤领域,Oncology,approved,5,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,批准上市,2016-12-08,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,乳腺癌,breast cancer,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 3,3,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,III期临床,2024-09-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,乳腺癌,breast cancer,ITM Isotope,肿瘤领域,Oncology,phase 3,3,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,III期临床,2024-09-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,乳腺癌,breast cancer,远大医药,肿瘤领域,Oncology,phase 3,3,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,III期临床,2024-09-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,乳腺癌,breast cancer,IASON(Curium Austria),肿瘤领域,Oncology,phase 3,3,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,III期临床,2024-09-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 3,3,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,III期临床,2023-10-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,ITM Isotope,肿瘤领域,Oncology,phase 3,3,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,III期临床,2023-10-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,远大医药,肿瘤领域,Oncology,phase 3,3,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,III期临床,2023-10-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,IASON(Curium Austria),肿瘤领域,Oncology,phase 3,3,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,III期临床,2023-10-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,细菌性心内膜炎,bacterial endocarditis,Advanced Accelerator Applications(Siemens Healthineers),感染领域,Infectious Diseases,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2021-12-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,细菌性心内膜炎,bacterial endocarditis,ITM Isotope,感染领域,Infectious Diseases,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2021-12-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,细菌性心内膜炎,bacterial endocarditis,远大医药,感染领域,Infectious Diseases,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2021-12-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,细菌性心内膜炎,bacterial endocarditis,IASON(Curium Austria),感染领域,Infectious Diseases,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2021-12-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,HER2阳性乳腺癌,HER2-positive breast cancer,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2025-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,HER2阳性乳腺癌,HER2-positive breast cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2025-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,HER2阳性乳腺癌,HER2-positive breast cancer,远大医药,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2025-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,HER2阳性乳腺癌,HER2-positive breast cancer,IASON(Curium Austria),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2025-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,神经母细胞瘤,Neuroblastoma,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2015-05-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,神经母细胞瘤,Neuroblastoma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2015-05-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,神经母细胞瘤,Neuroblastoma,远大医药,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2015-05-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,神经母细胞瘤,Neuroblastoma,IASON(Curium Austria),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2015-05-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,癌症脑转移,cancer brain metastasis,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2025-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,癌症脑转移,cancer brain metastasis,ITM Isotope,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2025-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,癌症脑转移,cancer brain metastasis,远大医药,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2025-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,癌症脑转移,cancer brain metastasis,IASON(Curium Austria),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,II期临床,2025-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,鼻咽癌,Nasopharyngeal cancer,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I/II期临床,2025-05-21,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,鼻咽癌,Nasopharyngeal cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I/II期临床,2025-05-21,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,鼻咽癌,Nasopharyngeal cancer,远大医药,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I/II期临床,2025-05-21,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,鼻咽癌,Nasopharyngeal cancer,IASON(Curium Austria),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I/II期临床,2025-05-21,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,副神经节瘤,paraganglioma,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I/II期临床,2014-06-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,副神经节瘤,paraganglioma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I/II期临床,2014-06-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,副神经节瘤,paraganglioma,远大医药,肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I/II期临床,2014-06-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,副神经节瘤,paraganglioma,IASON(Curium Austria),肿瘤领域,Oncology,phase 2,2,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I/II期临床,2014-06-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,抑郁症,depression,Advanced Accelerator Applications(Siemens Healthineers),精神领域,Psychiatry,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,抑郁症,depression,ITM Isotope,精神领域,Psychiatry,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,抑郁症,depression,远大医药,精神领域,Psychiatry,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,抑郁症,depression,IASON(Curium Austria),精神领域,Psychiatry,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,不孕不育,Infertility,Advanced Accelerator Applications(Siemens Healthineers),泌尿生殖领域,Genitourinary,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,不孕不育,Infertility,ITM Isotope,泌尿生殖领域,Genitourinary,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,不孕不育,Infertility,远大医药,泌尿生殖领域,Genitourinary,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,不孕不育,Infertility,IASON(Curium Austria),泌尿生殖领域,Genitourinary,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,嗜铬细胞瘤,Pheochromocytoma,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2018-07-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,嗜铬细胞瘤,Pheochromocytoma,ITM Isotope,肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2018-07-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,嗜铬细胞瘤,Pheochromocytoma,远大医药,肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2018-07-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,嗜铬细胞瘤,Pheochromocytoma,IASON(Curium Austria),肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2018-07-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,骨转移疼痛,bone metastasis pain,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,骨转移疼痛,bone metastasis pain,ITM Isotope,肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,骨转移疼痛,bone metastasis pain,远大医药,肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,骨转移疼痛,bone metastasis pain,IASON(Curium Austria),肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,Advanced Accelerator Applications(Siemens Healthineers),肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-01-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,True,True,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,ITM Isotope,肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-01-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,远大医药,肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-01-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
镓[68Ga]伊索曲肽,68Ga-edotreotide,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,IASON(Curium Austria),肿瘤领域,Oncology,phase 1,1,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,approved,5,2016-12-08,I期临床,2025-01-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,True,True,True,False,False,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),4
普卡那肽,plecanatide,便秘型肠易激综合征,constipation irritable bowel syndrome,Bausch Health,消化领域,Digestive System,approved,5,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,GC-C,GC-C激动剂,approved,5,2017-01-19,批准上市,2018-01-24,Active,创新药,化药,多肽,环肽,激动剂,False,True,False,False,False,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),3
普卡那肽,plecanatide,便秘型肠易激综合征,constipation irritable bowel syndrome,罗欣药业,消化领域,Digestive System,approved,5,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,GC-C,GC-C激动剂,approved,5,2017-01-19,批准上市,2018-01-24,Active,创新药,化药,多肽,环肽,激动剂,False,True,False,False,False,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),3
普卡那肽,plecanatide,便秘型肠易激综合征,constipation irritable bowel syndrome,Synergy Pharmaceuticals,消化领域,Digestive System,approved,5,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,GC-C,GC-C激动剂,approved,5,2017-01-19,批准上市,2018-01-24,Active,创新药,化药,多肽,环肽,激动剂,False,True,False,True,False,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),3
普卡那肽,plecanatide,慢性特发性便秘,chronic idiopathic constipation,Bausch Health,消化领域,Digestive System,approved,5,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,GC-C,GC-C激动剂,approved,5,2017-01-19,批准上市,2017-01-19,Active,创新药,化药,多肽,环肽,激动剂,False,True,False,False,False,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),3
普卡那肽,plecanatide,慢性特发性便秘,chronic idiopathic constipation,罗欣药业,消化领域,Digestive System,approved,5,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,GC-C,GC-C激动剂,approved,5,2017-01-19,批准上市,2017-01-19,Active,创新药,化药,多肽,环肽,激动剂,False,True,False,False,False,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),3
普卡那肽,plecanatide,慢性特发性便秘,chronic idiopathic constipation,Synergy Pharmaceuticals,消化领域,Digestive System,approved,5,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,GC-C,GC-C激动剂,approved,5,2017-01-19,批准上市,2017-01-19,Active,创新药,化药,多肽,环肽,激动剂,False,True,False,True,False,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),3
Noctiva,Noctiva (desmopressin),夜尿症,Nocturia,Avadel Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,Noctiva;Noctiva (去氨加压素);Noctiva (desmopressin);AV002;SER120,vasopressin,vasopressin类似物,approved,5,2017-03-03,批准上市,2017-03-03,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,False,True,False,Avadel Pharmaceuticals(原研);Serenity Pharmaceuticals(Acerus Pharmaceuticals),2
Noctiva,Noctiva (desmopressin),夜尿症,Nocturia,Serenity Pharmaceuticals(Acerus Pharmaceuticals),泌尿生殖领域,Genitourinary,approved,5,Noctiva;Noctiva (去氨加压素);Noctiva (desmopressin);AV002;SER120,vasopressin,vasopressin类似物,approved,5,2017-03-03,批准上市,2017-03-03,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,False,False,False,Avadel Pharmaceuticals(原研);Serenity Pharmaceuticals(Acerus Pharmaceuticals),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Novartis,肿瘤领域,Oncology,approved,5,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,批准上市,2017-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,approved,5,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,批准上市,2017-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 3,3,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,III期临床,2025-09-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 3,3,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,III期临床,2025-09-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 3,3,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,III期临床,2013-05-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 3,3,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,III期临床,2013-05-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,神经内分泌肿瘤,neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 3,3,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II/III期临床,2024-04-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,神经内分泌肿瘤,neuroendocrine tumors,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 3,3,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II/III期临床,2024-04-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,实体瘤,solid tumors,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2024-09-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,实体瘤,solid tumors,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2024-09-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,小细胞肺癌,small cell lung cancer,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,小细胞肺癌,small cell lung cancer,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,乳腺癌,breast cancer,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,乳腺癌,breast cancer,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,Merkel细胞瘤,Merkel cell tumor,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2022-10-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,Merkel细胞瘤,Merkel cell tumor,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2022-10-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,前列腺癌,prostate cancer,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2023-01-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,前列腺癌,prostate cancer,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2023-01-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胶质母细胞瘤,glioblastoma,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胶质母细胞瘤,glioblastoma,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,髓样甲状腺癌,medullary thyroid cancer,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2023-11-07,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,髓样甲状腺癌,medullary thyroid cancer,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2023-11-07,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,嗜铬细胞瘤,Pheochromocytoma,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2017-07-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,嗜铬细胞瘤,Pheochromocytoma,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2017-07-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,副神经节瘤,paraganglioma,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2017-07-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,副神经节瘤,paraganglioma,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2017-07-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,癌症肝转移,cancer liver metastasis,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2019-08-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,癌症肝转移,cancer liver metastasis,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2019-08-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,脑膜瘤,Meningioma,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2019-09-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,脑膜瘤,Meningioma,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,2019-09-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胸腺癌,thymic cancer,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,胸腺癌,thymic cancer,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,神经内分泌前列腺癌,neuroendocrine prostate cancer,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,神经内分泌前列腺癌,neuroendocrine prostate cancer,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,False,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,弥漫性内因性脑桥神经胶质瘤,Diffuse intrinsic pontine glioma,Novartis,肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,弥漫性内因性脑桥神经胶质瘤,Diffuse intrinsic pontine glioma,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 2,2,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,非霍奇金淋巴瘤,non-hodgkin lymphoma,Novartis,肿瘤领域,Oncology,phase 1,1,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,I期临床,2023-08-16,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,非霍奇金淋巴瘤,non-hodgkin lymphoma,FUJIFILM Toyama(PeptiDream),肿瘤领域,Oncology,phase 1,1,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,approved,5,2017-09-26,I期临床,2023-08-16,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),2
Cequa,Cequa (cyclosporine A),干眼病,dry eye disease,康哲药业,眼科领域,Ophthalmology,approved,5,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2018-08-14,批准上市,2018-08-14,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,False,False,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),3
Cequa,Cequa (cyclosporine A),干眼病,dry eye disease,Ocular Technologies(Sun Pharma),眼科领域,Ophthalmology,approved,5,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2018-08-14,批准上市,2018-08-14,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,False,False,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),3
Cequa,Cequa (cyclosporine A),干眼病,dry eye disease,Auven Therapeutics,眼科领域,Ophthalmology,approved,5,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2018-08-14,批准上市,2018-08-14,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),3
Cequa,Cequa (cyclosporine A),炎症(未指明),Inflammation (unspecified),康哲药业,免疫领域,Immunology,phase 1,1,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2018-08-14,I期临床,2023-07-24,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,False,False,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),3
Cequa,Cequa (cyclosporine A),炎症(未指明),Inflammation (unspecified),Ocular Technologies(Sun Pharma),免疫领域,Immunology,phase 1,1,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2018-08-14,I期临床,2023-07-24,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,False,False,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),3
Cequa,Cequa (cyclosporine A),炎症(未指明),Inflammation (unspecified),Auven Therapeutics,免疫领域,Immunology,phase 1,1,Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2018-08-14,I期临床,2023-07-24,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),3
普利肽新,普利肽新,多发性骨髓瘤,multiple myeloma,Boryung Pharmaceutical,肿瘤领域,Oncology,approved,5,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,批准上市,2018-12-11,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,True,False,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,多发性骨髓瘤,multiple myeloma,Chugai Pharmaceutical,肿瘤领域,Oncology,approved,5,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,批准上市,2018-12-11,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,True,False,True,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,多发性骨髓瘤,multiple myeloma,PharmaMar,肿瘤领域,Oncology,approved,5,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,批准上市,2018-12-11,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,True,True,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,多发性骨髓瘤,multiple myeloma,Specialised Therapeutics,肿瘤领域,Oncology,approved,5,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,批准上市,2018-12-11,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,True,False,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,新型冠状病毒感染,novel coronavirus infection,Boryung Pharmaceutical,感染领域,Infectious Diseases,phase 3,3,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,III期临床,2021-03-05,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,False,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,新型冠状病毒感染,novel coronavirus infection,Chugai Pharmaceutical,感染领域,Infectious Diseases,phase 3,3,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,III期临床,2021-03-05,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,False,True,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,新型冠状病毒感染,novel coronavirus infection,PharmaMar,感染领域,Infectious Diseases,phase 3,3,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,III期临床,2021-03-05,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,True,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,新型冠状病毒感染,novel coronavirus infection,Specialised Therapeutics,感染领域,Infectious Diseases,phase 3,3,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,III期临床,2021-03-05,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,False,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,长新冠,Long new crown,Boryung Pharmaceutical,感染领域,Infectious Diseases,phase 2,2,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,II期临床,2024-12-05,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,False,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,长新冠,Long new crown,Chugai Pharmaceutical,感染领域,Infectious Diseases,phase 2,2,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,II期临床,2024-12-05,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,False,True,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,长新冠,Long new crown,PharmaMar,感染领域,Infectious Diseases,phase 2,2,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,II期临床,2024-12-05,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,True,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
普利肽新,普利肽新,长新冠,Long new crown,Specialised Therapeutics,感染领域,Infectious Diseases,phase 2,2,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,EEF1A1,EEF1A1抑制剂,approved,5,2018-12-11,II期临床,2024-12-05,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,True,True,False,False,False,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,4
布美诺肽,bremelanotide,低反应性性欲障碍,hyporesponsive sexual desire disorder,KwangDong Pharmaceutical,精神领域,Psychiatry,approved,5,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,批准上市,2019-06-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,低反应性性欲障碍,hyporesponsive sexual desire disorder,复星医药,精神领域,Psychiatry,approved,5,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,批准上市,2019-06-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,低反应性性欲障碍,hyporesponsive sexual desire disorder,Cosette Pharmaceuticals,精神领域,Psychiatry,approved,5,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,批准上市,2019-06-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,低反应性性欲障碍,hyporesponsive sexual desire disorder,Gedeon Richter,精神领域,Psychiatry,approved,5,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,批准上市,2019-06-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,低反应性性欲障碍,hyporesponsive sexual desire disorder,AMAG Pharmaceuticals(Azurity Pharmaceuticals),精神领域,Psychiatry,approved,5,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,批准上市,2019-06-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,低反应性性欲障碍,hyporesponsive sexual desire disorder,Palatin Technologies,精神领域,Psychiatry,approved,5,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,批准上市,2019-06-21,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,肥胖,obesity,KwangDong Pharmaceutical,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,肥胖,obesity,复星医药,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,肥胖,obesity,Cosette Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,肥胖,obesity,Gedeon Richter,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,肥胖,obesity,AMAG Pharmaceuticals(Azurity Pharmaceuticals),内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,肥胖,obesity,Palatin Technologies,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-12,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,糖尿病肾病,diabetic nephropathy,KwangDong Pharmaceutical,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2023-02-02,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,糖尿病肾病,diabetic nephropathy,复星医药,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2023-02-02,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,糖尿病肾病,diabetic nephropathy,Cosette Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2023-02-02,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,糖尿病肾病,diabetic nephropathy,Gedeon Richter,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2023-02-02,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,糖尿病肾病,diabetic nephropathy,AMAG Pharmaceuticals(Azurity Pharmaceuticals),泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2023-02-02,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,糖尿病肾病,diabetic nephropathy,Palatin Technologies,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2023-02-02,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,勃起功能障碍,erectile dysfunction,KwangDong Pharmaceutical,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-20,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,勃起功能障碍,erectile dysfunction,复星医药,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-20,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,勃起功能障碍,erectile dysfunction,Cosette Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-20,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,勃起功能障碍,erectile dysfunction,Gedeon Richter,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-20,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,勃起功能障碍,erectile dysfunction,AMAG Pharmaceuticals(Azurity Pharmaceuticals),泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-20,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
布美诺肽,bremelanotide,勃起功能障碍,erectile dysfunction,Palatin Technologies,泌尿生殖领域,Genitourinary,phase 2,2,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,MC4R,MC4R激动剂,approved,5,2019-06-21,II期临床,2024-06-20,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),6
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,PET显像,PET imaging,Novartis,诊断试剂领域,Diagnostic Reagents,approved,5,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,批准上市,2020-09-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,PET显像,PET imaging,RadioMedix,诊断试剂领域,Diagnostic Reagents,approved,5,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,批准上市,2020-09-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,PET显像,PET imaging,Curium Pharma,诊断试剂领域,Diagnostic Reagents,approved,5,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,批准上市,2020-09-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,神经内分泌肿瘤,neuroendocrine tumors,Novartis,肿瘤领域,Oncology,approved,5,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,批准上市,2020-09-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,神经内分泌肿瘤,neuroendocrine tumors,RadioMedix,肿瘤领域,Oncology,approved,5,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,批准上市,2020-09-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,神经内分泌肿瘤,neuroendocrine tumors,Curium Pharma,肿瘤领域,Oncology,approved,5,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,批准上市,2020-09-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 2,2,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,II期临床,2023-02-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,RadioMedix,肿瘤领域,Oncology,phase 2,2,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,II期临床,2023-02-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Curium Pharma,肿瘤领域,Oncology,phase 2,2,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,II期临床,2023-02-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,前列腺癌,prostate cancer,Novartis,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2023-01-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,前列腺癌,prostate cancer,RadioMedix,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2023-01-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,前列腺癌,prostate cancer,Curium Pharma,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2023-01-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,神经母细胞瘤,Neuroblastoma,Novartis,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,神经母细胞瘤,Neuroblastoma,RadioMedix,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,神经母细胞瘤,Neuroblastoma,Curium Pharma,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,抑郁症,depression,Novartis,精神领域,Psychiatry,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,抑郁症,depression,RadioMedix,精神领域,Psychiatry,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,抑郁症,depression,Curium Pharma,精神领域,Psychiatry,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,不孕不育,Infertility,Novartis,泌尿生殖领域,Genitourinary,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,不孕不育,Infertility,RadioMedix,泌尿生殖领域,Genitourinary,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,不孕不育,Infertility,Curium Pharma,泌尿生殖领域,Genitourinary,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,嗜铬细胞瘤,Pheochromocytoma,Novartis,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,嗜铬细胞瘤,Pheochromocytoma,RadioMedix,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,嗜铬细胞瘤,Pheochromocytoma,Curium Pharma,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,骨转移疼痛,bone metastasis pain,Novartis,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,骨转移疼痛,bone metastasis pain,RadioMedix,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,骨转移疼痛,bone metastasis pain,Curium Pharma,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,副神经节瘤,paraganglioma,Novartis,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,副神经节瘤,paraganglioma,RadioMedix,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,副神经节瘤,paraganglioma,Curium Pharma,肿瘤领域,Oncology,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,True,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,莱姆病,Lyme disease,Novartis,感染领域,Infectious Diseases,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2024-04-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,莱姆病,Lyme disease,RadioMedix,感染领域,Infectious Diseases,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2024-04-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,莱姆病,Lyme disease,Curium Pharma,感染领域,Infectious Diseases,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2024-04-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,心脏结节病,cardiac sarcoidosis,Novartis,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2023-11-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,True,True,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,心脏结节病,cardiac sarcoidosis,RadioMedix,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2023-11-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,心脏结节病,cardiac sarcoidosis,Curium Pharma,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,approved,5,2020-09-03,I期临床,2023-11-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,3
setmelanotide,setmelanotide,肥胖,obesity,Ipsen,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2024-07-31,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,肥胖,obesity,Rhythm Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2024-07-31,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,肥胖,obesity,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2024-07-31,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,肥胖,obesity,琅钰集团,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2024-07-31,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,阿黑皮素原缺乏症,proopiomelanocortin deficiency,Ipsen,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2020-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,阿黑皮素原缺乏症,proopiomelanocortin deficiency,Rhythm Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2020-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,阿黑皮素原缺乏症,proopiomelanocortin deficiency,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2020-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,阿黑皮素原缺乏症,proopiomelanocortin deficiency,琅钰集团,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2020-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,瘦素受体缺乏,leptin receptor deficiency,Ipsen,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2020-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,瘦素受体缺乏,leptin receptor deficiency,Rhythm Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2020-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,瘦素受体缺乏,leptin receptor deficiency,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2020-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,瘦素受体缺乏,leptin receptor deficiency,琅钰集团,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2020-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,巴德-毕德氏症候群,Budd-Bide syndrome,Ipsen,,,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2022-06-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,巴德-毕德氏症候群,Budd-Bide syndrome,Rhythm Pharmaceuticals,,,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2022-06-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,巴德-毕德氏症候群,Budd-Bide syndrome,Camurus,,,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2022-06-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,巴德-毕德氏症候群,Budd-Bide syndrome,琅钰集团,,,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2022-06-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,PCSK1缺乏症,PCSK1 deficiency,Ipsen,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2021-07-23,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,PCSK1缺乏症,PCSK1 deficiency,Rhythm Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2021-07-23,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,PCSK1缺乏症,PCSK1 deficiency,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2021-07-23,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,PCSK1缺乏症,PCSK1 deficiency,琅钰集团,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,批准上市,2021-07-23,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,下丘脑性肥胖,hypothalamic obesity,Ipsen,内分泌及代谢领域,Endocrinology & Metabolism,pre-registration,4,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,申请上市,2025-08-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,下丘脑性肥胖,hypothalamic obesity,Rhythm Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,pre-registration,4,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,申请上市,2025-08-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,下丘脑性肥胖,hypothalamic obesity,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,pre-registration,4,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,申请上市,2025-08-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,下丘脑性肥胖,hypothalamic obesity,琅钰集团,内分泌及代谢领域,Endocrinology & Metabolism,pre-registration,4,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,申请上市,2025-08-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,Alström综合征,Alström syndrome,Ipsen,,,pre-registration,4,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,申请上市,2021-09-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,Alström综合征,Alström syndrome,Rhythm Pharmaceuticals,,,pre-registration,4,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,申请上市,2021-09-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,Alström综合征,Alström syndrome,Camurus,,,pre-registration,4,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,申请上市,2021-09-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,Alström综合征,Alström syndrome,琅钰集团,,,pre-registration,4,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,申请上市,2021-09-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,联合垂体激素缺乏症,combined pituitary hormone deficiency,Ipsen,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,III期临床,2025-01-07,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,联合垂体激素缺乏症,combined pituitary hormone deficiency,Rhythm Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,III期临床,2025-01-07,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,联合垂体激素缺乏症,combined pituitary hormone deficiency,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,III期临床,2025-01-07,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,联合垂体激素缺乏症,combined pituitary hormone deficiency,琅钰集团,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,III期临床,2025-01-07,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,视-隔发育不良,Opto-septal dysplasia,Ipsen,,,phase 3,3,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,III期临床,2025-01-07,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,视-隔发育不良,Opto-septal dysplasia,Rhythm Pharmaceuticals,,,phase 3,3,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,III期临床,2025-01-07,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,视-隔发育不良,Opto-septal dysplasia,Camurus,,,phase 3,3,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,III期临床,2025-01-07,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,视-隔发育不良,Opto-septal dysplasia,琅钰集团,,,phase 3,3,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,III期临床,2025-01-07,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,Prader-Willi综合征,Prader-Willi syndrome,Ipsen,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,II期临床,2014-12-08,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,Prader-Willi综合征,Prader-Willi syndrome,Rhythm Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,II期临床,2014-12-08,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,Prader-Willi综合征,Prader-Willi syndrome,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,II期临床,2014-12-08,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,Prader-Willi综合征,Prader-Willi syndrome,琅钰集团,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,II期临床,2014-12-08,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,True,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,多食症,polyphagia,Ipsen,精神领域,Psychiatry,phase 2,2,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,II期临床,2025-01-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,多食症,polyphagia,Rhythm Pharmaceuticals,精神领域,Psychiatry,phase 2,2,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,II期临床,2025-01-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,多食症,polyphagia,Camurus,精神领域,Psychiatry,phase 2,2,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,II期临床,2025-01-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
setmelanotide,setmelanotide,多食症,polyphagia,琅钰集团,精神领域,Psychiatry,phase 2,2,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,MC4R,MC4R激动剂,approved,5,2020-11-25,II期临床,2025-01-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,False,False,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),4
pegcetacoplan,pegcetacoplan,阵发性睡眠性血红蛋白尿症,paroxysmal nocturnal hemoglobinuria,Apellis Pharmaceuticals,血液领域,Hematology,approved,5,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,批准上市,2021-05-14,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,阵发性睡眠性血红蛋白尿症,paroxysmal nocturnal hemoglobinuria,Swedish Orphan Biovitrum,血液领域,Hematology,approved,5,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,批准上市,2021-05-14,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,C3肾小球病,C3 glomerulopathy,Apellis Pharmaceuticals,免疫领域,Immunology,approved,5,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,批准上市,2025-07-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,C3肾小球病,C3 glomerulopathy,Swedish Orphan Biovitrum,免疫领域,Immunology,approved,5,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,批准上市,2025-07-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,地图样萎缩,geographical atrophy,Apellis Pharmaceuticals,眼科领域,Ophthalmology,approved,5,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,批准上市,2023-02-17,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,地图样萎缩,geographical atrophy,Swedish Orphan Biovitrum,眼科领域,Ophthalmology,approved,5,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,批准上市,2023-02-17,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,免疫复合物介导的膜增生性肾小球肾炎,Immune complex-mediated membranoproliferative glomerulonephritis,Apellis Pharmaceuticals,泌尿生殖领域,Genitourinary,approved,5,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,批准上市,2025-07-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,免疫复合物介导的膜增生性肾小球肾炎,Immune complex-mediated membranoproliferative glomerulonephritis,Swedish Orphan Biovitrum,泌尿生殖领域,Genitourinary,approved,5,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,批准上市,2025-07-28,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,肾移植后移植物功能延迟恢复,Delayed recovery of graft function after kidney transplantation,Apellis Pharmaceuticals,免疫领域,Immunology,phase 3,3,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,III期临床,2025-06-13,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,肾移植后移植物功能延迟恢复,Delayed recovery of graft function after kidney transplantation,Swedish Orphan Biovitrum,免疫领域,Immunology,phase 3,3,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,III期临床,2025-06-13,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,冷凝集素病,cold agglutinin disease,Apellis Pharmaceuticals,血液领域,Hematology,phase 3,3,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,III期临床,2021-10-27,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,冷凝集素病,cold agglutinin disease,Swedish Orphan Biovitrum,血液领域,Hematology,phase 3,3,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,III期临床,2021-10-27,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,局灶性节段性肾小球硬化,focal segmental glomerulosclerosis,Apellis Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 3,3,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II/III期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,局灶性节段性肾小球硬化,focal segmental glomerulosclerosis,Swedish Orphan Biovitrum,泌尿生殖领域,Genitourinary,phase 3,3,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II/III期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,狼疮性肾炎,lupus nephritis,Apellis Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2018-03-05,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,狼疮性肾炎,lupus nephritis,Swedish Orphan Biovitrum,泌尿生殖领域,Genitourinary,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2018-03-05,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,IgA肾病,IgA nephropathy,Apellis Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2018-03-05,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,IgA肾病,IgA nephropathy,Swedish Orphan Biovitrum,泌尿生殖领域,Genitourinary,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2018-03-05,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,膜性肾病,membranous nephropathy,Apellis Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2018-03-05,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,膜性肾病,membranous nephropathy,Swedish Orphan Biovitrum,泌尿生殖领域,Genitourinary,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2018-03-05,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,温抗体型自身免疫溶血性贫血,Warm antibody autoimmune hemolytic anemia,Apellis Pharmaceuticals,血液领域,Hematology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2017-07-24,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,温抗体型自身免疫溶血性贫血,Warm antibody autoimmune hemolytic anemia,Swedish Orphan Biovitrum,血液领域,Hematology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2017-07-24,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,造血干细胞移植后血栓性微血管病,Thrombotic microangiopathy after hematopoietic stem cell transplantation,Apellis Pharmaceuticals,血液领域,Hematology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2021-12-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,造血干细胞移植后血栓性微血管病,Thrombotic microangiopathy after hematopoietic stem cell transplantation,Swedish Orphan Biovitrum,血液领域,Hematology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,II期临床,2021-12-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,恶性胸水,malignant pleural effusion,Apellis Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,恶性胸水,malignant pleural effusion,Swedish Orphan Biovitrum,肿瘤领域,Oncology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),Apellis Pharmaceuticals,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),Swedish Orphan Biovitrum,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,心肌梗塞,myocardial infarction,Apellis Pharmaceuticals,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,心肌梗塞,myocardial infarction,Swedish Orphan Biovitrum,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,卒中,Stroke,Apellis Pharmaceuticals,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,卒中,Stroke,Swedish Orphan Biovitrum,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,腹水,ascites,Apellis Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,腹水,ascites,Swedish Orphan Biovitrum,泌尿生殖领域,Genitourinary,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,年龄相关性黄斑变性,age-related macular degeneration,Apellis Pharmaceuticals,眼科领域,Ophthalmology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2018-03-14,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,年龄相关性黄斑变性,age-related macular degeneration,Swedish Orphan Biovitrum,眼科领域,Ophthalmology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2018-03-14,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,湿性年龄相关性黄斑变性,Wet age-related macular degeneration,Apellis Pharmaceuticals,眼科领域,Ophthalmology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,湿性年龄相关性黄斑变性,Wet age-related macular degeneration,Swedish Orphan Biovitrum,眼科领域,Ophthalmology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,干性年龄相关性黄斑变性,Dry age-related macular degeneration,Apellis Pharmaceuticals,眼科领域,Ophthalmology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-09-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,干性年龄相关性黄斑变性,Dry age-related macular degeneration,Swedish Orphan Biovitrum,眼科领域,Ophthalmology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-09-08,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,胰腺导管癌,pancreatic ductal carcinoma,Apellis Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,胰腺导管癌,pancreatic ductal carcinoma,Swedish Orphan Biovitrum,肿瘤领域,Oncology,phase 2,2,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,I/II期临床,2025-10-09,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,False,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,移植物抗宿主病,graft versus host disease,Apellis Pharmaceuticals,免疫领域,Immunology,pre-clinical,-1,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,临床前,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,True,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
pegcetacoplan,pegcetacoplan,移植物抗宿主病,graft versus host disease,Swedish Orphan Biovitrum,免疫领域,Immunology,pre-clinical,-1,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3,C3抑制剂,approved,5,2021-05-14,临床前,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,False,True,True,False,False,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,2
伏索利肽,vosoritide,软骨发育不全,Achondroplasia,BioMarin Pharmaceutical,骨骼肌肉领域,Musculoskeletal,approved,5,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,批准上市,2021-08-27,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,True,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,软骨发育不全,Achondroplasia,Samoh Pharm,骨骼肌肉领域,Musculoskeletal,approved,5,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,批准上市,2021-08-27,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,False,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,矮小,short,BioMarin Pharmaceutical,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2023-05-08,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,矮小,short,Samoh Pharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2023-05-08,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,特纳综合征,Turner syndrome,BioMarin Pharmaceutical,,,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2023-05-08,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,True,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,特纳综合征,Turner syndrome,Samoh Pharm,,,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2023-05-08,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,False,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,努南综合征,Noonan syndrome,BioMarin Pharmaceutical,,,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2024-10-31,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,True,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,努南综合征,Noonan syndrome,Samoh Pharm,,,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2024-10-31,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,False,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,特发性矮小,idiopathic short stature,BioMarin Pharmaceutical,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2024-04-24,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,True,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,特发性矮小,idiopathic short stature,Samoh Pharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2024-04-24,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,False,False,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,SHOX缺陷,SHOX defects,BioMarin Pharmaceutical,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2024-10-31,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,True,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,SHOX缺陷,SHOX defects,Samoh Pharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,II期临床,2024-10-31,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,False,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,VI型黏多糖贮积症,Mucopolysaccharidosis type VI,BioMarin Pharmaceutical,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,I/II期临床,2023-05-06,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,True,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,VI型黏多糖贮积症,Mucopolysaccharidosis type VI,Samoh Pharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,I/II期临床,2023-05-06,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,False,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,IVA型黏多糖贮积症,Mucopolysaccharidosis type IVA,BioMarin Pharmaceutical,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,I/II期临床,2023-05-06,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,True,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
伏索利肽,vosoritide,IVA型黏多糖贮积症,Mucopolysaccharidosis type IVA,Samoh Pharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,CNP,CNP类似物,approved,5,2021-08-26,I/II期临床,2023-05-06,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,False,True,True,False,False,BioMarin Pharmaceutical(原研);Samoh Pharm,2
CyclASol,CyclASol (cyclosporine A),干眼病,dry eye disease,恒瑞医药,眼科领域,Ophthalmology,approved,5,CyclASol;CyclASol (环孢素);CyclASol (cyclosporine A);SHR8028;Vevye;Vevizye,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2023-05-30,批准上市,2023-05-30,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,False,False,恒瑞医药;Novaliq(原研);Harrow,3
CyclASol,CyclASol (cyclosporine A),干眼病,dry eye disease,Novaliq,眼科领域,Ophthalmology,approved,5,CyclASol;CyclASol (环孢素);CyclASol (cyclosporine A);SHR8028;Vevye;Vevizye,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2023-05-30,批准上市,2023-05-30,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,恒瑞医药;Novaliq(原研);Harrow,3
CyclASol,CyclASol (cyclosporine A),干眼病,dry eye disease,Harrow,眼科领域,Ophthalmology,approved,5,CyclASol;CyclASol (环孢素);CyclASol (cyclosporine A);SHR8028;Vevye;Vevizye,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,2023-05-30,批准上市,2023-05-30,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,False,False,恒瑞医药;Novaliq(原研);Harrow,3
培莫沙肽,Pegol-sihematide,慢性肾病贫血,chronic kidney disease anemia,翰森制药,血液领域,Hematology,approved,5,培莫沙肽;Pegol-sihematide;培化西海马肽;pegol-sihematide;EPO-018B;HS-20039;圣罗莱;pegmolesatide,EPO receptor,EPO receptor激动剂,approved,5,2023-06-30,批准上市,2023-06-30,Active,创新药,化药,多肽,环肽;差异化疾病,激动剂,False,True,False,True,False,翰森制药(原研),1
莫替福肽,motixafortide,多发性骨髓瘤,multiple myeloma,BioLineRx,肿瘤领域,Oncology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,多发性骨髓瘤,multiple myeloma,劲方医药,肿瘤领域,Oncology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,多发性骨髓瘤,multiple myeloma,Biokine Therapeutics,肿瘤领域,Oncology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,True,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,多发性骨髓瘤,multiple myeloma,誉衡生物,肿瘤领域,Oncology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,多发性骨髓瘤,multiple myeloma,Ayrmid,肿瘤领域,Oncology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,干细胞动员,stem cell mobilization,BioLineRx,血液领域,Hematology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,干细胞动员,stem cell mobilization,劲方医药,血液领域,Hematology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,干细胞动员,stem cell mobilization,Biokine Therapeutics,血液领域,Hematology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,True,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,干细胞动员,stem cell mobilization,誉衡生物,血液领域,Hematology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,干细胞动员,stem cell mobilization,Ayrmid,血液领域,Hematology,approved,5,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,批准上市,2023-09-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胰腺癌,pancreatic cancer,BioLineRx,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2016-07-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胰腺癌,pancreatic cancer,劲方医药,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2016-07-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胰腺癌,pancreatic cancer,Biokine Therapeutics,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2016-07-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,True,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胰腺癌,pancreatic cancer,誉衡生物,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2016-07-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胰腺癌,pancreatic cancer,Ayrmid,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2016-07-11,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,急性髓系白血病,acute myeloid leukemia,BioLineRx,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2013-04-24,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,急性髓系白血病,acute myeloid leukemia,劲方医药,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2013-04-24,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,急性髓系白血病,acute myeloid leukemia,Biokine Therapeutics,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2013-04-24,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,True,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,急性髓系白血病,acute myeloid leukemia,誉衡生物,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2013-04-24,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,急性髓系白血病,acute myeloid leukemia,Ayrmid,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,II期临床,2013-04-24,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胃癌,stomach cancer,BioLineRx,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I/II期临床,2017-09-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胃癌,stomach cancer,劲方医药,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I/II期临床,2017-09-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胃癌,stomach cancer,Biokine Therapeutics,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I/II期临床,2017-09-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胃癌,stomach cancer,誉衡生物,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I/II期临床,2017-09-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,胃癌,stomach cancer,Ayrmid,肿瘤领域,Oncology,phase 2,2,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I/II期临床,2017-09-13,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,镰状细胞病,sickle cell disease,BioLineRx,血液领域,Hematology,phase 1,1,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I期临床,2022-11-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,镰状细胞病,sickle cell disease,劲方医药,血液领域,Hematology,phase 1,1,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I期临床,2022-11-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,镰状细胞病,sickle cell disease,Biokine Therapeutics,血液领域,Hematology,phase 1,1,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I期临床,2022-11-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,True,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,镰状细胞病,sickle cell disease,誉衡生物,血液领域,Hematology,phase 1,1,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I期临床,2022-11-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
莫替福肽,motixafortide,镰状细胞病,sickle cell disease,Ayrmid,血液领域,Hematology,phase 1,1,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,CXCR4,CXCR4拮抗剂,approved,5,2023-09-08,I期临床,2022-11-16,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,True,False,False,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,5
泽卢克布仑钠,zilucoplan,重症肌无力,myasthenia gravis,Ra Pharmaceuticals(UCB),免疫领域,Immunology,approved,5,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,C5,C5抑制剂,approved,5,2023-09-25,批准上市,2023-09-25,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,False,True,True,True,False,Ra Pharmaceuticals(UCB)(原研),1
泽卢克布仑钠,zilucoplan,脑膜炎,meningitis,Ra Pharmaceuticals(UCB),神经领域,Neurology,phase 3,3,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,C5,C5抑制剂,approved,5,2023-09-25,III期临床,2025-10-14,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,False,True,False,True,False,Ra Pharmaceuticals(UCB)(原研),1
泽卢克布仑钠,zilucoplan,新型冠状病毒感染,novel coronavirus infection,Ra Pharmaceuticals(UCB),感染领域,Infectious Diseases,phase 3,3,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,C5,C5抑制剂,approved,5,2023-09-25,III期临床,2020-10-19,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,False,True,False,True,False,Ra Pharmaceuticals(UCB)(原研),1
泽卢克布仑钠,zilucoplan,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,Ra Pharmaceuticals(UCB),神经领域,Neurology,phase 3,3,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,C5,C5抑制剂,approved,5,2023-09-25,II/III期临床,2020-03-05,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,False,True,True,True,False,Ra Pharmaceuticals(UCB)(原研),1
泽卢克布仑钠,zilucoplan,狼疮性肾炎,lupus nephritis,Ra Pharmaceuticals(UCB),泌尿生殖领域,Genitourinary,pre-clinical,-1,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,C5,C5抑制剂,approved,5,2023-09-25,临床前,,Active,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,False,True,False,True,False,Ra Pharmaceuticals(UCB)(原研),1
倍维巴肽,bevifibatide,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),百奥泰,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,GPIIb/IIIa,GPIIb/IIIa拮抗剂,approved,5,2024-06-25,批准上市,2024-06-28,Active,创新药,化药,多肽,环肽;差异化疾病,拮抗剂,False,True,False,True,False,百奥泰(原研),1
倍维巴肽,bevifibatide,急性冠脉综合征,acute coronary syndrome,百奥泰,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,GPIIb/IIIa,GPIIb/IIIa拮抗剂,approved,5,2024-06-25,批准上市,2024-06-28,Active,创新药,化药,多肽,环肽;差异化疾病,拮抗剂,False,True,False,True,False,百奥泰(原研),1
倍维巴肽,bevifibatide,心肌梗塞,myocardial infarction,百奥泰,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,GPIIb/IIIa,GPIIb/IIIa拮抗剂,approved,5,2024-06-25,III期临床,2024-11-14,Active,创新药,化药,多肽,环肽;差异化疾病,拮抗剂,False,True,False,True,False,百奥泰(原研),1
倍维巴肽,bevifibatide,不稳定性心绞痛,unstable angina,百奥泰,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,GPIIb/IIIa,GPIIb/IIIa拮抗剂,approved,5,2024-06-25,III期临床,2018-05-02,Active,创新药,化药,多肽,环肽;差异化疾病,拮抗剂,False,True,False,True,False,百奥泰(原研),1
倍维巴肽,bevifibatide,非ST段抬高型心肌梗死,Non-ST segment elevation myocardial infarction,百奥泰,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,GPIIb/IIIa,GPIIb/IIIa拮抗剂,approved,5,2024-06-25,III期临床,2018-05-02,Active,创新药,化药,多肽,环肽;差异化疾病,拮抗剂,False,True,False,True,False,百奥泰(原研),1
倍维巴肽,bevifibatide,缺血性卒中,ischemic stroke,百奥泰,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,GPIIb/IIIa,GPIIb/IIIa拮抗剂,approved,5,2024-06-25,II期临床,2024-12-02,Active,创新药,化药,多肽,环肽;差异化疾病,拮抗剂,False,True,False,True,False,百奥泰(原研),1
倍维巴肽,bevifibatide,血栓闭塞性脉管炎,Thromboangitis obliterans,百奥泰,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,GPIIb/IIIa,GPIIb/IIIa拮抗剂,approved,5,2024-06-25,I期临床,2025-01-22,Active,创新药,化药,多肽,环肽;差异化疾病,拮抗剂,False,True,False,True,False,百奥泰(原研),1
CAM2029,CAM2029 (octreotide),肢端肥大症,acromegaly,Novartis,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,somatostatin,somatostatin类似物,approved,5,2025-06-30,批准上市,2025-06-30,Active,微创新,化药,多肽,环肽,类似物,True,True,True,False,True,Novartis(Top20 MNC);Camurus(原研),2
CAM2029,CAM2029 (octreotide),肢端肥大症,acromegaly,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,somatostatin,somatostatin类似物,approved,5,2025-06-30,批准上市,2025-06-30,Active,微创新,化药,多肽,环肽,类似物,True,True,True,True,False,Novartis(Top20 MNC);Camurus(原研),2
CAM2029,CAM2029 (octreotide),胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Novartis,肿瘤领域,Oncology,phase 3,3,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,somatostatin,somatostatin类似物,approved,5,2025-06-30,III期临床,2021-09-21,Active,微创新,化药,多肽,环肽,类似物,True,True,True,False,True,Novartis(Top20 MNC);Camurus(原研),2
CAM2029,CAM2029 (octreotide),胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Camurus,肿瘤领域,Oncology,phase 3,3,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,somatostatin,somatostatin类似物,approved,5,2025-06-30,III期临床,2021-09-21,Active,微创新,化药,多肽,环肽,类似物,True,True,True,True,False,Novartis(Top20 MNC);Camurus(原研),2
CAM2029,CAM2029 (octreotide),多囊肝病,polycystic liver disease,Novartis,消化领域,Digestive System,phase 3,3,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,somatostatin,somatostatin类似物,approved,5,2025-06-30,II/III期临床,2022-03-16,Active,微创新,化药,多肽,环肽,类似物,True,True,True,False,True,Novartis(Top20 MNC);Camurus(原研),2
CAM2029,CAM2029 (octreotide),多囊肝病,polycystic liver disease,Camurus,消化领域,Digestive System,phase 3,3,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,somatostatin,somatostatin类似物,approved,5,2025-06-30,II/III期临床,2022-03-16,Active,微创新,化药,多肽,环肽,类似物,True,True,True,True,False,Novartis(Top20 MNC);Camurus(原研),2
CAM2029,CAM2029 (octreotide),多囊肾病,polycystic kidney disease,Novartis,泌尿生殖领域,Genitourinary,pre-clinical,-1,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,somatostatin,somatostatin类似物,approved,5,2025-06-30,临床前,,Active,微创新,化药,多肽,环肽,类似物,True,True,True,False,True,Novartis(Top20 MNC);Camurus(原研),2
CAM2029,CAM2029 (octreotide),多囊肾病,polycystic kidney disease,Camurus,泌尿生殖领域,Genitourinary,pre-clinical,-1,CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,somatostatin,somatostatin类似物,approved,5,2025-06-30,临床前,,Active,微创新,化药,多肽,环肽,类似物,True,True,True,True,False,Novartis(Top20 MNC);Camurus(原研),2
Cyporin N,Cyporin N (cyclosporine nanoemulsion),干眼病,dry eye disease,Taejoon Pharm,眼科领域,Ophthalmology,approved,5,Cyporin N;Cyporin N (环孢素纳米乳);Cyporin N (cyclosporine nanoemulsion);TJO-087,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,approved,5,,批准上市,,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,False,True,False,True,False,Taejoon Pharm(原研),1
Octreonax,Octreonax (octreotide injectable microsphere),肢端肥大症,acromegaly,Nanox Release Technology,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,Octreonax;Octreonax(注射用奥曲肽微球);Octreonax (octreotide injectable microsphere),somatostatin,somatostatin类似物,approved,5,,批准上市,,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,True,True,False,Nanox Release Technology(原研),1
Octreonax,Octreonax (octreotide injectable microsphere),巨人症,gigantism,Nanox Release Technology,内分泌及代谢领域,Endocrinology & Metabolism,approved,5,Octreonax;Octreonax(注射用奥曲肽微球);Octreonax (octreotide injectable microsphere),somatostatin,somatostatin类似物,approved,5,,批准上市,,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,False,True,False,Nanox Release Technology(原研),1
伐普肽,vapreotide,食管静脉曲张出血,Esophageal variceal bleeding,Debiopharm,消化领域,Digestive System,approved,5,伐普肽;vapreotide;Sanvar;RC-160,somatostatin,somatostatin类似物,approved,5,,批准上市,,Active,创新药,化药,多肽,环肽,类似物,False,True,False,True,False,Debiopharm(原研),1
夫沙芬净,fusafungin,上呼吸道感染,upper respiratory tract infection,Servier,感染领域,Infectious Diseases,approved,5,夫沙芬净;fusafungin;fusafungine;S-314;Bioparox;Locabiotal,not available,,approved,5,,批准上市,,Active,创新药,化药,小分子,环肽,其他,False,True,False,True,False,Servier(原研),1
普那霉素,pristinamycin,细菌感染,bacterial infection,Rhône-Poulenc(Sanofi),感染领域,Infectious Diseases,approved,5,普那霉素;pristinamycin;Pyostacine;pristinamycine;RP 7293;原始霉素,50S subunit,链阳性菌素类抗生素,approved,5,,批准上市,,Active,创新药,化药,其他,环肽;First-in-Class;差异化疾病,链阳性菌素类抗生素,True,True,False,True,True,Rhône-Poulenc(Sanofi)(Top20 MNC)(原研),1
苯赖加压素,felypressin,局部麻醉,local anesthesia,Sandoz,麻醉镇痛领域,Anesthesia & Analgesia,approved,5,苯赖加压素;felypressin;Octapressin,vasopressin,vasopressin类似物,approved,5,,批准上市,,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Sandoz(原研),1
重组水蛭素,recombinant hirudin,深静脉血栓,deep vein thrombosis,Minapharm,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,hirudin,重组hirudin,approved,5,,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,True,True,False,True,False,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),2
重组水蛭素,recombinant hirudin,深静脉血栓,deep vein thrombosis,Rhein biotech,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,hirudin,重组hirudin,approved,5,,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,True,True,False,True,True,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),2
重组水蛭素,recombinant hirudin,静脉曲张,Varicose veins,Minapharm,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,hirudin,重组hirudin,approved,5,,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,True,True,False,True,False,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),2
重组水蛭素,recombinant hirudin,静脉曲张,Varicose veins,Rhein biotech,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,hirudin,重组hirudin,approved,5,,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,True,True,False,True,True,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),2
重组水蛭素,recombinant hirudin,血栓性静脉炎,thrombophlebitis,Minapharm,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,hirudin,重组hirudin,approved,5,,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,True,True,False,True,False,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),2
重组水蛭素,recombinant hirudin,血栓性静脉炎,thrombophlebitis,Rhein biotech,心脑血管领域,Cardiovascular & Cerebrovascular,approved,5,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,hirudin,重组hirudin,approved,5,,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,True,True,False,True,True,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),2
重组水蛭素,recombinant hirudin,血肿,hematoma,Minapharm,其他领域,Others,approved,5,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,hirudin,重组hirudin,approved,5,,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,True,True,False,True,False,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),2
重组水蛭素,recombinant hirudin,血肿,hematoma,Rhein biotech,其他领域,Others,approved,5,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,hirudin,重组hirudin,approved,5,,批准上市,,Active,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,True,True,False,True,True,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),2
环孢素A眼凝胶,cyclosporine A ophthalmic gel,干眼病,dry eye disease,兆科眼科,眼科领域,Ophthalmology,pre-registration,4,环孢素A眼凝胶;cyclosporine A ophthalmic gel,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,pre-registration,4,2022-06-09,申请上市,2022-06-09,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,兆科眼科(原研),1
那韦培肽,navepegritide,软骨发育不全,Achondroplasia,Teijin,骨骼肌肉领域,Musculoskeletal,pre-registration,4,那韦培肽;navepegritide;TransCon CNP,CNP,CNP类似物,pre-registration,4,2025-03-31,申请上市,2025-03-31,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Teijin;Ascendis Pharma(原研);维昇药业,3
那韦培肽,navepegritide,软骨发育不全,Achondroplasia,Ascendis Pharma,骨骼肌肉领域,Musculoskeletal,pre-registration,4,那韦培肽;navepegritide;TransCon CNP,CNP,CNP类似物,pre-registration,4,2025-03-31,申请上市,2025-03-31,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,True,False,Teijin;Ascendis Pharma(原研);维昇药业,3
那韦培肽,navepegritide,软骨发育不全,Achondroplasia,维昇药业,骨骼肌肉领域,Musculoskeletal,pre-registration,4,那韦培肽;navepegritide;TransCon CNP,CNP,CNP类似物,pre-registration,4,2025-03-31,申请上市,2025-03-31,Active,创新药,化药,多肽,环肽;差异化疾病,类似物,False,True,True,False,False,Teijin;Ascendis Pharma(原研);维昇药业,3
ET-600,ET-600 (desmopressin oral solution),中枢性尿崩症,central diabetes insipidus,Eton Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,pre-registration,4,ET-600;ET-600 (去氨加压素口服溶液);ET-600 (desmopressin oral solution),vasopressin,vasopressin类似物,pre-registration,4,2025-04-28,申请上市,2025-04-28,Active,微创新,化药,多肽,环肽,类似物,False,True,False,True,False,Eton Pharmaceuticals(原研),1
镥[177Lu]依多曲肽,177Lu-edotreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,ITM Isotope,肿瘤领域,Oncology,pre-registration,4,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,申请上市,2025-11-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,远大医药,肿瘤领域,Oncology,pre-registration,4,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,申请上市,2025-11-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Duchembio,肿瘤领域,Oncology,pre-registration,4,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,申请上市,2025-11-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,神经内分泌肿瘤,neuroendocrine tumors,ITM Isotope,肿瘤领域,Oncology,phase 3,3,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,III期临床,2022-05-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,神经内分泌肿瘤,neuroendocrine tumors,远大医药,肿瘤领域,Oncology,phase 3,3,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,III期临床,2022-05-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,神经内分泌肿瘤,neuroendocrine tumors,Duchembio,肿瘤领域,Oncology,phase 3,3,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,III期临床,2022-05-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,嗜铬细胞瘤,Pheochromocytoma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,2019-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,嗜铬细胞瘤,Pheochromocytoma,远大医药,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,2019-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,嗜铬细胞瘤,Pheochromocytoma,Duchembio,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,2019-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,副神经节瘤,paraganglioma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,2020-02-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,副神经节瘤,paraganglioma,远大医药,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,2020-02-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,副神经节瘤,paraganglioma,Duchembio,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,2020-02-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,脑膜瘤,Meningioma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,脑膜瘤,Meningioma,远大医药,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,脑膜瘤,Meningioma,Duchembio,肿瘤领域,Oncology,phase 2,2,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,实体瘤,solid tumors,ITM Isotope,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2025-03-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,实体瘤,solid tumors,远大医药,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2025-03-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,实体瘤,solid tumors,Duchembio,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2025-03-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,脑癌,brain cancer,ITM Isotope,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2024-06-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,脑癌,brain cancer,远大医药,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2024-06-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,脑癌,brain cancer,Duchembio,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2024-06-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,淋巴瘤,Lymphoma,ITM Isotope,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2024-06-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,淋巴瘤,Lymphoma,远大医药,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2024-06-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,淋巴瘤,Lymphoma,Duchembio,肿瘤领域,Oncology,phase 1,1,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,I期临床,2024-06-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,ITM Isotope,肿瘤领域,Oncology,ind,0,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,申报临床,2024-09-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,远大医药,肿瘤领域,Oncology,ind,0,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,申报临床,2024-09-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
镥[177Lu]依多曲肽,177Lu-edotreotide,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,Duchembio,肿瘤领域,Oncology,ind,0,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,pre-registration,4,2025-11-13,申报临床,2024-09-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,ITM Isotope(原研);远大医药;Duchembio,3
LV-101,LV-101 (intranasal carbetocin),Prader-Willi综合征,Prader-Willi syndrome,Ferring Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,pre-registration,4,LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101,oxytocin,oxytocin类似物,pre-registration,4,,申请上市,,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,True,True,False,Ferring Pharmaceuticals(原研);Levo Therapeutics(Acadia Pharmaceuticals),2
LV-101,LV-101 (intranasal carbetocin),Prader-Willi综合征,Prader-Willi syndrome,Levo Therapeutics(Acadia Pharmaceuticals),内分泌及代谢领域,Endocrinology & Metabolism,pre-registration,4,LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101,oxytocin,oxytocin类似物,pre-registration,4,,申请上市,,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,True,False,False,Ferring Pharmaceuticals(原研);Levo Therapeutics(Acadia Pharmaceuticals),2
LV-101,LV-101 (intranasal carbetocin),多食症,polyphagia,Ferring Pharmaceuticals,精神领域,Psychiatry,phase 3,3,LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101,oxytocin,oxytocin类似物,pre-registration,4,,III期临床,2024-05-20,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,False,True,False,Ferring Pharmaceuticals(原研);Levo Therapeutics(Acadia Pharmaceuticals),2
LV-101,LV-101 (intranasal carbetocin),多食症,polyphagia,Levo Therapeutics(Acadia Pharmaceuticals),精神领域,Psychiatry,phase 3,3,LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101,oxytocin,oxytocin类似物,pre-registration,4,,III期临床,2024-05-20,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,False,False,False,Ferring Pharmaceuticals(原研);Levo Therapeutics(Acadia Pharmaceuticals),2
CMS I-neb,CMS I-neb (colistimethate sodium powder for nebulization),支气管扩张,bronchiectasis,Zambon,呼吸领域,Respiratory,phase 3,3,CMS I-neb;CMS I-neb (多粘菌素E甲磺酸钠雾化剂);CMS I-neb (colistimethate sodium powder for nebulization);Promixin,not available,多粘菌素类抗生素,phase 3,3,2017-02-10,III期临床,2017-02-10,Active,微创新,化药,其他,环肽,多粘菌素类抗生素,False,True,False,True,False,Zambon(原研),1
莫瑞伐定,murepavadin,囊性纤维化,cystic fibrosis,Polyphor(Spexis),呼吸领域,Respiratory,ind,0,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877,LptD,抗生素,phase 3,3,2018-01-24,申报临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抗生素,True,True,True,True,False,Polyphor(Spexis)(原研);Roche(Top20 MNC)(无权益),2
莫瑞伐定,murepavadin,囊性纤维化,cystic fibrosis,Roche,呼吸领域,Respiratory,ind,0,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877,LptD,抗生素,phase 3,3,2018-01-24,申报临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抗生素,True,True,True,False,True,Polyphor(Spexis)(原研);Roche(Top20 MNC)(无权益),2
Liposomal cyclosporine A,Liposomal cyclosporine A,闭塞性细支气管炎,bronchiolitis obliterans,Breath Therapeutics(Zambon),呼吸领域,Respiratory,phase 3,3,Liposomal cyclosporine A;环孢素A脂质体 (Breath Therapeutics);L-CsA-i,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,phase 3,3,2018-09-04,III期临床,2018-09-04,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,True,True,False,Breath Therapeutics(Zambon)(原研),1
巴利福肽,balixafortide,乳腺癌,breast cancer,复星医药,肿瘤领域,Oncology,phase 3,3,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,III期临床,2018-12-24,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,乳腺癌,breast cancer,Polyphor(Spexis),肿瘤领域,Oncology,phase 3,3,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,III期临床,2018-12-24,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,乳腺癌,breast cancer,University of Zurich,肿瘤领域,Oncology,phase 3,3,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,III期临床,2018-12-24,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,心肌梗塞,myocardial infarction,复星医药,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,心肌梗塞,myocardial infarction,Polyphor(Spexis),心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,心肌梗塞,myocardial infarction,University of Zurich,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,胰腺导管癌,pancreatic ductal carcinoma,复星医药,肿瘤领域,Oncology,phase 1,1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,I期临床,2025-05-21,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,胰腺导管癌,pancreatic ductal carcinoma,Polyphor(Spexis),肿瘤领域,Oncology,phase 1,1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,I期临床,2025-05-21,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,胰腺导管癌,pancreatic ductal carcinoma,University of Zurich,肿瘤领域,Oncology,phase 1,1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,I期临床,2025-05-21,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,B细胞淋巴瘤,B cell lymphoma,复星医药,肿瘤领域,Oncology,pre-clinical,-1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,B细胞淋巴瘤,B cell lymphoma,Polyphor(Spexis),肿瘤领域,Oncology,pre-clinical,-1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,B细胞淋巴瘤,B cell lymphoma,University of Zurich,肿瘤领域,Oncology,pre-clinical,-1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,新型冠状病毒感染,novel coronavirus infection,复星医药,感染领域,Infectious Diseases,pre-clinical,-1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,False,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,新型冠状病毒感染,novel coronavirus infection,Polyphor(Spexis),感染领域,Infectious Diseases,pre-clinical,-1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
巴利福肽,balixafortide,新型冠状病毒感染,novel coronavirus infection,University of Zurich,感染领域,Infectious Diseases,pre-clinical,-1,巴利福肽;balixafortide;POL6326;SPX6326,CXCR4,CXCR4拮抗剂,phase 3,3,2018-12-24,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,False,True,False,True,False,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),3
TNX-2900,TNX-2900 (intranasal potentiated oxytocin),Prader-Willi综合征,Prader-Willi syndrome,Tonix Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin),oxytocin,合成的oxytocin,phase 3,3,2020-02-25,III期临床,2020-02-25,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,True,True,False,Tonix Pharmaceuticals(原研);Institut National de la Sante et de la Recherche Medicale (INSERM),2
TNX-2900,TNX-2900 (intranasal potentiated oxytocin),Prader-Willi综合征,Prader-Willi syndrome,Institut National de la Sante et de la Recherche Medicale (INSERM),内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin),oxytocin,合成的oxytocin,phase 3,3,2020-02-25,III期临床,2020-02-25,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,True,False,False,Tonix Pharmaceuticals(原研);Institut National de la Sante et de la Recherche Medicale (INSERM),2
氟[18F]阿法肽,alfatide F-18,非小细胞肺癌,non-small cell lung cancer,东诚药业,肿瘤领域,Oncology,phase 3,3,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,phase 3,3,2020-08-06,III期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,False,False,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),4
氟[18F]阿法肽,alfatide F-18,非小细胞肺癌,non-small cell lung cancer,National Institute of Biomedical Imaging and Bioengineering,肿瘤领域,Oncology,phase 3,3,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,phase 3,3,2020-08-06,III期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,False,False,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),4
氟[18F]阿法肽,alfatide F-18,非小细胞肺癌,non-small cell lung cancer,施美康,肿瘤领域,Oncology,phase 3,3,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,phase 3,3,2020-08-06,III期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,False,False,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),4
氟[18F]阿法肽,alfatide F-18,非小细胞肺癌,non-small cell lung cancer,厦门大学,肿瘤领域,Oncology,phase 3,3,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,phase 3,3,2020-08-06,III期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),4
氟[18F]阿法肽,alfatide F-18,PET显像,PET imaging,东诚药业,诊断试剂领域,Diagnostic Reagents,phase 3,3,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,phase 3,3,2020-08-06,III期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,False,False,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),4
氟[18F]阿法肽,alfatide F-18,PET显像,PET imaging,National Institute of Biomedical Imaging and Bioengineering,诊断试剂领域,Diagnostic Reagents,phase 3,3,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,phase 3,3,2020-08-06,III期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,False,False,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),4
氟[18F]阿法肽,alfatide F-18,PET显像,PET imaging,施美康,诊断试剂领域,Diagnostic Reagents,phase 3,3,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,phase 3,3,2020-08-06,III期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,False,False,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),4
氟[18F]阿法肽,alfatide F-18,PET显像,PET imaging,厦门大学,诊断试剂领域,Diagnostic Reagents,phase 3,3,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,phase 3,3,2020-08-06,III期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),4
PL-8331,PL-8331,干眼病,dry eye disease,Palatin Technologies,眼科领域,Ophthalmology,phase 3,3,PL-8331;PL-9643;PL9643;PL8331,MC1R;MC5R,MC5R激动剂;MC1R激动剂,phase 3,3,2022-01-21,III期临床,2022-01-21,Active,创新药,其他,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,False,True,False,True,False,Palatin Technologies(原研),1
PL-8331,PL-8331,葡萄膜炎,uveitis,Palatin Technologies,眼科领域,Ophthalmology,pre-clinical,-1,PL-8331;PL-9643;PL9643;PL8331,MC1R;MC5R,MC5R激动剂;MC1R激动剂,phase 3,3,2022-01-21,临床前,,Active,创新药,其他,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,False,True,False,True,False,Palatin Technologies(原研),1
PL-8331,PL-8331,糖尿病视网膜病变,diabetic retinopathy,Palatin Technologies,眼科领域,Ophthalmology,pre-clinical,-1,PL-8331;PL-9643;PL9643;PL8331,MC1R;MC5R,MC5R激动剂;MC1R激动剂,phase 3,3,2022-01-21,临床前,,Active,创新药,其他,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,False,True,False,True,False,Palatin Technologies(原研),1
rusfertide,rusfertide,真性红细胞增多症,polycythemia vera,Takeda Pharmaceuticals,肿瘤领域,Oncology,phase 3,3,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,Hepc,合成的Hepc,phase 3,3,2022-01-27,III期临床,2022-01-27,Active,创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,True,True,True,False,True,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),2
rusfertide,rusfertide,真性红细胞增多症,polycythemia vera,Protagonist Therapeutics,肿瘤领域,Oncology,phase 3,3,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,Hepc,合成的Hepc,phase 3,3,2022-01-27,III期临床,2022-01-27,Active,创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,True,True,True,True,False,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),2
rusfertide,rusfertide,铁负荷过载,iron load overload,Takeda Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,Hepc,合成的Hepc,phase 3,3,2022-01-27,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,True,True,True,False,True,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),2
rusfertide,rusfertide,铁负荷过载,iron load overload,Protagonist Therapeutics,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,Hepc,合成的Hepc,phase 3,3,2022-01-27,II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,True,True,True,True,False,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),2
rusfertide,rusfertide,遗传性血色素沉着病,hereditary hemochromatosis,Takeda Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,Hepc,合成的Hepc,phase 3,3,2022-01-27,II期临床,2019-12-18,Active,创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,True,True,True,False,True,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),2
rusfertide,rusfertide,遗传性血色素沉着病,hereditary hemochromatosis,Protagonist Therapeutics,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,Hepc,合成的Hepc,phase 3,3,2022-01-27,II期临床,2019-12-18,Active,创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,True,True,True,True,False,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),2
RYZ101,RYZ101,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 3,3,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 3,3,2022-07-28,III期临床,2022-07-28,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,True,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
RYZ101,RYZ101,HR阳性乳腺癌,HR positive breast cancer,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 2,2,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 3,3,2022-07-28,I/II期临床,2024-09-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
RYZ101,RYZ101,脑膜瘤,Meningioma,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 2,2,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 3,3,2022-07-28,I/II期临床,2025-09-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
RYZ101,RYZ101,小细胞肺癌,small cell lung cancer,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 1,1,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 3,3,2022-07-28,I期临床,2022-10-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,True,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
RYZ101,RYZ101,多发性骨髓瘤,multiple myeloma,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 1,1,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 3,3,2022-07-28,I期临床,2024-05-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,True,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
[68Ga]CBP8,[68Ga]CBP8,PET显像,PET imaging,Massachusetts General Hospital,诊断试剂领域,Diagnostic Reagents,phase 3,3,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,III期临床,2022-11-16,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研),1
[68Ga]CBP8,[68Ga]CBP8,心脏淀粉样变性,cardiac amyloidosis,Massachusetts General Hospital,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,III期临床,2022-11-16,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,Massachusetts General Hospital(原研),1
[68Ga]CBP8,[68Ga]CBP8,肺癌,lung cancer,Massachusetts General Hospital,肿瘤领域,Oncology,phase 2,2,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研),1
[68Ga]CBP8,[68Ga]CBP8,特发性肺纤维化,idiopathic pulmonary fibrosis,Massachusetts General Hospital,呼吸领域,Respiratory,phase 2,2,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,Massachusetts General Hospital(原研),1
[68Ga]CBP8,[68Ga]CBP8,间质性肺病,interstitial lung disease,Massachusetts General Hospital,呼吸领域,Respiratory,phase 2,2,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,II期临床,2022-06-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研),1
[68Ga]CBP8,[68Ga]CBP8,进展性肺纤维化,progressive pulmonary fibrosis,Massachusetts General Hospital,呼吸领域,Respiratory,phase 2,2,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,II期临床,2024-08-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,Massachusetts General Hospital(原研),1
[68Ga]CBP8,[68Ga]CBP8,原发性硬化性胆管炎,primary sclerosing cholangitis,Massachusetts General Hospital,消化领域,Digestive System,phase 1,1,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,I期临床,2024-02-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,Massachusetts General Hospital(原研),1
[68Ga]CBP8,[68Ga]CBP8,克罗恩病,Crohn's disease,Massachusetts General Hospital,消化领域,Digestive System,phase 1,1,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,I期临床,2024-02-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研),1
[68Ga]CBP8,[68Ga]CBP8,子宫内膜异位,endometriosis,Massachusetts General Hospital,泌尿生殖领域,Genitourinary,phase 1,1,[68Ga]CBP8;68Ga-CBP8,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,phase 3,3,2022-11-16,I期临床,2024-04-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研),1
solnatide,solnatide,慢性肾病高磷血症,Chronic kidney disease hyperphosphatemia,Apeptico,泌尿生殖领域,Genitourinary,phase 3,3,solnatide;AP301;AP-301;TIP-peptide,ENaC,ENaC激活剂,phase 3,3,2023-06-30,III期临床,2023-06-30,Active,创新药,化药,多肽,环肽;Potential First-in-Class,激活剂,False,True,False,True,False,Apeptico(原研),1
enlicitide,enlicitide,血脂异常,dyslipidemia,Merck & Co.,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,PCSK9,PCSK9抑制剂,phase 3,3,2023-07-19,III期临床,2025-11-19,Active,创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
enlicitide,enlicitide,高胆固醇血症,hypercholesterolemia,Merck & Co.,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,PCSK9,PCSK9抑制剂,phase 3,3,2023-07-19,III期临床,2023-08-25,Active,创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
enlicitide,enlicitide,家族性高胆固醇血症,familial hypercholesterolemia,Merck & Co.,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,PCSK9,PCSK9抑制剂,phase 3,3,2023-07-19,III期临床,2023-07-19,Active,创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
enlicitide,enlicitide,心血管风险,cardiovascular risk,Merck & Co.,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,PCSK9,PCSK9抑制剂,phase 3,3,2023-07-19,III期临床,2023-08-24,Active,创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
enlicitide,enlicitide,杂合子型家族性高胆固醇血症,Heterozygous familial hypercholesterolemia,Merck & Co.,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,PCSK9,PCSK9抑制剂,phase 3,3,2023-07-19,III期临床,2023-07-19,Active,创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
enlicitide,enlicitide,动脉粥样硬化性心血管疾病,atherosclerotic cardiovascular disease,Merck & Co.,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,PCSK9,PCSK9抑制剂,phase 3,3,2023-07-19,III期临床,2023-11-06,Active,创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
68Ga-pentixafor,68Ga-pentixafor,PET显像,PET imaging,PentixaPharm,诊断试剂领域,Diagnostic Reagents,phase 3,3,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,III期临床,2023-11-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,PET显像,PET imaging,Scintomics,诊断试剂领域,Diagnostic Reagents,phase 3,3,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,III期临床,2023-11-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,边缘区淋巴瘤,marginal zone lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 3,3,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,III期临床,2023-11-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,边缘区淋巴瘤,marginal zone lymphoma,Scintomics,肿瘤领域,Oncology,phase 3,3,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,III期临床,2023-11-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,肾上腺疾病,Adrenal gland disease,PentixaPharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II/III期临床,2021-04-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,肾上腺疾病,Adrenal gland disease,Scintomics,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II/III期临床,2021-04-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,醛固酮过多症,Hyperaldosteronism,PentixaPharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II/III期临床,2024-03-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,醛固酮过多症,Hyperaldosteronism,Scintomics,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II/III期临床,2024-03-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,多发性骨髓瘤,multiple myeloma,PentixaPharm,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,2020-09-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,多发性骨髓瘤,multiple myeloma,Scintomics,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,2020-09-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,库欣综合征,Cushing's syndrome,PentixaPharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,2024-02-07,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,库欣综合征,Cushing's syndrome,Scintomics,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,2024-02-07,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,B细胞淋巴瘤,B cell lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,2024-06-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,B细胞淋巴瘤,B cell lymphoma,Scintomics,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,2024-06-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,心脏移植排斥,heart transplant rejection,PentixaPharm,免疫领域,Immunology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,心脏移植排斥,heart transplant rejection,Scintomics,免疫领域,Immunology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,惰性非霍奇金淋巴瘤,indolent non-Hodgkin lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,2024-06-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,惰性非霍奇金淋巴瘤,indolent non-Hodgkin lymphoma,Scintomics,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,2024-06-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,中枢神经系统淋巴瘤,central nervous system lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,中枢神经系统淋巴瘤,central nervous system lymphoma,Scintomics,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,心脏结节病,cardiac sarcoidosis,PentixaPharm,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,心脏结节病,cardiac sarcoidosis,Scintomics,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,免疫检查点抑制剂引起的心肌炎,Myocarditis caused by immune checkpoint inhibitors,PentixaPharm,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,免疫检查点抑制剂引起的心肌炎,Myocarditis caused by immune checkpoint inhibitors,Scintomics,肿瘤领域,Oncology,phase 2,2,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,小细胞肺癌,small cell lung cancer,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-06-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,小细胞肺癌,small cell lung cancer,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-06-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,三阴性乳腺癌,triple negative breast cancer,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-05-08,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,三阴性乳腺癌,triple negative breast cancer,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-05-08,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,分化型甲状腺癌,differentiated thyroid cancer,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2024-05-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,分化型甲状腺癌,differentiated thyroid cancer,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2024-05-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,非霍奇金淋巴瘤,non-hodgkin lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2021-10-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,非霍奇金淋巴瘤,non-hodgkin lymphoma,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2021-10-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,高血压,hypertension,PentixaPharm,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-06-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,高血压,hypertension,Scintomics,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-06-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,神经内分泌肿瘤,neuroendocrine tumors,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2017-11-08,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,神经内分泌肿瘤,neuroendocrine tumors,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2017-11-08,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,肾上腺皮质癌,adrenocortical carcinoma,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-09-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,肾上腺皮质癌,adrenocortical carcinoma,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-09-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,小淋巴细胞性淋巴瘤,small lymphocytic lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2024-03-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,小淋巴细胞性淋巴瘤,small lymphocytic lymphoma,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2024-03-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,Erdheim-Chester病,Erdheim-Chester disease,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,Erdheim-Chester病,Erdheim-Chester disease,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,胸腺瘤,thymoma,PentixaPharm,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2023-10-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,胸腺瘤,thymoma,Scintomics,肿瘤领域,Oncology,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2023-10-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,假性醛固酮减少症,pseudohypoaldosteronism,PentixaPharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-01-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,假性醛固酮减少症,pseudohypoaldosteronism,Scintomics,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2025-01-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,罗道病,Rhododendron,PentixaPharm,,,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,罗道病,Rhododendron,Scintomics,,,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,自主皮质醇分泌,Autonomous cortisol secretion,PentixaPharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2024-10-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,PentixaPharm;Scintomics(原研),2
68Ga-pentixafor,68Ga-pentixafor,自主皮质醇分泌,Autonomous cortisol secretion,Scintomics,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,phase 3,3,2023-11-09,I期临床,2024-10-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,PentixaPharm;Scintomics(原研),2
emodepside,emodepside,蛔虫病,Ascariasis,Bayer,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,蛔虫病,Ascariasis,Astellas Pharma,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,True,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,蛔虫病,Ascariasis,DNDi,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,False,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,钩虫病,hookworm disease,Bayer,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,钩虫病,hookworm disease,Astellas Pharma,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,True,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,钩虫病,hookworm disease,DNDi,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,False,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,鞭虫病,Trichuris,Bayer,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,鞭虫病,Trichuris,Astellas Pharma,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,True,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,鞭虫病,Trichuris,DNDi,感染领域,Infectious Diseases,phase 3,3,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,III期临床,2024-12-17,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,False,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,类圆线虫病,strongyloidiasis,Bayer,感染领域,Infectious Diseases,phase 2,2,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,II期临床,2024-04-18,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,类圆线虫病,strongyloidiasis,Astellas Pharma,感染领域,Infectious Diseases,phase 2,2,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,II期临床,2024-04-18,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,True,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,类圆线虫病,strongyloidiasis,DNDi,感染领域,Infectious Diseases,phase 2,2,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,II期临床,2024-04-18,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,False,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,盘尾丝虫病,onchocerciasis,Bayer,感染领域,Infectious Diseases,phase 2,2,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,II期临床,2022-01-06,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,盘尾丝虫病,onchocerciasis,Astellas Pharma,感染领域,Infectious Diseases,phase 2,2,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,II期临床,2022-01-06,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,True,True,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
emodepside,emodepside,盘尾丝虫病,onchocerciasis,DNDi,感染领域,Infectious Diseases,phase 2,2,emodepside;BAY 44-4400,not available,,phase 3,3,2024-12-17,II期临床,2022-01-06,Active,创新药,化药,小分子,环肽;中国无申报,其他,True,True,False,False,False,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,3
脑利钠肽,nesiritide biosimilar,急性心力衰竭,acute heart failure,沃泰生物,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,脑利钠肽;重组人脑利钠肽(沃泰生物);nesiritide biosimilar,BNP,重组BNP,phase 3,3,2025-04-03,III期临床,2025-04-03,Active,生物类似药,生物,多肽,环肽,重组,False,True,False,True,False,沃泰生物(原研),1
Debio 4126,Debio 4126 (12-week prolonged-release octreotide),肢端肥大症,acromegaly,Debiopharm,内分泌及代谢领域,Endocrinology & Metabolism,phase 3,3,Debio 4126;Debio 4126 (12周缓释奥曲肽);Debio 4126 (12-week prolonged-release octreotide),somatostatin,somatostatin类似物,phase 3,3,2025-04-16,III期临床,2025-04-16,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,Debiopharm(原研),1
Debio 4126,Debio 4126 (12-week prolonged-release octreotide),胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Debiopharm,肿瘤领域,Oncology,phase 2,2,Debio 4126;Debio 4126 (12周缓释奥曲肽);Debio 4126 (12-week prolonged-release octreotide),somatostatin,somatostatin类似物,phase 3,3,2025-04-16,II期临床,,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,Debiopharm(原研),1
SYHX2008,SYHX2008 (long-acting octreotide),神经内分泌肿瘤,neuroendocrine tumors,石药集团,肿瘤领域,Oncology,phase 3,3,SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),somatostatin,somatostatin类似物,phase 3,3,2025-10-10,III期临床,2025-11-12,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,石药集团(原研),1
SYHX2008,SYHX2008 (long-acting octreotide),胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,石药集团,肿瘤领域,Oncology,phase 3,3,SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),somatostatin,somatostatin类似物,phase 3,3,2025-10-10,II/III期临床,2025-09-10,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,石药集团(原研),1
SYHX2008,SYHX2008 (long-acting octreotide),肢端肥大症,acromegaly,石药集团,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),somatostatin,somatostatin类似物,phase 3,3,2025-10-10,II期临床,2024-01-30,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,石药集团(原研),1
SYHX2008,SYHX2008 (long-acting octreotide),胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,石药集团,肿瘤领域,Oncology,phase 2,2,SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),somatostatin,somatostatin类似物,phase 3,3,2025-10-10,II期临床,2024-07-17,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,石药集团(原研),1
PNT2003,PNT2003,神经内分泌肿瘤,neuroendocrine tumors,Lantheus,肿瘤领域,Oncology,phase 3,3,PNT2003;177Lu-PNT2003,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 3,3,,III期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,True,False,False,Lantheus;POINT Biopharma(Eli Lilly)(Top20 MNC)(原研),2
PNT2003,PNT2003,神经内分泌肿瘤,neuroendocrine tumors,POINT Biopharma(Eli Lilly),肿瘤领域,Oncology,phase 3,3,PNT2003;177Lu-PNT2003,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 3,3,,III期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,True,True,True,Lantheus;POINT Biopharma(Eli Lilly)(Top20 MNC)(原研),2
68Ga-DOTA-NOC,68Ga-DOTA-NOC,神经母细胞瘤,Neuroblastoma,,肿瘤领域,Oncology,phase 1,1,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 3,3,2016-07-06,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,--,0
68Ga-DOTA-NOC,68Ga-DOTA-NOC,抑郁症,depression,,精神领域,Psychiatry,phase 1,1,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 3,3,2016-07-06,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,--,0
68Ga-DOTA-NOC,68Ga-DOTA-NOC,不孕不育,Infertility,,泌尿生殖领域,Genitourinary,phase 1,1,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 3,3,2016-07-06,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,--,0
68Ga-DOTA-NOC,68Ga-DOTA-NOC,嗜铬细胞瘤,Pheochromocytoma,,肿瘤领域,Oncology,phase 1,1,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 3,3,2016-07-06,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,--,0
68Ga-DOTA-NOC,68Ga-DOTA-NOC,骨转移疼痛,bone metastasis pain,,肿瘤领域,Oncology,phase 1,1,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 3,3,2016-07-06,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,--,0
68Ga-DOTA-NOC,68Ga-DOTA-NOC,副神经节瘤,paraganglioma,,肿瘤领域,Oncology,phase 1,1,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 3,3,2016-07-06,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,--,0
VT1021,VT1021,实体瘤,solid tumors,Vigeo Therapeutics,肿瘤领域,Oncology,phase 2,2,VT1021,THBS1,THBS1诱导剂,phase 3,3,2019-05-31,I/II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,诱导剂,False,True,False,True,False,Vigeo Therapeutics(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,PET显像,PET imaging,中南大学湘雅医院,诊断试剂领域,Diagnostic Reagents,phase 3,3,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II/III期临床,2020-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,神经内分泌肿瘤,neuroendocrine tumors,中南大学湘雅医院,肿瘤领域,Oncology,phase 3,3,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II/III期临床,2020-09-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,心肌梗塞,myocardial infarction,中南大学湘雅医院,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II期临床,2025-08-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,动脉粥样硬化,atherosclerosis,中南大学湘雅医院,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II期临床,2024-11-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,卒中,Stroke,中南大学湘雅医院,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II期临床,2025-08-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,心脏停搏,cardiac arrest,中南大学湘雅医院,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II期临床,2025-08-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,不稳定性心绞痛,unstable angina,中南大学湘雅医院,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II期临床,2025-08-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,颈动脉疾病,carotid artery disease,中南大学湘雅医院,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II期临床,2024-11-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,颈动脉狭窄,Carotid artery stenosis,中南大学湘雅医院,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,II期临床,2025-08-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,神经母细胞瘤,Neuroblastoma,中南大学湘雅医院,肿瘤领域,Oncology,phase 1,1,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,抑郁症,depression,中南大学湘雅医院,精神领域,Psychiatry,phase 1,1,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,不孕不育,Infertility,中南大学湘雅医院,泌尿生殖领域,Genitourinary,phase 1,1,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,嗜铬细胞瘤,Pheochromocytoma,中南大学湘雅医院,肿瘤领域,Oncology,phase 1,1,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,骨转移疼痛,bone metastasis pain,中南大学湘雅医院,肿瘤领域,Oncology,phase 1,1,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,副神经节瘤,paraganglioma,中南大学湘雅医院,肿瘤领域,Oncology,phase 1,1,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 3,3,2020-09-17,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,中南大学湘雅医院(原研),1
18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI,癌症,cancer,北京大学,肿瘤领域,Oncology,phase 3,3,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,FAP,18F标记的PET药物,phase 3,3,2023-03-01,II/III期临床,2023-03-01,Active,创新药,化药,放射性药物;其他,环肽;诊断用放射性药物,18F标记的PET药物,False,True,False,True,False,北京大学(原研),1
18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI,PET显像,PET imaging,北京大学,诊断试剂领域,Diagnostic Reagents,phase 3,3,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,FAP,18F标记的PET药物,phase 3,3,2023-03-01,II/III期临床,2023-03-01,Active,创新药,化药,放射性药物;其他,环肽;诊断用放射性药物,18F标记的PET药物,False,True,False,True,False,北京大学(原研),1
18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI,胃癌,stomach cancer,北京大学,肿瘤领域,Oncology,phase 1,1,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,FAP,18F标记的PET药物,phase 3,3,2023-03-01,I期临床,2022-06-24,Active,创新药,化药,放射性药物;其他,环肽;诊断用放射性药物,18F标记的PET药物,False,True,False,True,False,北京大学(原研),1
zelenectide pevedotin,zelenectide pevedotin,尿路上皮癌,urothelial carcinoma,Bicycle Therapeutics,肿瘤领域,Oncology,phase 3,3,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,II/III期临床,2024-01-26,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,HR阳性乳腺癌,HR positive breast cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,II期临床,2025-02-21,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,三阴性乳腺癌,triple negative breast cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,II期临床,2025-02-21,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,鳞状非小细胞肺癌,Squamous non-small cell lung cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,II期临床,2025-04-18,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,非鳞状非小细胞肺癌,non-squamous non-small cell lung cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,II期临床,2025-04-18,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,癌症,cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,I/II期临床,2024-05-28,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,非小细胞肺癌,non-small cell lung cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,I/II期临床,2020-09-23,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,胃癌,stomach cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,I/II期临床,,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,食管癌,Esophageal cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,I/II期临床,,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,胰腺癌,pancreatic cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,I/II期临床,,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,True,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,卵巢癌,ovarian cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,I/II期临床,2020-09-23,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,True,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,膀胱癌,bladder cancer,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,I/II期临床,2020-09-23,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
zelenectide pevedotin,zelenectide pevedotin,实体瘤,solid tumors,Bicycle Therapeutics,肿瘤领域,Oncology,phase 1,1,zelenectide pevedotin;BT8009,nectin-4,多肽偶联药物,phase 3,3,2024-01-26,I期临床,2024-07-26,Active,创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
脑利钠肽,nesiritide biosimilar,急性失代偿性心力衰竭,acute decompensated heart failure,步长制药,心脑血管领域,Cardiovascular & Cerebrovascular,phase 3,3,脑利钠肽;BC003 (重组人脑利钠肽);nesiritide biosimilar,BNP,重组BNP,phase 3,3,2025-03-04,II/III期临床,2025-03-04,Active,生物类似药,生物,多肽,环肽,重组,False,True,False,True,False,步长制药(原研),1
Tc99m-maraciclatide,Tc99m-maraciclatide,间质性肺病,interstitial lung disease,GE Healthcare,呼吸领域,Respiratory,phase 2,2,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,phase 2,2,2004-11-10,II期临床,2024-09-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,GE Healthcare(原研),1
Tc99m-maraciclatide,Tc99m-maraciclatide,类风湿性关节炎,rheumatoid arthritis,GE Healthcare,免疫领域,Immunology,phase 1,1,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,phase 2,2,2004-11-10,I期临床,2023-08-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,GE Healthcare(原研),1
Tc99m-maraciclatide,Tc99m-maraciclatide,子宫内膜异位,endometriosis,GE Healthcare,泌尿生殖领域,Genitourinary,pre-clinical,-1,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,phase 2,2,2004-11-10,临床前,2024-07-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,GE Healthcare(原研),1
TI-001,TI-001,肥胖,obesity,Tonix Pharmaceuticals,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2022-12-23,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,肥胖,obesity,University of Geneva,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2022-12-23,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,肥胖,obesity,Trigemina,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2022-12-23,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,True,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,社交恐惧症,social phobia,Tonix Pharmaceuticals,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,社交恐惧症,social phobia,University of Geneva,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,社交恐惧症,social phobia,Trigemina,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,True,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,自闭症,autism,Tonix Pharmaceuticals,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2024-03-21,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,自闭症,autism,University of Geneva,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2024-03-21,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,自闭症,autism,Trigemina,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2024-03-21,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,True,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,暴食症,Bulimia,Tonix Pharmaceuticals,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2022-12-23,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,暴食症,Bulimia,University of Geneva,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2022-12-23,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,暴食症,Bulimia,Trigemina,精神领域,Psychiatry,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2022-12-23,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,True,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,偏头痛,Migraine,Tonix Pharmaceuticals,麻醉镇痛领域,Anesthesia & Analgesia,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2013-04-24,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,偏头痛,Migraine,University of Geneva,麻醉镇痛领域,Anesthesia & Analgesia,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2013-04-24,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,偏头痛,Migraine,Trigemina,麻醉镇痛领域,Anesthesia & Analgesia,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2013-04-24,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,True,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,骨密度低,low bone density,Tonix Pharmaceuticals,骨骼肌肉领域,Musculoskeletal,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2023-11-13,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,骨密度低,low bone density,University of Geneva,骨骼肌肉领域,Musculoskeletal,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2023-11-13,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,骨密度低,low bone density,Trigemina,骨骼肌肉领域,Musculoskeletal,phase 2,2,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,II期临床,2023-11-13,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,True,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,面部神经痛,Facial neuralgia,Tonix Pharmaceuticals,神经领域,Neurology,pre-clinical,-1,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,临床前,,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,面部神经痛,Facial neuralgia,University of Geneva,神经领域,Neurology,pre-clinical,-1,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,临床前,,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,False,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
TI-001,TI-001,面部神经痛,Facial neuralgia,Trigemina,神经领域,Neurology,pre-clinical,-1,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,oxytocin,合成的oxytocin,phase 2,2,2013-04-24,临床前,,Active,微创新,化药,多肽,环肽;中国无申报,合成的,False,True,False,True,False,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),3
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,小细胞肺癌,small cell lung cancer,Ariceum Therapeutics,肿瘤领域,Oncology,phase 2,2,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-07-18,II期临床,2023-05-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,True,False,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,小细胞肺癌,small cell lung cancer,Ipsen,肿瘤领域,Oncology,phase 2,2,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-07-18,II期临床,2023-05-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,True,True,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,PET显像,PET imaging,Ariceum Therapeutics,诊断试剂领域,Diagnostic Reagents,phase 2,2,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-07-18,II期临床,2017-07-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,PET显像,PET imaging,Ipsen,诊断试剂领域,Diagnostic Reagents,phase 2,2,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-07-18,II期临床,2017-07-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,神经内分泌肿瘤,neuroendocrine tumors,Ariceum Therapeutics,肿瘤领域,Oncology,phase 2,2,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-07-18,II期临床,2020-07-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,True,False,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,神经内分泌肿瘤,neuroendocrine tumors,Ipsen,肿瘤领域,Oncology,phase 2,2,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-07-18,II期临床,2020-07-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,True,True,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,肺神经内分泌肿瘤,Pulmonary neuroendocrine tumors,Ariceum Therapeutics,肿瘤领域,Oncology,phase 2,2,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-07-18,II期临床,2023-05-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,True,False,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,肺神经内分泌肿瘤,Pulmonary neuroendocrine tumors,Ipsen,肿瘤领域,Oncology,phase 2,2,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-07-18,II期临床,2023-05-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,True,True,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2,PET显像,PET imaging,Rigshospitalet,诊断试剂领域,Diagnostic Reagents,phase 2,2,68Ga-NODAGA-E[c(RGDyK)]2,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,phase 2,2,2017-09-05,II期临床,2017-09-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Rigshospitalet(原研),1
[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE,PET显像,PET imaging,University of Alberta,诊断试剂领域,Diagnostic Reagents,phase 2,2,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 2,2,2019-01-23,II期临床,2019-01-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,University of Alberta(原研),1
[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE,神经内分泌肿瘤,neuroendocrine tumors,University of Alberta,肿瘤领域,Oncology,phase 2,2,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 2,2,2019-01-23,II期临床,2021-05-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,University of Alberta(原研),1
cRGD-ZW800-1 ,cRGD-ZW800-1 ,胰腺癌,pancreatic cancer,Leiden University,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2022-08-26,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,True,False,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,胰腺癌,pancreatic cancer,Curadel,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2022-08-26,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,True,True,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,光学成像剂,optical imaging agent,Leiden University,诊断试剂领域,Diagnostic Reagents,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2022-08-26,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,False,False,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,光学成像剂,optical imaging agent,Curadel,诊断试剂领域,Diagnostic Reagents,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2022-08-26,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,False,True,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,喉癌,Throat cancer,Leiden University,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2023-03-02,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,False,False,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,喉癌,Throat cancer,Curadel,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2023-03-02,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,False,True,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,口腔癌,oral cancer,Leiden University,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2019-12-09,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,True,False,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,口腔癌,oral cancer,Curadel,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2019-12-09,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,True,True,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,胆管癌,cholangiocarcinoma,Leiden University,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,True,False,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,胆管癌,cholangiocarcinoma,Curadel,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,True,True,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,下咽癌,hypopharyngeal cancer,Leiden University,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2023-03-02,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,False,False,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,下咽癌,hypopharyngeal cancer,Curadel,肿瘤领域,Oncology,phase 2,2,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,II期临床,2023-03-02,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,False,True,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,结肠癌,colon cancer,Leiden University,肿瘤领域,Oncology,phase 1,1,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,I期临床,,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,False,False,False,Leiden University;Curadel(原研),2
cRGD-ZW800-1 ,cRGD-ZW800-1 ,结肠癌,colon cancer,Curadel,肿瘤领域,Oncology,phase 1,1,cRGD-ZW800-1 ;cRGD-ZW800-1,αvβ6;αvβ3;αvβ5,荧光显像剂,phase 2,2,2019-12-09,I期临床,,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,False,True,False,True,False,Leiden University;Curadel(原研),2
PL-8177,PL-8177,溃疡性结肠炎,ulcerative colitis,Palatin Technologies,免疫领域,Immunology,phase 2,2,PL-8177;PL8177,MC1R,MC1R激动剂,phase 2,2,2020-01-20,II期临床,2022-07-20,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Melanogenesis,激动剂,False,True,False,True,False,Palatin Technologies(原研),1
PL-8177,PL-8177,糖尿病肾病,diabetic nephropathy,Palatin Technologies,泌尿生殖领域,Genitourinary,pre-clinical,-1,PL-8177;PL8177,MC1R,MC1R激动剂,phase 2,2,2020-01-20,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Melanogenesis,激动剂,False,True,False,True,False,Palatin Technologies(原研),1
68Ga-NODAGA-LM3,68Ga-NODAGA-LM3,PET显像,PET imaging,University Hospital of Basel,诊断试剂领域,Diagnostic Reagents,phase 2,2,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,phase 2,2,2020-07-29,II期临床,2020-07-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,University Hospital of Basel(原研),1
68Ga-NODAGA-LM3,68Ga-NODAGA-LM3,神经内分泌肿瘤,neuroendocrine tumors,University Hospital of Basel,肿瘤领域,Oncology,phase 2,2,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,phase 2,2,2020-07-29,II期临床,2020-07-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,University Hospital of Basel(原研),1
68Ga-NODAGA-LM3,68Ga-NODAGA-LM3,希佩尔-林道综合征,Hippel-Lindau syndrome,University Hospital of Basel,肿瘤领域,Oncology,phase 2,2,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,phase 2,2,2020-07-29,II期临床,2023-04-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,University Hospital of Basel(原研),1
THR-149,THR-149,糖尿病黄斑水肿,diabetic macular edema,Oxurion,眼科领域,Ophthalmology,phase 2,2,THR-149,PKK,PKK抑制剂,phase 2,2,2020-08-26,II期临床,2020-08-26,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,False,False,Oxurion;Bicycle Therapeutics(原研),2
THR-149,THR-149,糖尿病黄斑水肿,diabetic macular edema,Bicycle Therapeutics,眼科领域,Ophthalmology,phase 2,2,THR-149,PKK,PKK抑制剂,phase 2,2,2020-08-26,II期临床,2020-08-26,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,Oxurion;Bicycle Therapeutics(原研),2
certepetide,certepetide,胰腺癌,pancreatic cancer,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胰腺癌,pancreatic cancer,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胰腺癌,pancreatic cancer,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胰腺癌,pancreatic cancer,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胶质瘤,glioma,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胶质瘤,glioma,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胶质瘤,glioma,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胶质瘤,glioma,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胶质母细胞瘤,glioblastoma,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-10-17,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胶质母细胞瘤,glioblastoma,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-10-17,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胶质母细胞瘤,glioblastoma,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-10-17,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胶质母细胞瘤,glioblastoma,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-10-17,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胰腺导管癌,pancreatic ductal carcinoma,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2021-09-13,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胰腺导管癌,pancreatic ductal carcinoma,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2021-09-13,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胰腺导管癌,pancreatic ductal carcinoma,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2021-09-13,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胰腺导管癌,pancreatic ductal carcinoma,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2021-09-13,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,肝内胆管癌,intrahepatic cholangiocarcinoma,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,肝内胆管癌,intrahepatic cholangiocarcinoma,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,肝内胆管癌,intrahepatic cholangiocarcinoma,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,肝内胆管癌,intrahepatic cholangiocarcinoma,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胆囊癌,gallbladder cancer,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胆囊癌,gallbladder cancer,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胆囊癌,gallbladder cancer,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胆囊癌,gallbladder cancer,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胆管癌,cholangiocarcinoma,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胆管癌,cholangiocarcinoma,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胆管癌,cholangiocarcinoma,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,胆管癌,cholangiocarcinoma,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,肝外胆管癌,extrahepatic cholangiocarcinoma,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,肝外胆管癌,extrahepatic cholangiocarcinoma,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,肝外胆管癌,extrahepatic cholangiocarcinoma,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,肝外胆管癌,extrahepatic cholangiocarcinoma,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,食管鳞状细胞癌,Esophageal squamous cell carcinoma,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,食管鳞状细胞癌,Esophageal squamous cell carcinoma,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,食管鳞状细胞癌,Esophageal squamous cell carcinoma,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,食管鳞状细胞癌,Esophageal squamous cell carcinoma,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,II期临床,2023-02-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,结肠癌,colon cancer,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I/II期临床,2021-11-16,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,结肠癌,colon cancer,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I/II期临床,2021-11-16,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,结肠癌,colon cancer,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I/II期临床,2021-11-16,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,结肠癌,colon cancer,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I/II期临床,2021-11-16,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,阑尾癌,appendix cancer,齐鲁制药,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I/II期临床,2021-11-16,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,阑尾癌,appendix cancer,Lisata Therapeutics,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I/II期临床,2021-11-16,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,阑尾癌,appendix cancer,GATC Health,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I/II期临床,2021-11-16,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,阑尾癌,appendix cancer,Kuva Labs,肿瘤领域,Oncology,phase 2,2,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I/II期临床,2021-11-16,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,腹膜转移癌,peritoneal metastasis cancer,齐鲁制药,肿瘤领域,Oncology,phase 1,1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I期临床,2024-01-22,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,腹膜转移癌,peritoneal metastasis cancer,Lisata Therapeutics,肿瘤领域,Oncology,phase 1,1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I期临床,2024-01-22,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,腹膜转移癌,peritoneal metastasis cancer,GATC Health,肿瘤领域,Oncology,phase 1,1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I期临床,2024-01-22,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,腹膜转移癌,peritoneal metastasis cancer,Kuva Labs,肿瘤领域,Oncology,phase 1,1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,I期临床,2024-01-22,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,False,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,骨肉瘤,Osteosarcoma,齐鲁制药,肿瘤领域,Oncology,pre-clinical,-1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,临床前,2024-03-21,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,骨肉瘤,Osteosarcoma,Lisata Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,临床前,2024-03-21,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,骨肉瘤,Osteosarcoma,GATC Health,肿瘤领域,Oncology,pre-clinical,-1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,临床前,2024-03-21,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,骨肉瘤,Osteosarcoma,Kuva Labs,肿瘤领域,Oncology,pre-clinical,-1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,临床前,2024-03-21,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,腹膜癌,peritoneal cancer,齐鲁制药,肿瘤领域,Oncology,pre-clinical,-1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,腹膜癌,peritoneal cancer,Lisata Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,True,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,腹膜癌,peritoneal cancer,GATC Health,肿瘤领域,Oncology,pre-clinical,-1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
certepetide,certepetide,腹膜癌,peritoneal cancer,Kuva Labs,肿瘤领域,Oncology,pre-clinical,-1,certepetide;CEND-1;iRGD;QLC12102;LSTA1,CD51,CD51结合剂,phase 2,2,2021-09-13,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,False,True,True,False,False,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,4
212Pb-dotamtate,212Pb-dotamtate,神经内分泌肿瘤,neuroendocrine tumors,Sanofi,肿瘤领域,Oncology,phase 2,2,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,phase 2,2,2021-12-10,II期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,True,True,True,False,True,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),3
212Pb-dotamtate,212Pb-dotamtate,神经内分泌肿瘤,neuroendocrine tumors,Orano Med,肿瘤领域,Oncology,phase 2,2,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,phase 2,2,2021-12-10,II期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,True,True,True,True,False,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),3
212Pb-dotamtate,212Pb-dotamtate,神经内分泌肿瘤,neuroendocrine tumors,RadioMedix,肿瘤领域,Oncology,phase 2,2,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,phase 2,2,2021-12-10,II期临床,2021-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,True,True,True,True,False,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),3
212Pb-dotamtate,212Pb-dotamtate,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Sanofi,肿瘤领域,Oncology,phase 2,2,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,phase 2,2,2021-12-10,II期临床,2024-02-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,True,True,True,False,True,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),3
212Pb-dotamtate,212Pb-dotamtate,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Orano Med,肿瘤领域,Oncology,phase 2,2,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,phase 2,2,2021-12-10,II期临床,2024-02-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,True,True,True,True,False,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),3
212Pb-dotamtate,212Pb-dotamtate,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,RadioMedix,肿瘤领域,Oncology,phase 2,2,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,phase 2,2,2021-12-10,II期临床,2024-02-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,True,True,True,True,False,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),3
GT-02037,GT-02037,肢端肥大症,acromegaly,永信药品,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,GT-02037,somatostatin;SSTR1;SSTR2;SSTR4;SSTR5;SSTR3,SSTR1激动剂;SSTR4激动剂;SSTR2激动剂;SSTR3激动剂;SSTR5激动剂;somatostatin类似物,phase 2,2,2022-06-22,II期临床,2022-06-22,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,类似物;激动剂,False,True,True,False,False,永信药品;GlyTech(原研),2
GT-02037,GT-02037,肢端肥大症,acromegaly,GlyTech,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,GT-02037,somatostatin;SSTR1;SSTR2;SSTR4;SSTR5;SSTR3,SSTR1激动剂;SSTR4激动剂;SSTR2激动剂;SSTR3激动剂;SSTR5激动剂;somatostatin类似物,phase 2,2,2022-06-22,II期临床,2022-06-22,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,类似物;激动剂,False,True,True,True,False,永信药品;GlyTech(原研),2
SCAI-001,SCAI-001 (cyclosporine),干眼病,dry eye disease,SCAI Therapeutics,眼科领域,Ophthalmology,phase 2,2,SCAI-001;SCAI-001 (环孢素);SCAI-001 (cyclosporine),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,phase 2,2,2023-02-17,II期临床,2023-02-17,Active,微创新,化药,小分子,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,False,True,False,True,False,SCAI Therapeutics(原研),1
thiostrepton,thiostrepton,恶性胸水,malignant pleural effusion,RS Oncology,肿瘤领域,Oncology,phase 2,2,thiostrepton;RSO-021,FOXM1;PRDX3,FOXM1抑制剂;PRDX3抑制剂;多肽类抗生素,phase 2,2,2024-02-01,II期临床,2024-02-01,Active,创新药,化药,多肽,环肽;Potential First-in-Class,多肽类抗生素;抑制剂,False,True,True,True,False,RS Oncology(原研),1
thiostrepton,thiostrepton,胸膜间皮瘤,Pleural mesothelioma,RS Oncology,肿瘤领域,Oncology,phase 2,2,thiostrepton;RSO-021,FOXM1;PRDX3,FOXM1抑制剂;PRDX3抑制剂;多肽类抗生素,phase 2,2,2024-02-01,II期临床,2024-02-01,Active,创新药,化药,多肽,环肽;Potential First-in-Class,多肽类抗生素;抑制剂,False,True,True,True,False,RS Oncology(原研),1
M-ANP,M-ANP,高血压,hypertension,Mayo Clinic,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,M-ANP;MANP;M-Atrial Natriuretic Peptide,NPR1,NPR1激活剂,phase 2,2,2024-04-02,II期临床,2024-04-02,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,激活剂,False,True,False,True,False,Mayo Clinic(原研);E-Star BioTech,2
M-ANP,M-ANP,高血压,hypertension,E-Star BioTech,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,M-ANP;MANP;M-Atrial Natriuretic Peptide,NPR1,NPR1激活剂,phase 2,2,2024-04-02,II期临床,2024-04-02,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,激活剂,False,True,False,False,False,Mayo Clinic(原研);E-Star BioTech,2
M-ANP,M-ANP,射血分数保留的心力衰竭,heart failure with preserved ejection fraction,Mayo Clinic,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,M-ANP;MANP;M-Atrial Natriuretic Peptide,NPR1,NPR1激活剂,phase 2,2,2024-04-02,I/II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,激活剂,False,True,False,True,False,Mayo Clinic(原研);E-Star BioTech,2
M-ANP,M-ANP,射血分数保留的心力衰竭,heart failure with preserved ejection fraction,E-Star BioTech,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,M-ANP;MANP;M-Atrial Natriuretic Peptide,NPR1,NPR1激活剂,phase 2,2,2024-04-02,I/II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,激活剂,False,True,False,False,False,Mayo Clinic(原研);E-Star BioTech,2
DD01,DD01,肥胖,obesity,信立泰,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,II期临床,2024-05-13,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,False,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,肥胖,obesity,D&D Pharmatech,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,II期临床,2024-05-13,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,True,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,代谢相关脂肪性肝炎,Metabolic related steatohepatitis,信立泰,消化领域,Digestive System,phase 2,2,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,II期临床,2024-05-13,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,False,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,代谢相关脂肪性肝炎,Metabolic related steatohepatitis,D&D Pharmatech,消化领域,Digestive System,phase 2,2,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,II期临床,2024-05-13,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,True,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,超重,overweight,信立泰,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,II期临床,2024-05-13,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,False,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,超重,overweight,D&D Pharmatech,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,II期临床,2024-05-13,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,True,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,2型糖尿病,type 2 diabetes,信立泰,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,I期临床,2021-03-23,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,False,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,2型糖尿病,type 2 diabetes,D&D Pharmatech,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,I期临床,2021-03-23,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,True,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,代谢相关脂肪性肝病,metabolic related fatty liver disease,信立泰,消化领域,Digestive System,phase 1,1,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,I期临床,2021-03-23,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,False,False,信立泰;D&D Pharmatech(原研),2
DD01,DD01,代谢相关脂肪性肝病,metabolic related fatty liver disease,D&D Pharmatech,消化领域,Digestive System,phase 1,1,DD01;SAL0125,GLP-1R;GCGR,GLP-1R×GCGR激动剂,phase 2,2,2024-05-13,I期临床,2021-03-23,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,True,False,信立泰;D&D Pharmatech(原研),2
咔喏霉素,kynomycin,急性细菌性皮肤和皮肤结构感染,Acute bacterial skin and skin structure infections,友搏药业(九芝堂),感染领域,Infectious Diseases,phase 2,2,咔喏霉素;kynomycin;YB211;YBD211,not available,脂肽类抗生素,phase 2,2,2025-03-07,II期临床,2025-03-07,Active,创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,False,True,False,False,False,友搏药业(九芝堂);香港大学(原研),2
咔喏霉素,kynomycin,急性细菌性皮肤和皮肤结构感染,Acute bacterial skin and skin structure infections,香港大学,感染领域,Infectious Diseases,phase 2,2,咔喏霉素;kynomycin;YB211;YBD211,not available,脂肽类抗生素,phase 2,2,2025-03-07,II期临床,2025-03-07,Active,创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,False,True,False,True,False,友搏药业(九芝堂);香港大学(原研),2
咔喏霉素,kynomycin,皮肤/皮肤结构感染,Skin/skin structure infection,友搏药业(九芝堂),感染领域,Infectious Diseases,phase 1,1,咔喏霉素;kynomycin;YB211;YBD211,not available,脂肽类抗生素,phase 2,2,2025-03-07,I期临床,2023-11-20,Active,创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,False,True,False,False,False,友搏药业(九芝堂);香港大学(原研),2
咔喏霉素,kynomycin,皮肤/皮肤结构感染,Skin/skin structure infection,香港大学,感染领域,Infectious Diseases,phase 1,1,咔喏霉素;kynomycin;YB211;YBD211,not available,脂肽类抗生素,phase 2,2,2025-03-07,I期临床,2023-11-20,Active,创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,False,True,False,True,False,友搏药业(九芝堂);香港大学(原研),2
咔喏霉素,kynomycin,复杂性皮肤和皮肤结构感染,Complicated skin and skin structure infections,友搏药业(九芝堂),感染领域,Infectious Diseases,phase 1,1,咔喏霉素;kynomycin;YB211;YBD211,not available,脂肽类抗生素,phase 2,2,2025-03-07,I期临床,2023-12-14,Active,创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,False,True,False,False,False,友搏药业(九芝堂);香港大学(原研),2
咔喏霉素,kynomycin,复杂性皮肤和皮肤结构感染,Complicated skin and skin structure infections,香港大学,感染领域,Infectious Diseases,phase 1,1,咔喏霉素;kynomycin;YB211;YBD211,not available,脂肽类抗生素,phase 2,2,2025-03-07,I期临床,2023-12-14,Active,创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,False,True,False,True,False,友搏药业(九芝堂);香港大学(原研),2
咔喏霉素,kynomycin,感染,Infect,友搏药业(九芝堂),感染领域,Infectious Diseases,ind,0,咔喏霉素;kynomycin;YB211;YBD211,not available,脂肽类抗生素,phase 2,2,2025-03-07,申报临床,2023-07-07,Active,创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,False,True,False,False,False,友搏药业(九芝堂);香港大学(原研),2
咔喏霉素,kynomycin,感染,Infect,香港大学,感染领域,Infectious Diseases,ind,0,咔喏霉素;kynomycin;YB211;YBD211,not available,脂肽类抗生素,phase 2,2,2025-03-07,申报临床,2023-07-07,Active,创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,False,True,False,True,False,友搏药业(九芝堂);香港大学(原研),2
177Lu-FAP-2286,177Lu-FAP-2286,非小细胞肺癌,non-small cell lung cancer,Novartis,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,True,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,非小细胞肺癌,non-small cell lung cancer,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,非小细胞肺癌,non-small cell lung cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,乳腺癌,breast cancer,Novartis,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,True,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,乳腺癌,breast cancer,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,乳腺癌,breast cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,尿路上皮癌,urothelial carcinoma,Novartis,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-03-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,True,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,尿路上皮癌,urothelial carcinoma,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-03-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,尿路上皮癌,urothelial carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-03-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,胰腺导管癌,pancreatic ductal carcinoma,Novartis,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,True,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,胰腺导管癌,pancreatic ductal carcinoma,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,胰腺导管癌,pancreatic ductal carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,实体瘤,solid tumors,Novartis,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,I/II期临床,2021-06-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,True,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,实体瘤,solid tumors,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,I/II期临床,2021-06-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,实体瘤,solid tumors,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,I/II期临床,2021-06-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,骨转移疼痛,bone metastasis pain,Novartis,肿瘤领域,Oncology,phase 1,1,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,I期临床,2025-05-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,True,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,骨转移疼痛,bone metastasis pain,Clovis Oncology,肿瘤领域,Oncology,phase 1,1,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,I期临床,2025-05-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
177Lu-FAP-2286,177Lu-FAP-2286,骨转移疼痛,bone metastasis pain,3B Pharmaceuticals,肿瘤领域,Oncology,phase 1,1,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-03-18,I期临床,2025-05-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,False,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),3
TCMCB07,TCMCB07,恶病质,Cachexia,Endevica,内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,TCMCB07,MC4R,MC4R拮抗剂,phase 2,2,2025-04-17,II期临床,2025-04-17,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;瘦素-黑皮素通路,拮抗剂,False,True,False,True,False,Endevica(原研),1
TCMCB07,TCMCB07,癌性恶病质,cancer cachexia,Endevica,肿瘤领域,Oncology,phase 2,2,TCMCB07,MC4R,MC4R拮抗剂,phase 2,2,2025-04-17,II期临床,2025-04-22,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;瘦素-黑皮素通路,拮抗剂,False,True,False,True,False,Endevica(原研),1
ALXN2420,ALXN2420,肢端肥大症,acromegaly,Alexion Pharmaceuticals(AstraZeneca),内分泌及代谢领域,Endocrinology & Metabolism,phase 2,2,ALXN2420,GHR,GHR拮抗剂,phase 2,2,2025-06-25,II期临床,2025-06-25,Active,创新药,化药,多肽,环肽,拮抗剂,True,True,True,True,True,Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),1
68Ga-FAP-2286,68Ga-FAP-2286,非小细胞肺癌,non-small cell lung cancer,Novartis,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,非小细胞肺癌,non-small cell lung cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,非小细胞肺癌,non-small cell lung cancer,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,乳腺癌,breast cancer,Novartis,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,乳腺癌,breast cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,乳腺癌,breast cancer,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,胰腺导管癌,pancreatic ductal carcinoma,Novartis,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,胰腺导管癌,pancreatic ductal carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,胰腺导管癌,pancreatic ductal carcinoma,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,II期临床,2025-08-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,实体瘤,solid tumors,Novartis,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I/II期临床,2021-06-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,实体瘤,solid tumors,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I/II期临床,2021-06-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,实体瘤,solid tumors,Clovis Oncology,肿瘤领域,Oncology,phase 2,2,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I/II期临床,2021-06-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肿瘤,tumor,Novartis,肿瘤领域,Oncology,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2025-08-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肿瘤,tumor,3B Pharmaceuticals,肿瘤领域,Oncology,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2025-08-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肿瘤,tumor,Clovis Oncology,肿瘤领域,Oncology,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2025-08-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肺纤维化,pulmonary fibrosis,Novartis,呼吸领域,Respiratory,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肺纤维化,pulmonary fibrosis,3B Pharmaceuticals,呼吸领域,Respiratory,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肺纤维化,pulmonary fibrosis,Clovis Oncology,呼吸领域,Respiratory,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肝纤维化,liver fibrosis,Novartis,消化领域,Digestive System,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2022-01-06,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肝纤维化,liver fibrosis,3B Pharmaceuticals,消化领域,Digestive System,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2022-01-06,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,肝纤维化,liver fibrosis,Clovis Oncology,消化领域,Digestive System,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2022-01-06,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,PET显像,PET imaging,Novartis,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2020-11-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,PET显像,PET imaging,3B Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2020-11-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
68Ga-FAP-2286,68Ga-FAP-2286,PET显像,PET imaging,Clovis Oncology,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-FAP-2286;3B-202,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-08-26,I期临床,2020-11-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
LS301,LS301,非小细胞肺癌,non-small cell lung cancer,Washington University in St. Louis,肿瘤领域,Oncology,phase 2,2,LS301;LS301-IT,ANXA2,荧光显像剂,phase 2,2,2025-12-11,II期临床,2025-12-11,Active,创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,False,True,False,False,False,Washington University in St. Louis;Integro Theranostics(原研),2
LS301,LS301,非小细胞肺癌,non-small cell lung cancer,Integro Theranostics,肿瘤领域,Oncology,phase 2,2,LS301;LS301-IT,ANXA2,荧光显像剂,phase 2,2,2025-12-11,II期临床,2025-12-11,Active,创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,False,True,False,True,False,Washington University in St. Louis;Integro Theranostics(原研),2
LS301,LS301,光学成像剂,optical imaging agent,Washington University in St. Louis,诊断试剂领域,Diagnostic Reagents,phase 2,2,LS301;LS301-IT,ANXA2,荧光显像剂,phase 2,2,2025-12-11,II期临床,2025-12-11,Active,创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,False,True,False,False,False,Washington University in St. Louis;Integro Theranostics(原研),2
LS301,LS301,光学成像剂,optical imaging agent,Integro Theranostics,诊断试剂领域,Diagnostic Reagents,phase 2,2,LS301;LS301-IT,ANXA2,荧光显像剂,phase 2,2,2025-12-11,II期临床,2025-12-11,Active,创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,False,True,False,True,False,Washington University in St. Louis;Integro Theranostics(原研),2
LS301,LS301,原位导管癌,Ductal carcinoma in situ,Washington University in St. Louis,肿瘤领域,Oncology,phase 2,2,LS301;LS301-IT,ANXA2,荧光显像剂,phase 2,2,2025-12-11,I/II期临床,2023-06-13,Active,创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,False,True,False,False,False,Washington University in St. Louis;Integro Theranostics(原研),2
LS301,LS301,原位导管癌,Ductal carcinoma in situ,Integro Theranostics,肿瘤领域,Oncology,phase 2,2,LS301;LS301-IT,ANXA2,荧光显像剂,phase 2,2,2025-12-11,I/II期临床,2023-06-13,Active,创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,False,True,False,True,False,Washington University in St. Louis;Integro Theranostics(原研),2
LS301,LS301,肺癌,lung cancer,Washington University in St. Louis,肿瘤领域,Oncology,phase 1,1,LS301;LS301-IT,ANXA2,荧光显像剂,phase 2,2,2025-12-11,I期临床,2024-12-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,False,True,False,False,False,Washington University in St. Louis;Integro Theranostics(原研),2
LS301,LS301,肺癌,lung cancer,Integro Theranostics,肿瘤领域,Oncology,phase 1,1,LS301;LS301-IT,ANXA2,荧光显像剂,phase 2,2,2025-12-11,I期临床,2024-12-03,Active,创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,False,True,False,True,False,Washington University in St. Louis;Integro Theranostics(原研),2
68Ga-BOT5035,68Ga-BOT5035,射血分数保留的心力衰竭,heart failure with preserved ejection fraction,BiOrion,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,68Ga-BOT5035,PDGFRβ,anti-PDGFRβ多肽偶联核素;68Ga标记的PET药物,phase 2,2,,II期临床,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,BiOrion(原研);Cortalix,2
68Ga-BOT5035,68Ga-BOT5035,射血分数保留的心力衰竭,heart failure with preserved ejection fraction,Cortalix,心脑血管领域,Cardiovascular & Cerebrovascular,phase 2,2,68Ga-BOT5035,PDGFRβ,anti-PDGFRβ多肽偶联核素;68Ga标记的PET药物,phase 2,2,,II期临床,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,BiOrion(原研);Cortalix,2
68Ga-BOT5035,68Ga-BOT5035,特发性肺纤维化,idiopathic pulmonary fibrosis,BiOrion,呼吸领域,Respiratory,pre-clinical,-1,68Ga-BOT5035,PDGFRβ,anti-PDGFRβ多肽偶联核素;68Ga标记的PET药物,phase 2,2,,临床前,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,BiOrion(原研);Cortalix,2
68Ga-BOT5035,68Ga-BOT5035,特发性肺纤维化,idiopathic pulmonary fibrosis,Cortalix,呼吸领域,Respiratory,pre-clinical,-1,68Ga-BOT5035,PDGFRβ,anti-PDGFRβ多肽偶联核素;68Ga标记的PET药物,phase 2,2,,临床前,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,False,False,BiOrion(原研);Cortalix,2
OTX-CSI,OTX-CSI (cyclosporine A intracanalicular insert),干眼病,dry eye disease,Ocular Therapeutix,眼科领域,Ophthalmology,phase 2,2,OTX-CSI;OTX-CSI (环孢素);OTX-CSI (cyclosporine A intracanalicular insert),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,phase 2,2,,II期临床,,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Ocular Therapeutix(原研),1
SomaDex,SomaDex,去势抵抗前列腺癌,Castration-resistant prostate cancer,DexTech,肿瘤领域,Oncology,phase 2,2,SomaDex,somatostatin,somatostatin类似物,phase 2,2,,II期临床,,Active,创新药,化药,其他,环肽,类似物,False,True,False,True,False,DexTech(原研),1
SomaDex,SomaDex,肢端肥大症,acromegaly,DexTech,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,SomaDex,somatostatin,somatostatin类似物,phase 2,2,,临床前,,Active,创新药,化药,其他,环肽,类似物,False,True,True,True,False,DexTech(原研),1
SomaDex,SomaDex,神经内分泌肿瘤,neuroendocrine tumors,DexTech,肿瘤领域,Oncology,pre-clinical,-1,SomaDex,somatostatin,somatostatin类似物,phase 2,2,,临床前,,Active,创新药,化药,其他,环肽,类似物,False,True,True,True,False,DexTech(原研),1
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,神经内分泌肿瘤,neuroendocrine tumors,Ariceum Therapeutics,肿瘤领域,Oncology,phase 2,2,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2015-10-29,I/II期临床,2015-10-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,神经内分泌肿瘤,neuroendocrine tumors,Ipsen,肿瘤领域,Oncology,phase 2,2,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2015-10-29,I/II期临床,2015-10-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,脑膜瘤,Meningioma,Ariceum Therapeutics,肿瘤领域,Oncology,phase 2,2,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2015-10-29,I/II期临床,2021-08-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,脑膜瘤,Meningioma,Ipsen,肿瘤领域,Oncology,phase 2,2,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2015-10-29,I/II期临床,2021-08-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,小细胞肺癌,small cell lung cancer,Ariceum Therapeutics,肿瘤领域,Oncology,phase 1,1,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2015-10-29,I期临床,2023-02-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,小细胞肺癌,small cell lung cancer,Ipsen,肿瘤领域,Oncology,phase 1,1,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2015-10-29,I期临床,2023-02-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,Ariceum Therapeutics;Ipsen(原研)(无权益),2
lonodelestat,lonodelestat,α1-抗胰蛋白酶缺乏症,α1-antitrypsin deficiency,Polyphor(Spexis),呼吸领域,Respiratory,phase 1,1,lonodelestat;POL6014,ELA2,ELA2抑制剂,phase 2,2,2017-06-23,I期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,True,True,False,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),2
lonodelestat,lonodelestat,α1-抗胰蛋白酶缺乏症,α1-antitrypsin deficiency,Santhera Pharmaceuticals,呼吸领域,Respiratory,phase 1,1,lonodelestat;POL6014,ELA2,ELA2抑制剂,phase 2,2,2017-06-23,I期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,True,False,False,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),2
lonodelestat,lonodelestat,原发性纤毛运动障碍,primary ciliary dyskinesia,Polyphor(Spexis),呼吸领域,Respiratory,phase 1,1,lonodelestat;POL6014,ELA2,ELA2抑制剂,phase 2,2,2017-06-23,I期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,True,True,False,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),2
lonodelestat,lonodelestat,原发性纤毛运动障碍,primary ciliary dyskinesia,Santhera Pharmaceuticals,呼吸领域,Respiratory,phase 1,1,lonodelestat;POL6014,ELA2,ELA2抑制剂,phase 2,2,2017-06-23,I期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,True,False,False,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),2
67Cu-SARTATE,67Cu-SARTATE,神经母细胞瘤,Neuroblastoma,Clarity Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,phase 2,2,2018-03-01,I/II期临床,2019-07-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,False,True,True,True,False,Clarity Pharmaceuticals(原研),1
67Cu-SARTATE,67Cu-SARTATE,神经内分泌肿瘤,neuroendocrine tumors,Clarity Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,phase 2,2,2018-03-01,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,False,True,True,True,False,Clarity Pharmaceuticals(原研),1
67Cu-SARTATE,67Cu-SARTATE,脑膜瘤,Meningioma,Clarity Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,phase 2,2,2018-03-01,I/II期临床,2018-03-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,False,True,False,True,False,Clarity Pharmaceuticals(原研),1
BT5528,BT5528,实体瘤,solid tumors,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,BT5528,EphA2,多肽偶联药物,phase 2,2,2019-11-27,I/II期临床,2019-11-27,Active,创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
IDP-121,IDP-121,小细胞肺癌,small cell lung cancer,IDP Pharma,肿瘤领域,Oncology,phase 2,2,IDP-121,c-Myc,c-Myc抑制剂,phase 2,2,2021-10-19,I/II期临床,2025-12-18,Active,创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,False,True,True,True,False,IDP Pharma(原研),1
IDP-121,IDP-121,血液系统肿瘤,hematological tumors,IDP Pharma,肿瘤领域,Oncology,phase 2,2,IDP-121,c-Myc,c-Myc抑制剂,phase 2,2,2021-10-19,I/II期临床,2023-10-26,Active,创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,False,True,False,True,False,IDP Pharma(原研),1
IDP-121,IDP-121,慢性淋巴细胞白血病,chronic lymphocytic leukemia,IDP Pharma,肿瘤领域,Oncology,phase 2,2,IDP-121,c-Myc,c-Myc抑制剂,phase 2,2,2021-10-19,I/II期临床,2021-10-19,Active,创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,False,True,True,True,False,IDP Pharma(原研),1
IDP-121,IDP-121,弥漫性大B细胞淋巴瘤,Diffuse large B-cell lymphoma,IDP Pharma,肿瘤领域,Oncology,phase 2,2,IDP-121,c-Myc,c-Myc抑制剂,phase 2,2,2021-10-19,I/II期临床,2021-10-19,Active,创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,False,True,True,True,False,IDP Pharma(原研),1
IDP-121,IDP-121,多发性骨髓瘤,multiple myeloma,IDP Pharma,肿瘤领域,Oncology,phase 2,2,IDP-121,c-Myc,c-Myc抑制剂,phase 2,2,2021-10-19,I/II期临床,2021-10-19,Active,创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,False,True,True,True,False,IDP Pharma(原研),1
IDP-121,IDP-121,B细胞淋巴瘤,B cell lymphoma,IDP Pharma,肿瘤领域,Oncology,phase 2,2,IDP-121,c-Myc,c-Myc抑制剂,phase 2,2,2021-10-19,I/II期临床,2024-12-30,Active,创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,False,True,False,True,False,IDP Pharma(原研),1
IDP-121,IDP-121,双重打击淋巴瘤,double hit lymphoma,IDP Pharma,肿瘤领域,Oncology,phase 2,2,IDP-121,c-Myc,c-Myc抑制剂,phase 2,2,2021-10-19,I/II期临床,,Active,创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,False,True,False,True,False,IDP Pharma(原研),1
BT7480,BT7480,实体瘤,solid tumors,Bicycle Therapeutics,肿瘤领域,Oncology,phase 2,2,BT7480,nectin-4;4-1BB,4-1BB激动剂;nectin-4配体,phase 2,2,2021-12-20,I/II期临床,2021-12-20,Active,创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,激动剂;配体,False,True,False,True,False,Bicycle Therapeutics(原研),1
64Cu-FBP8,64Cu-FBP8,PET显像,PET imaging,Massachusetts General Hospital,诊断试剂领域,Diagnostic Reagents,phase 2,2,64Cu-FBP8;[64Cu]FBP8,fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,phase 2,2,2022-04-20,I/II期临床,2022-04-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研),1
64Cu-FBP8,64Cu-FBP8,阿尔茨海默病性痴呆,Alzheimer's disease dementia,Massachusetts General Hospital,神经领域,Neurology,phase 2,2,64Cu-FBP8;[64Cu]FBP8,fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,phase 2,2,2022-04-20,I/II期临床,2022-04-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研),1
64Cu-FBP8,64Cu-FBP8,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),Massachusetts General Hospital,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,64Cu-FBP8;[64Cu]FBP8,fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,phase 2,2,2022-04-20,I期临床,2019-02-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研),1
177Lu-LNC1010,177Lu-LNC1010,实体瘤,solid tumors,蓝纳成生物,肿瘤领域,Oncology,phase 1,1,177Lu-LNC1010;177Lu-EB-TATE-01,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2022-06-08,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,蓝纳成生物(原研),1
177Lu-LNC1010,177Lu-LNC1010,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,蓝纳成生物,肿瘤领域,Oncology,phase 1,1,177Lu-LNC1010;177Lu-EB-TATE-01,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2022-06-08,I期临床,2024-08-28,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,False,True,True,True,False,蓝纳成生物(原研),1
68Ga-FAPI-RGD,68Ga-FAPI-RGD,癌症,cancer,,肿瘤领域,Oncology,phase 2,2,68Ga-FAPI-RGD;68Ga-FAP-RGD,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2022-08-25,I/II期临床,2022-08-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,--,0
68Ga-FAPI-RGD,68Ga-FAPI-RGD,PET显像,PET imaging,,诊断试剂领域,Diagnostic Reagents,phase 2,2,68Ga-FAPI-RGD;68Ga-FAP-RGD,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2022-08-25,I/II期临床,2022-08-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,--,0
68Ga-FAPI-RGD,68Ga-FAPI-RGD,肿瘤,tumor,,肿瘤领域,Oncology,phase 1,1,68Ga-FAPI-RGD;68Ga-FAP-RGD,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,phase 2,2,2022-08-25,I期临床,2024-10-15,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,False,False,--,0
90Y-pentixather,90Y-pentixather,多发性骨髓瘤,multiple myeloma,Eckert & Ziegler,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-01-26,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,True,False,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,多发性骨髓瘤,multiple myeloma,PentixaPharm,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-01-26,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,True,True,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,多发性骨髓瘤,multiple myeloma,Technische Universität München,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-01-26,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,True,False,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,原发性中枢神经系统淋巴瘤,primary central nervous system lymphoma,Eckert & Ziegler,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-11-15,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,False,False,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,原发性中枢神经系统淋巴瘤,primary central nervous system lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-11-15,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,False,True,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,原发性中枢神经系统淋巴瘤,primary central nervous system lymphoma,Technische Universität München,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-11-15,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,False,False,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,继发性中枢神经系统淋巴瘤,secondary central nervous system lymphoma,Eckert & Ziegler,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-11-15,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,True,False,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,继发性中枢神经系统淋巴瘤,secondary central nervous system lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-11-15,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,True,True,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,继发性中枢神经系统淋巴瘤,secondary central nervous system lymphoma,Technische Universität München,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-11-15,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,True,False,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,T细胞非霍奇金淋巴瘤,T-cell non-Hodgkin lymphoma,Eckert & Ziegler,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-01-26,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,False,False,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,T细胞非霍奇金淋巴瘤,T-cell non-Hodgkin lymphoma,PentixaPharm,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-01-26,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,False,True,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
90Y-pentixather,90Y-pentixather,T细胞非霍奇金淋巴瘤,T-cell non-Hodgkin lymphoma,Technische Universität München,肿瘤领域,Oncology,phase 2,2,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,CXCR4,90Y标记的放射性药物,phase 2,2,2023-01-26,I/II期临床,2023-01-26,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,False,True,False,False,False,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,3
177Lu-DPI-4452,177Lu-DPI-4452,非小细胞肺癌,non-small cell lung cancer,Debiopharm,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,非小细胞肺癌,non-small cell lung cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,非小细胞肺癌,non-small cell lung cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,三阴性乳腺癌,triple negative breast cancer,Debiopharm,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,三阴性乳腺癌,triple negative breast cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,三阴性乳腺癌,triple negative breast cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,头颈癌,Head and neck cancer,Debiopharm,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,头颈癌,Head and neck cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,头颈癌,Head and neck cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,尿路上皮癌,urothelial carcinoma,Debiopharm,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,尿路上皮癌,urothelial carcinoma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,尿路上皮癌,urothelial carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,肾病,kidney disease,Debiopharm,泌尿生殖领域,Genitourinary,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,肾病,kidney disease,ITM Isotope,泌尿生殖领域,Genitourinary,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,肾病,kidney disease,3B Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,结直肠癌,colorectal cancer,Debiopharm,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,结直肠癌,colorectal cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,结直肠癌,colorectal cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,胰腺导管癌,pancreatic ductal carcinoma,Debiopharm,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,胰腺导管癌,pancreatic ductal carcinoma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,胰腺导管癌,pancreatic ductal carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,肾透明细胞癌,clear cell renal cell carcinoma,Debiopharm,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,肾透明细胞癌,clear cell renal cell carcinoma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
177Lu-DPI-4452,177Lu-DPI-4452,肾透明细胞癌,clear cell renal cell carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,非小细胞肺癌,non-small cell lung cancer,Debiopharm,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,非小细胞肺癌,non-small cell lung cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,非小细胞肺癌,non-small cell lung cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,三阴性乳腺癌,triple negative breast cancer,Debiopharm,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,三阴性乳腺癌,triple negative breast cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,三阴性乳腺癌,triple negative breast cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,头颈癌,Head and neck cancer,Debiopharm,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,头颈癌,Head and neck cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,头颈癌,Head and neck cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,尿路上皮癌,urothelial carcinoma,Debiopharm,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,尿路上皮癌,urothelial carcinoma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,尿路上皮癌,urothelial carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,肾病,kidney disease,Debiopharm,泌尿生殖领域,Genitourinary,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,肾病,kidney disease,ITM Isotope,泌尿生殖领域,Genitourinary,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,肾病,kidney disease,3B Pharmaceuticals,泌尿生殖领域,Genitourinary,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2024-03-25,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,PET显像,PET imaging,Debiopharm,诊断试剂领域,Diagnostic Reagents,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,PET显像,PET imaging,ITM Isotope,诊断试剂领域,Diagnostic Reagents,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,PET显像,PET imaging,3B Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,结直肠癌,colorectal cancer,Debiopharm,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,结直肠癌,colorectal cancer,ITM Isotope,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,结直肠癌,colorectal cancer,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,胰腺导管癌,pancreatic ductal carcinoma,Debiopharm,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,胰腺导管癌,pancreatic ductal carcinoma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,胰腺导管癌,pancreatic ductal carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,肾透明细胞癌,clear cell renal cell carcinoma,Debiopharm,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,肾透明细胞癌,clear cell renal cell carcinoma,ITM Isotope,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,False,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
68Ga-DPI-4452,68Ga-DPI-4452,肾透明细胞癌,clear cell renal cell carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,phase 2,2,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,phase 2,2,2023-01-31,I/II期临床,2023-01-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),3
FOG-001,FOG-001,实体瘤,solid tumors,Parabilis Medicines,肿瘤领域,Oncology,phase 2,2,FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,phase 2,2,2023-06-26,I/II期临床,2023-06-26,Active,创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Parabilis Medicines(原研),1
FOG-001,FOG-001,非小细胞肺癌,non-small cell lung cancer,Parabilis Medicines,肿瘤领域,Oncology,phase 2,2,FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,phase 2,2,2023-06-26,I/II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Parabilis Medicines(原研),1
FOG-001,FOG-001,胃癌,stomach cancer,Parabilis Medicines,肿瘤领域,Oncology,phase 2,2,FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,phase 2,2,2023-06-26,I/II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Parabilis Medicines(原研),1
FOG-001,FOG-001,结直肠癌,colorectal cancer,Parabilis Medicines,肿瘤领域,Oncology,phase 2,2,FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,phase 2,2,2023-06-26,I/II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Parabilis Medicines(原研),1
FOG-001,FOG-001,胃食管交界处癌,gastroesophageal junction cancer,Parabilis Medicines,肿瘤领域,Oncology,phase 2,2,FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,phase 2,2,2023-06-26,I/II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Parabilis Medicines(原研),1
FOG-001,FOG-001,硬纤维瘤,desmoid tumor,Parabilis Medicines,肿瘤领域,Oncology,phase 2,2,FOG-001,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,phase 2,2,2023-06-26,I/II期临床,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,False,True,True,True,False,Parabilis Medicines(原研),1
177Lu-pentixather,177Lu-pentixather,急性淋巴细胞白血病,acute lymphoblastic leukemia,Scintomics,肿瘤领域,Oncology,phase 2,2,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,CXCR4,177Lu标记的放射性药物,phase 2,2,2024-04-10,I/II期临床,2024-11-21,Active,创新药,化药,小分子;放射性药物,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,False,True,True,True,False,Scintomics(原研),1
177Lu-pentixather,177Lu-pentixather,急性髓系白血病,acute myeloid leukemia,Scintomics,肿瘤领域,Oncology,phase 2,2,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,CXCR4,177Lu标记的放射性药物,phase 2,2,2024-04-10,I/II期临床,2024-11-21,Active,创新药,化药,小分子;放射性药物,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,False,True,True,True,False,Scintomics(原研),1
177Lu-pentixather,177Lu-pentixather,急性白血病,acute leukemia,Scintomics,肿瘤领域,Oncology,phase 2,2,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,CXCR4,177Lu标记的放射性药物,phase 2,2,2024-04-10,I/II期临床,2024-04-10,Active,创新药,化药,小分子;放射性药物,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,False,True,False,True,False,Scintomics(原研),1
177Lu-pentixather,177Lu-pentixather,多发性骨髓瘤,multiple myeloma,Scintomics,肿瘤领域,Oncology,phase 1,1,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,CXCR4,177Lu标记的放射性药物,phase 2,2,2024-04-10,I期临床,,Active,创新药,化药,小分子;放射性药物,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,False,True,True,True,False,Scintomics(原研),1
61Cu-NODAGA-LM3,61Cu-NODAGA-LM3,PET显像,PET imaging,University Hospital of Basel,诊断试剂领域,Diagnostic Reagents,phase 2,2,61Cu-NODAGA-LM3,SSTR2,61Cu标记的PET药物;anti-SSTR2多肽偶联核素,phase 2,2,2024-06-12,I/II期临床,2024-06-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,61Cu标记的PET药物;多肽偶联核素,False,True,False,True,False,University Hospital of Basel(原研),1
61Cu-NODAGA-LM3,61Cu-NODAGA-LM3,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,University Hospital of Basel,肿瘤领域,Oncology,phase 2,2,61Cu-NODAGA-LM3,SSTR2,61Cu标记的PET药物;anti-SSTR2多肽偶联核素,phase 2,2,2024-06-12,I/II期临床,2024-06-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,61Cu标记的PET药物;多肽偶联核素,False,True,True,True,False,University Hospital of Basel(原研),1
[18F]-FET-βAG-TOCA,[18F]-FET-βAG-TOCA,PET显像,PET imaging,Imperial College London,诊断试剂领域,Diagnostic Reagents,phase 2,2,[18F]-FET-βAG-TOCA,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 2,2,2024-06-13,I/II期临床,2024-06-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,Imperial College London(原研),1
[18F]-FET-βAG-TOCA,[18F]-FET-βAG-TOCA,神经内分泌肿瘤,neuroendocrine tumors,Imperial College London,肿瘤领域,Oncology,phase 2,2,[18F]-FET-βAG-TOCA,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 2,2,2024-06-13,I/II期临床,2024-06-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,Imperial College London(原研),1
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,肿瘤,tumor,山东省肿瘤医院,肿瘤领域,Oncology,phase 2,2,[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,phase 2,2,2024-11-15,I/II期临床,,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,False,True,False,True,False,山东省肿瘤医院(原研),1
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,非小细胞肺癌,non-small cell lung cancer,山东省肿瘤医院,肿瘤领域,Oncology,phase 2,2,[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,phase 2,2,2024-11-15,I/II期临床,2024-11-15,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,False,True,False,True,False,山东省肿瘤医院(原研),1
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,食管癌,Esophageal cancer,山东省肿瘤医院,肿瘤领域,Oncology,phase 2,2,[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,phase 2,2,2024-11-15,I/II期临床,2024-11-15,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,False,True,False,True,False,山东省肿瘤医院(原研),1
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,胶质母细胞瘤,glioblastoma,山东省肿瘤医院,肿瘤领域,Oncology,phase 2,2,[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,phase 2,2,2024-11-15,I/II期临床,2024-11-15,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,False,True,True,True,False,山东省肿瘤医院(原研),1
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,PET显像,PET imaging,山东省肿瘤医院,诊断试剂领域,Diagnostic Reagents,phase 2,2,[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,phase 2,2,2024-11-15,I/II期临床,2024-11-15,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,False,True,False,True,False,山东省肿瘤医院(原研),1
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,山东省肿瘤医院,肿瘤领域,Oncology,phase 2,2,[18F]AlF-NOTA-PCP2,PDL1,18F标记的PET药物,phase 2,2,2024-11-15,I/II期临床,2024-11-15,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,False,True,False,True,False,山东省肿瘤医院(原研),1
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,实体瘤,solid tumors,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,胃癌,stomach cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,食管癌,Esophageal cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,头颈癌,Head and neck cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,卵巢癌,ovarian cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,False,True,True,True,False,Perspective Therapeutics(原研),1
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,SPECT显像,SPECT imaging,Perspective Therapeutics,诊断试剂领域,Diagnostic Reagents,phase 2,2,[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,结直肠癌,colorectal cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,胰腺导管癌,pancreatic ductal carcinoma,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[203Pb]Pb-PSV359,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,实体瘤,solid tumors,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,胃癌,stomach cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,食管癌,Esophageal cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,头颈癌,Head and neck cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,卵巢癌,ovarian cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,True,True,False,Perspective Therapeutics(原研),1
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,结直肠癌,colorectal cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,胰腺导管癌,pancreatic ductal carcinoma,Perspective Therapeutics,肿瘤领域,Oncology,phase 2,2,[212Pb]Pb-PSV359,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,phase 2,2,2024-11-29,I/II期临床,2024-11-29,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,False,True,False,Perspective Therapeutics(原研),1
225Ac-SSO110,225Ac-SSO110,小细胞肺癌,small cell lung cancer,Ariceum Therapeutics,肿瘤领域,Oncology,phase 2,2,225Ac-SSO110;225Ac-satoreotide,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2025-04-22,I/II期临床,2025-04-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,False,True,True,True,False,Ariceum Therapeutics(原研),1
225Ac-SSO110,225Ac-SSO110,Merkel细胞瘤,Merkel cell tumor,Ariceum Therapeutics,肿瘤领域,Oncology,phase 2,2,225Ac-SSO110;225Ac-satoreotide,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2025-04-22,I/II期临床,2025-04-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,False,True,True,True,False,Ariceum Therapeutics(原研),1
225Ac-SSO110,225Ac-SSO110,肿瘤,tumor,Ariceum Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,225Ac-SSO110;225Ac-satoreotide,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 2,2,2025-04-22,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,False,True,False,True,False,Ariceum Therapeutics(原研),1
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,许特尔细胞瘤,Hütter cell tumor,National Institutes of Health,肿瘤领域,Oncology,phase 2,2,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-05-28,I/II期临床,2025-05-28,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,National Institutes of Health(原研);Molecular Targeting Technologies,2
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,许特尔细胞瘤,Hütter cell tumor,Molecular Targeting Technologies,肿瘤领域,Oncology,phase 2,2,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-05-28,I/II期临床,2025-05-28,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,National Institutes of Health(原研);Molecular Targeting Technologies,2
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,神经内分泌肿瘤,neuroendocrine tumors,National Institutes of Health,肿瘤领域,Oncology,phase 1,1,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-05-28,I期临床,2017-10-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,National Institutes of Health(原研);Molecular Targeting Technologies,2
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,神经内分泌肿瘤,neuroendocrine tumors,Molecular Targeting Technologies,肿瘤领域,Oncology,phase 1,1,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-05-28,I期临床,2017-10-12,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,National Institutes of Health(原研);Molecular Targeting Technologies,2
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,鼻咽癌,Nasopharyngeal cancer,National Institutes of Health,肿瘤领域,Oncology,ind,0,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-05-28,申报临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,National Institutes of Health(原研);Molecular Targeting Technologies,2
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,鼻咽癌,Nasopharyngeal cancer,Molecular Targeting Technologies,肿瘤领域,Oncology,ind,0,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-05-28,申报临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,True,False,False,National Institutes of Health(原研);Molecular Targeting Technologies,2
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,甲状腺癌,Thyroid cancer,National Institutes of Health,肿瘤领域,Oncology,ind,0,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-05-28,申报临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,National Institutes of Health(原研);Molecular Targeting Technologies,2
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,甲状腺癌,Thyroid cancer,Molecular Targeting Technologies,肿瘤领域,Oncology,ind,0,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,phase 2,2,2025-05-28,申报临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,False,False,National Institutes of Health(原研);Molecular Targeting Technologies,2
镓[68Ga]氧奥曲肽,gallium [68Ga] oxodotreotide,小细胞肺癌,small cell lung cancer,Novartis,肿瘤领域,Oncology,phase 2,2,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-06-03,I/II期临床,2025-06-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,True,True,True,True,True,Novartis(Top20 MNC)(原研),1
镓[68Ga]氧奥曲肽,gallium [68Ga] oxodotreotide,未知/待定,unknown/pending,Novartis,其他领域,Others,ind,0,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-06-03,申报临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
镓[68Ga]氧奥曲肽,gallium [68Ga] oxodotreotide,PET显像,PET imaging,Novartis,诊断试剂领域,Diagnostic Reagents,ind,0,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,phase 2,2,2025-06-03,申报临床,2025-01-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
64Cu-NODAGA-LM3,64Cu-NODAGA-LM3,PET显像,PET imaging,University Hospital of Basel,诊断试剂领域,Diagnostic Reagents,phase 2,2,64Cu-NODAGA-LM3;(64)Cu-NODAGA-LM3,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,phase 2,2,,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,University Hospital of Basel(原研),1
64Cu-NODAGA-LM3,64Cu-NODAGA-LM3,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,University Hospital of Basel,肿瘤领域,Oncology,phase 2,2,64Cu-NODAGA-LM3;(64)Cu-NODAGA-LM3,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,phase 2,2,,I/II期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,True,True,False,University Hospital of Basel(原研),1
NeuroSTAT,NeuroSTAT (cyclosporine),外伤性脑损伤,traumatic brain injury,Abliva(Pharming),神经领域,Neurology,phase 2,2,NeuroSTAT;NeuroSTAT (环孢素);NeuroSTAT (cyclosporine);OWL-1410,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,phase 2,2,,I/II期临床,,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,False,True,False,True,False,Abliva(Pharming)(原研);Owl Therapeutics,2
NeuroSTAT,NeuroSTAT (cyclosporine),外伤性脑损伤,traumatic brain injury,Owl Therapeutics,神经领域,Neurology,phase 2,2,NeuroSTAT;NeuroSTAT (环孢素);NeuroSTAT (cyclosporine);OWL-1410,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,phase 2,2,,I/II期临床,,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,False,True,False,False,False,Abliva(Pharming)(原研);Owl Therapeutics,2
68Ga-DOTA-JR11,68Ga-DOTA-JR11,PET显像,PET imaging,University Hospital Freiburg,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-DOTA-JR11,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,phase 1,1,2015-11-20,I期临床,2020-12-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,University Hospital Freiburg(原研),1
68Ga-DOTA-JR11,68Ga-DOTA-JR11,神经内分泌肿瘤,neuroendocrine tumors,University Hospital Freiburg,肿瘤领域,Oncology,phase 1,1,68Ga-DOTA-JR11,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,phase 1,1,2015-11-20,I期临床,2015-11-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,University Hospital Freiburg(原研),1
68Ga-DOTA-JR11,68Ga-DOTA-JR11,肿瘤性骨软化症,neoplastic osteomalacia,University Hospital Freiburg,肿瘤领域,Oncology,phase 1,1,68Ga-DOTA-JR11,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,phase 1,1,2015-11-20,I期临床,2020-12-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,University Hospital Freiburg(原研),1
[18F]FP-R01-MG-F2,[18F]FP-R01-MG-F2,胰腺癌,pancreatic cancer,Stanford University,肿瘤领域,Oncology,phase 1,1,[18F]FP-R01-MG-F2,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,phase 1,1,2016-02-17,I期临床,2016-02-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,Stanford University(原研),1
[18F]FP-R01-MG-F2,[18F]FP-R01-MG-F2,PET显像,PET imaging,Stanford University,诊断试剂领域,Diagnostic Reagents,phase 1,1,[18F]FP-R01-MG-F2,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,phase 1,1,2016-02-17,I期临床,2016-02-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,Stanford University(原研),1
68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD,甲状腺癌,Thyroid cancer,天津医科大学,肿瘤领域,Oncology,phase 1,1,68Ga-NOTA-3PTATE-RGD,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,phase 1,1,2016-06-29,I期临床,2024-10-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,天津医科大学(原研),1
68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD,脑膜瘤,Meningioma,天津医科大学,肿瘤领域,Oncology,phase 1,1,68Ga-NOTA-3PTATE-RGD,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,phase 1,1,2016-06-29,I期临床,2024-10-09,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,天津医科大学(原研),1
68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9,PET显像,PET imaging,University of Turku,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-DOTA-Siglec-9,VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,phase 1,1,2018-11-27,I期临床,2018-11-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,University of Turku(原研),1
68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9,炎症(未指明),Inflammation (unspecified),University of Turku,免疫领域,Immunology,pre-clinical,-1,68Ga-DOTA-Siglec-9,VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,phase 1,1,2018-11-27,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,University of Turku(原研),1
[18F]BMS-986229,[18F]BMS-986229,胃癌,stomach cancer,Bristol-Myers Squibb,肿瘤领域,Oncology,phase 1,1,[18F]BMS-986229;18F-BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2019-11-13,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,2
[18F]BMS-986229,[18F]BMS-986229,胃癌,stomach cancer,PeptiDream,肿瘤领域,Oncology,phase 1,1,[18F]BMS-986229;18F-BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2019-11-13,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,True,True,False,False,False,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,2
[18F]BMS-986229,[18F]BMS-986229,食管癌,Esophageal cancer,Bristol-Myers Squibb,肿瘤领域,Oncology,phase 1,1,[18F]BMS-986229;18F-BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2019-11-13,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,2
[18F]BMS-986229,[18F]BMS-986229,食管癌,Esophageal cancer,PeptiDream,肿瘤领域,Oncology,phase 1,1,[18F]BMS-986229;18F-BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2019-11-13,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,True,True,False,False,False,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,2
[18F]BMS-986229,[18F]BMS-986229,PET显像,PET imaging,Bristol-Myers Squibb,诊断试剂领域,Diagnostic Reagents,phase 1,1,[18F]BMS-986229;18F-BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2019-11-13,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,2
[18F]BMS-986229,[18F]BMS-986229,PET显像,PET imaging,PeptiDream,诊断试剂领域,Diagnostic Reagents,phase 1,1,[18F]BMS-986229;18F-BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2019-11-13,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,True,True,False,False,False,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,2
[18F]BMS-986229,[18F]BMS-986229,胃食管交界处癌,gastroesophageal junction cancer,Bristol-Myers Squibb,肿瘤领域,Oncology,phase 1,1,[18F]BMS-986229;18F-BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2019-11-13,I期临床,2019-11-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,2
[18F]BMS-986229,[18F]BMS-986229,胃食管交界处癌,gastroesophageal junction cancer,PeptiDream,肿瘤领域,Oncology,phase 1,1,[18F]BMS-986229;18F-BMS-986229,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2019-11-13,I期临床,2019-11-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,True,True,False,False,False,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,2
ALS-205,ALS-205,帕金森病,Parkinson's disease,University of Queensland,神经领域,Neurology,phase 1,1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,I期临床,2019-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,False,True,False,University of Queensland(原研);Alsonex;Promics(原研),3
ALS-205,ALS-205,帕金森病,Parkinson's disease,Alsonex,神经领域,Neurology,phase 1,1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,I期临床,2019-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,False,False,False,University of Queensland(原研);Alsonex;Promics(原研),3
ALS-205,ALS-205,帕金森病,Parkinson's disease,Promics,神经领域,Neurology,phase 1,1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,I期临床,2019-11-25,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,False,True,False,University of Queensland(原研);Alsonex;Promics(原研),3
ALS-205,ALS-205,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,University of Queensland,神经领域,Neurology,phase 1,1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,I期临床,2022-06-29,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,True,True,False,University of Queensland(原研);Alsonex;Promics(原研),3
ALS-205,ALS-205,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,Alsonex,神经领域,Neurology,phase 1,1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,I期临床,2022-06-29,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,True,False,False,University of Queensland(原研);Alsonex;Promics(原研),3
ALS-205,ALS-205,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,Promics,神经领域,Neurology,phase 1,1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,I期临床,2022-06-29,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,True,True,False,University of Queensland(原研);Alsonex;Promics(原研),3
ALS-205,ALS-205,亨廷顿氏病,Huntington's disease,University of Queensland,神经领域,Neurology,pre-clinical,-1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,True,True,False,University of Queensland(原研);Alsonex;Promics(原研),3
ALS-205,ALS-205,亨廷顿氏病,Huntington's disease,Alsonex,神经领域,Neurology,pre-clinical,-1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,True,False,False,University of Queensland(原研);Alsonex;Promics(原研),3
ALS-205,ALS-205,亨廷顿氏病,Huntington's disease,Promics,神经领域,Neurology,pre-clinical,-1,ALS-205;PMX205,C5aR,C5aR拮抗剂,phase 1,1,2019-11-25,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,False,True,True,True,False,University of Queensland(原研);Alsonex;Promics(原研),3
18F-WL12,18F-WL12,实体瘤,solid tumors,北京大学肿瘤医院,肿瘤领域,Oncology,phase 1,1,18F-WL12,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2020-03-11,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学肿瘤医院(原研),1
zosurabalpin,zosurabalpin,鲍曼不动杆菌-醋酸钙不动杆菌复合体感染,Acinetobacter baumannii-Acinetobacter calaceticus complex infection,Roche,感染领域,Infectious Diseases,phase 1,1,zosurabalpin;RG6006;Abx MCP;RO7223280,Lpt,抗生素,phase 1,1,2020-10-28,I期临床,2023-01-06,Active,创新药,化药,小分子,环肽;Potential First-in-Class,抗生素,True,True,False,True,True,Roche(Top20 MNC)(原研),1
zosurabalpin,zosurabalpin,鲍曼不动杆菌感染,Acinetobacter baumannii infection,Roche,感染领域,Infectious Diseases,phase 1,1,zosurabalpin;RG6006;Abx MCP;RO7223280,Lpt,抗生素,phase 1,1,2020-10-28,I期临床,,Active,创新药,化药,小分子,环肽;Potential First-in-Class,抗生素,True,True,False,True,True,Roche(Top20 MNC)(原研),1
zosurabalpin,zosurabalpin,感染,Infect,Roche,感染领域,Infectious Diseases,ind,0,zosurabalpin;RG6006;Abx MCP;RO7223280,Lpt,抗生素,phase 1,1,2020-10-28,申报临床,2022-07-14,Active,创新药,化药,小分子,环肽;Potential First-in-Class,抗生素,True,True,False,True,True,Roche(Top20 MNC)(原研),1
Soralimixin,Soralimixin,细菌感染,bacterial infection,健康元,感染领域,Infectious Diseases,phase 1,1,Soralimixin;QPX9003;BRII-693,not available,多粘菌素类抗生素,phase 1,1,2021-03-22,I期临床,2021-03-22,Active,创新药,化药,多肽,环肽,多粘菌素类抗生素,False,True,False,False,False,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),4
Soralimixin,Soralimixin,细菌感染,bacterial infection,腾盛博药,感染领域,Infectious Diseases,phase 1,1,Soralimixin;QPX9003;BRII-693,not available,多粘菌素类抗生素,phase 1,1,2021-03-22,I期临床,2021-03-22,Active,创新药,化药,多肽,环肽,多粘菌素类抗生素,False,True,False,False,False,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),4
Soralimixin,Soralimixin,细菌感染,bacterial infection,Monash University,感染领域,Infectious Diseases,phase 1,1,Soralimixin;QPX9003;BRII-693,not available,多粘菌素类抗生素,phase 1,1,2021-03-22,I期临床,2021-03-22,Active,创新药,化药,多肽,环肽,多粘菌素类抗生素,False,True,False,True,False,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),4
Soralimixin,Soralimixin,细菌感染,bacterial infection,Qpex Biopharma(Shionogi),感染领域,Infectious Diseases,phase 1,1,Soralimixin;QPX9003;BRII-693,not available,多粘菌素类抗生素,phase 1,1,2021-03-22,I期临床,2021-03-22,Active,创新药,化药,多肽,环肽,多粘菌素类抗生素,False,True,False,False,False,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),4
Soralimixin,Soralimixin,感染,Infect,健康元,感染领域,Infectious Diseases,ind,0,Soralimixin;QPX9003;BRII-693,not available,多粘菌素类抗生素,phase 1,1,2021-03-22,申报临床,2024-07-20,Active,创新药,化药,多肽,环肽,多粘菌素类抗生素,False,True,False,False,False,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),4
Soralimixin,Soralimixin,感染,Infect,腾盛博药,感染领域,Infectious Diseases,ind,0,Soralimixin;QPX9003;BRII-693,not available,多粘菌素类抗生素,phase 1,1,2021-03-22,申报临床,2024-07-20,Active,创新药,化药,多肽,环肽,多粘菌素类抗生素,False,True,False,False,False,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),4
Soralimixin,Soralimixin,感染,Infect,Monash University,感染领域,Infectious Diseases,ind,0,Soralimixin;QPX9003;BRII-693,not available,多粘菌素类抗生素,phase 1,1,2021-03-22,申报临床,2024-07-20,Active,创新药,化药,多肽,环肽,多粘菌素类抗生素,False,True,False,True,False,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),4
Soralimixin,Soralimixin,感染,Infect,Qpex Biopharma(Shionogi),感染领域,Infectious Diseases,ind,0,Soralimixin;QPX9003;BRII-693,not available,多粘菌素类抗生素,phase 1,1,2021-03-22,申报临床,2024-07-20,Active,创新药,化药,多肽,环肽,多粘菌素类抗生素,False,True,False,False,False,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),4
[68Ga]VMT02,[68Ga]VMT02,黑色素瘤,melanoma,Viewpoint Molecular Targeting(Perspective Therapeutics),肿瘤领域,Oncology,phase 1,1,[68Ga]VMT02,MC1R,anti-MC1R多肽偶联核素;68Ga标记的PET药物,phase 1,1,2021-05-27,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,Viewpoint Molecular Targeting(Perspective Therapeutics)(原研),1
177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,实体瘤,solid tumors,北京大学,肿瘤领域,Oncology,phase 1,1,177Lu-AB-3PRGD2,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,phase 1,1,2021-08-19,I期临床,2024-04-19,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,北京大学(原研),1
177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,非小细胞肺癌,non-small cell lung cancer,北京大学,肿瘤领域,Oncology,phase 1,1,177Lu-AB-3PRGD2,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,phase 1,1,2021-08-19,I期临床,2021-08-19,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,北京大学(原研),1
177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,神经内分泌肿瘤,neuroendocrine tumors,北京大学,肿瘤领域,Oncology,phase 1,1,177Lu-AB-3PRGD2,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,phase 1,1,2021-08-19,I期临床,2024-10-09,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,False,True,True,True,False,北京大学(原研),1
Tdura,Tdura,SPECT显像,SPECT imaging,Molecular Targeting Technologies,诊断试剂领域,Diagnostic Reagents,phase 1,1,Tdura;99mTc-Duramycin,not available,含锝放射性示踪剂;多肽偶联核素,phase 1,1,2022-01-04,I期临床,2022-01-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,Molecular Targeting Technologies(原研);University of Antwerp(原研),2
Tdura,Tdura,SPECT显像,SPECT imaging,University of Antwerp,诊断试剂领域,Diagnostic Reagents,phase 1,1,Tdura;99mTc-Duramycin,not available,含锝放射性示踪剂;多肽偶联核素,phase 1,1,2022-01-04,I期临床,2022-01-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,Molecular Targeting Technologies(原研);University of Antwerp(原研),2
Tdura,Tdura,结肠癌,colon cancer,Molecular Targeting Technologies,肿瘤领域,Oncology,phase 1,1,Tdura;99mTc-Duramycin,not available,含锝放射性示踪剂;多肽偶联核素,phase 1,1,2022-01-04,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,Molecular Targeting Technologies(原研);University of Antwerp(原研),2
Tdura,Tdura,结肠癌,colon cancer,University of Antwerp,肿瘤领域,Oncology,phase 1,1,Tdura;99mTc-Duramycin,not available,含锝放射性示踪剂;多肽偶联核素,phase 1,1,2022-01-04,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,Molecular Targeting Technologies(原研);University of Antwerp(原研),2
Oph1,Oph1 (0.5% Cyclosporine A),干眼病,dry eye disease,OphRx,眼科领域,Ophthalmology,phase 1,1,Oph1;Oph1 (0.5%环孢素滴眼液);Oph1 (0.5% Cyclosporine A);OPH-100,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,phase 1,1,2022-01-11,I期临床,2022-01-11,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,False,True,False,True,False,OphRx(原研),1
PA-001,PA-001,新型冠状病毒感染,novel coronavirus infection,PeptiDream,感染领域,Infectious Diseases,phase 1,1,PA-001,SARS-CoV-2 S protein,,phase 1,1,2022-02-07,I期临床,2022-02-07,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,PeptiDream(原研),1
68Ga-N188,68Ga-N188,肺癌,lung cancer,北京大学肿瘤医院,肿瘤领域,Oncology,phase 1,1,68Ga-N188;[68Ga]N188,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,phase 1,1,2022-04-11,I期临床,2024-10-18,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学肿瘤医院(原研),1
68Ga-N188,68Ga-N188,尿路上皮癌,urothelial carcinoma,北京大学肿瘤医院,肿瘤领域,Oncology,phase 1,1,68Ga-N188;[68Ga]N188,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,phase 1,1,2022-04-11,I期临床,2022-04-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学肿瘤医院(原研),1
68Ga-N188,68Ga-N188,PET显像,PET imaging,北京大学肿瘤医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-N188;[68Ga]N188,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,phase 1,1,2022-04-11,I期临床,2022-04-11,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学肿瘤医院(原研),1
161Tb-DOTA-LM3,161Tb-DOTA-LM3,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Paul Scherrer Institute,肿瘤领域,Oncology,phase 1,1,161Tb-DOTA-LM3,SSTR2,161Tb标记的放射性药物;anti-SSTR2多肽偶联核素,phase 1,1,2022-05-03,I期临床,2022-05-03,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,161Tb标记的放射性药物;多肽偶联核素,False,True,True,True,False,Paul Scherrer Institute(原研),1
68Ga-pentixather,68Ga-pentixather,多发性骨髓瘤,multiple myeloma,北京协和医院,肿瘤领域,Oncology,phase 1,1,68Ga-pentixather,CXCR4,68Ga标记的PET药物,phase 1,1,2022-05-06,I期临床,2022-05-06,Active,创新药,化药,小分子;放射性药物,环肽;差异化疾病;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物,False,True,True,True,False,北京协和医院(原研),1
68Ga-pentixather,68Ga-pentixather,PET显像,PET imaging,北京协和医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-pentixather,CXCR4,68Ga标记的PET药物,phase 1,1,2022-05-06,I期临床,2022-05-06,Active,创新药,化药,小分子;放射性药物,环肽;差异化疾病;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物,False,True,False,True,False,北京协和医院(原研),1
PHIN-214,PHIN-214,肝硬化,Cirrhosis,PharmaIN,消化领域,Digestive System,phase 1,1,PHIN-214,AVPR1A,AVPR1A部分激动剂,phase 1,1,2022-08-08,I期临床,2022-08-08,Active,创新药,化药,多肽,环肽;Potential First-in-Class,部分激动剂,False,True,False,True,False,PharmaIN(原研),1
PHIN-214,PHIN-214,低血压,hypotension,PharmaIN,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,PHIN-214,AVPR1A,AVPR1A部分激动剂,phase 1,1,2022-08-08,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,部分激动剂,False,True,False,True,False,PharmaIN(原研),1
203Pb-pentixather,203Pb-pentixather,小细胞肺癌,small cell lung cancer,University of Iowa,肿瘤领域,Oncology,phase 1,1,203Pb-pentixather,CXCR4,203Pb标记的放射性示踪剂,phase 1,1,2022-09-28,I期临床,2022-09-28,Active,创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,False,True,True,True,False,University of Iowa(原研),1
203Pb-pentixather,203Pb-pentixather,SPECT显像,SPECT imaging,University of Iowa,诊断试剂领域,Diagnostic Reagents,phase 1,1,203Pb-pentixather,CXCR4,203Pb标记的放射性示踪剂,phase 1,1,2022-09-28,I期临床,,Active,创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,False,True,False,True,False,University of Iowa(原研),1
203Pb-pentixather,203Pb-pentixather,肺类癌,lung carcinoid,University of Iowa,肿瘤领域,Oncology,phase 1,1,203Pb-pentixather,CXCR4,203Pb标记的放射性示踪剂,phase 1,1,2022-09-28,I期临床,2022-09-28,Active,创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,False,True,True,True,False,University of Iowa(原研),1
212Pb-pentixather,212Pb-pentixather,小细胞肺癌,small cell lung cancer,University of Iowa,肿瘤领域,Oncology,phase 1,1,212Pb-pentixather,CXCR4,212Pb标记的放射性药物,phase 1,1,2022-09-28,I期临床,2022-09-28,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,212Pb标记的放射性药物,False,True,True,True,False,University of Iowa(原研),1
212Pb-pentixather,212Pb-pentixather,肺类癌,lung carcinoid,University of Iowa,肿瘤领域,Oncology,phase 1,1,212Pb-pentixather,CXCR4,212Pb标记的放射性药物,phase 1,1,2022-09-28,I期临床,2022-09-28,Active,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,212Pb标记的放射性药物,False,True,True,True,False,University of Iowa(原研),1
[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04,癌症,cancer,四川省肿瘤医院,肿瘤领域,Oncology,phase 1,1,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,FAP,18F标记的PET药物,phase 1,1,2022-10-12,I期临床,2025-01-26,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,False,True,False,True,False,四川省肿瘤医院(原研),1
[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04,肾炎,Nephritis,四川省肿瘤医院,泌尿生殖领域,Genitourinary,phase 1,1,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,FAP,18F标记的PET药物,phase 1,1,2022-10-12,I期临床,2023-03-02,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,False,True,False,True,False,四川省肿瘤医院(原研),1
[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04,PET显像,PET imaging,四川省肿瘤医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,FAP,18F标记的PET药物,phase 1,1,2022-10-12,I期临床,2022-10-12,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,False,True,False,True,False,四川省肿瘤医院(原研),1
[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04,肾纤维化,renal fibrosis,四川省肿瘤医院,泌尿生殖领域,Genitourinary,phase 1,1,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,FAP,18F标记的PET药物,phase 1,1,2022-10-12,I期临床,2023-03-02,Active,创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,False,True,False,True,False,四川省肿瘤医院(原研),1
[68Ga]-trivehexin,[68Ga]-trivehexin,癌症,cancer,Radiopharm Theranostics,肿瘤领域,Oncology,phase 1,1,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,phase 1,1,2023-04-05,I期临床,2023-04-28,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Radiopharm Theranostics(原研),1
[68Ga]-trivehexin,[68Ga]-trivehexin,PET显像,PET imaging,Radiopharm Theranostics,诊断试剂领域,Diagnostic Reagents,phase 1,1,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,phase 1,1,2023-04-05,I期临床,2023-04-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Radiopharm Theranostics(原研),1
[68Ga]-trivehexin,[68Ga]-trivehexin,胰腺导管癌,pancreatic ductal carcinoma,Radiopharm Theranostics,肿瘤领域,Oncology,phase 1,1,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,phase 1,1,2023-04-05,I期临床,2023-04-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Radiopharm Theranostics(原研),1
[18F]AlF-NOTA-pentixather,[18F]AlF-NOTA-pentixather,醛固酮过多症,Hyperaldosteronism,Technische Universität München,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,[18F]AlF-NOTA-pentixather,CXCR4,18F标记的PET药物,phase 1,1,2023-04-18,I期临床,2023-04-18,Active,创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体,18F标记的PET药物,False,True,False,True,False,Technische Universität München(原研),1
[18F]AlF-NOTA-pentixather,[18F]AlF-NOTA-pentixather,PET显像,PET imaging,Technische Universität München,诊断试剂领域,Diagnostic Reagents,phase 1,1,[18F]AlF-NOTA-pentixather,CXCR4,18F标记的PET药物,phase 1,1,2023-04-18,I期临床,2023-04-18,Active,创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体,18F标记的PET药物,False,True,False,True,False,Technische Universität München(原研),1
AZP-3813,AZP-3813,肢端肥大症,acromegaly,PeptiDream,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,AZP-3813,GHR,GHR拮抗剂,phase 1,1,2023-04-24,I期临床,2023-04-24,Active,创新药,化药,多肽,环肽;中国无申报,拮抗剂,True,True,True,True,False,PeptiDream(原研);Amolyt Pharma(AstraZeneca)(Top20 MNC),2
AZP-3813,AZP-3813,肢端肥大症,acromegaly,Amolyt Pharma(AstraZeneca),内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,AZP-3813,GHR,GHR拮抗剂,phase 1,1,2023-04-24,I期临床,2023-04-24,Active,创新药,化药,多肽,环肽;中国无申报,拮抗剂,True,True,True,False,True,PeptiDream(原研);Amolyt Pharma(AstraZeneca)(Top20 MNC),2
TB-B002,TB-B002,特发性肺纤维化,idiopathic pulmonary fibrosis,图微安创,呼吸领域,Respiratory,phase 1,1,TB-B002;TB-B002D,not available,抑制剂,phase 1,1,2023-05-06,I期临床,2023-05-06,Active,创新药,化药,多肽,环肽,抑制剂,False,True,True,True,False,图微安创(原研),1
TB-B002,TB-B002,肺损伤,lung damage,图微安创,呼吸领域,Respiratory,ind,0,TB-B002;TB-B002D,not available,抑制剂,phase 1,1,2023-05-06,申报临床,2023-08-25,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,图微安创(原研),1
TE-8214,TE-8214,肢端肥大症,acromegaly,免疫功坊,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,TE-8214,somatostatin,somatostatin类似物,phase 1,1,2024-04-18,I期临床,2024-04-18,Active,创新药,化药,多肽,环肽,类似物,False,True,True,True,False,免疫功坊(原研),1
TE-8214,TE-8214,神经内分泌肿瘤,neuroendocrine tumors,免疫功坊,肿瘤领域,Oncology,pre-clinical,-1,TE-8214,somatostatin,somatostatin类似物,phase 1,1,2024-04-18,临床前,,Active,创新药,化药,多肽,环肽,类似物,False,True,True,True,False,免疫功坊(原研),1
64Cu-PD-32766,64Cu-PD-32766,PET显像,PET imaging,PeptiDream,诊断试剂领域,Diagnostic Reagents,phase 1,1,64Cu-PD-32766,CAIX,64Cu标记的放射性示踪剂;anti-CAIX多肽偶联核素,phase 1,1,2024-04-24,I期临床,2024-04-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,PeptiDream(原研),1
64Cu-PD-32766,64Cu-PD-32766,肾透明细胞癌,clear cell renal cell carcinoma,PeptiDream,肿瘤领域,Oncology,phase 1,1,64Cu-PD-32766,CAIX,64Cu标记的放射性示踪剂;anti-CAIX多肽偶联核素,phase 1,1,2024-04-24,I期临床,2024-04-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,PeptiDream(原研),1
68Ga-FAPI-JH04,68Ga-FAPI-JH04,癌症,cancer,福建医科大学附属第一医院,肿瘤领域,Oncology,phase 1,1,68Ga-FAPI-JH04;68Ga-JH04,FAP,68Ga标记的PET药物,phase 1,1,2024-05-31,I期临床,2024-05-31,Active,创新药,其他,放射性药物;其他,环肽;诊断用放射性药物,68Ga标记的PET药物,False,True,False,True,False,福建医科大学附属第一医院(原研),1
68Ga-FAPI-JH04,68Ga-FAPI-JH04,PET显像,PET imaging,福建医科大学附属第一医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-FAPI-JH04;68Ga-JH04,FAP,68Ga标记的PET药物,phase 1,1,2024-05-31,I期临床,2024-05-31,Active,创新药,其他,放射性药物;其他,环肽;诊断用放射性药物,68Ga标记的PET药物,False,True,False,True,False,福建医科大学附属第一医院(原研),1
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,非小细胞肺癌,non-small cell lung cancer,Novartis,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,非小细胞肺癌,non-small cell lung cancer,PeptiDream,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,False,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,HR阳性乳腺癌,HR positive breast cancer,Novartis,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,HR阳性乳腺癌,HR positive breast cancer,PeptiDream,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,False,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,三阴性乳腺癌,triple negative breast cancer,Novartis,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,三阴性乳腺癌,triple negative breast cancer,PeptiDream,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,False,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,结直肠癌,colorectal cancer,Novartis,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,结直肠癌,colorectal cancer,PeptiDream,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,False,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,胰腺导管癌,pancreatic ductal carcinoma,Novartis,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,胰腺导管癌,pancreatic ductal carcinoma,PeptiDream,肿瘤领域,Oncology,phase 1,1,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-08-20,I期临床,2024-08-20,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,False,Novartis(Top20 MNC)(原研);PeptiDream(原研),2
CID-078,CID-078,实体瘤,solid tumors,Circle Pharma,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2024-10-15,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,实体瘤,solid tumors,Vall d'Hebron Institute of Oncology,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2024-10-15,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,肺癌,lung cancer,Circle Pharma,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2024-08-29,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,肺癌,lung cancer,Vall d'Hebron Institute of Oncology,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2024-08-29,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,小细胞肺癌,small cell lung cancer,Circle Pharma,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2025-06-16,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,True,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,小细胞肺癌,small cell lung cancer,Vall d'Hebron Institute of Oncology,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2025-06-16,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,True,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,三阴性乳腺癌,triple negative breast cancer,Circle Pharma,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2024-08-29,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,三阴性乳腺癌,triple negative breast cancer,Vall d'Hebron Institute of Oncology,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2024-08-29,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,神经内分泌肿瘤,neuroendocrine tumors,Circle Pharma,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2024-08-29,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,True,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,神经内分泌肿瘤,neuroendocrine tumors,Vall d'Hebron Institute of Oncology,肿瘤领域,Oncology,phase 1,1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,I期临床,2024-08-29,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,True,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,癌症,cancer,Circle Pharma,肿瘤领域,Oncology,pre-clinical,-1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,临床前,,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,癌症,cancer,Vall d'Hebron Institute of Oncology,肿瘤领域,Oncology,pre-clinical,-1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,临床前,,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,非小细胞肺癌,non-small cell lung cancer,Circle Pharma,肿瘤领域,Oncology,pre-clinical,-1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,临床前,,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,非小细胞肺癌,non-small cell lung cancer,Vall d'Hebron Institute of Oncology,肿瘤领域,Oncology,pre-clinical,-1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,临床前,,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,乳腺癌,breast cancer,Circle Pharma,肿瘤领域,Oncology,pre-clinical,-1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,临床前,,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
CID-078,CID-078,乳腺癌,breast cancer,Vall d'Hebron Institute of Oncology,肿瘤领域,Oncology,pre-clinical,-1,CID-078;CID-016;CIR7-7321;CIR-7321,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,phase 1,1,2024-08-29,临床前,,Active,创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,False,True,False,True,False,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),2
NN6537-7650,NN6537-7650,心力衰竭,heart failure,Novo Nordisk,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,NN6537-7650;NN6537,CNP,CNP类似物,phase 1,1,2024-10-03,I期临床,2024-10-03,Active,创新药,化药,多肽,环肽,类似物,True,True,False,True,True,Novo Nordisk(Top20 MNC)(原研),1
177Lu-JH04,177Lu-JH04,肿瘤,tumor,晶核生物,肿瘤领域,Oncology,phase 1,1,177Lu-JH04;JH004;[177Lu]JH040182,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,phase 1,1,2024-10-10,I期临床,2024-10-10,Active,创新药,化药,小分子;多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,晶核生物(原研),1
[18F]AlF-ETN,[18F]AlF-ETN,实体瘤,solid tumors,北京大学第一医院,肿瘤领域,Oncology,phase 1,1,[18F]AlF-ETN,EphA2,18F标记的PET药物;anti-EphA2多肽偶联核素,phase 1,1,2024-10-14,I期临床,2024-10-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,北京大学第一医院(原研),1
[18F]AlF-ETN,[18F]AlF-ETN,PET显像,PET imaging,北京大学第一医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,[18F]AlF-ETN,EphA2,18F标记的PET药物;anti-EphA2多肽偶联核素,phase 1,1,2024-10-14,I期临床,2024-10-14,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,北京大学第一医院(原研),1
ZP9830,ZP9830,自身免疫性疾病,autoimmune disease,Zealand Pharma,免疫领域,Immunology,phase 1,1,ZP9830;ZP 9830,Kv1.3,Kv1.3阻断剂,phase 1,1,2024-11-12,I期临床,2024-11-12,Active,创新药,化药,多肽,环肽,阻断剂,False,True,False,True,False,Zealand Pharma(原研),1
ZP9830,ZP9830,炎症性肠病,inflammatory bowel disease,Zealand Pharma,免疫领域,Immunology,pre-clinical,-1,ZP9830;ZP 9830,Kv1.3,Kv1.3阻断剂,phase 1,1,2024-11-12,临床前,,Active,创新药,化药,多肽,环肽,阻断剂,False,True,False,True,False,Zealand Pharma(原研),1
68Ga-MMP14,68Ga-MMP14,实体瘤,solid tumors,北京大学肿瘤医院,肿瘤领域,Oncology,phase 1,1,68Ga-MMP14,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,phase 1,1,2024-12-06,I期临床,2024-12-06,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学肿瘤医院(原研),1
68Ga-MMP14,68Ga-MMP14,PET显像,PET imaging,北京大学肿瘤医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-MMP14,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,phase 1,1,2024-12-06,I期临床,2024-12-06,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学肿瘤医院(原研),1
225Ac-RAYZ-8009,225Ac-RAYZ-8009,肝细胞癌,hepatocellular carcinoma,PeptiDream,肿瘤领域,Oncology,phase 1,1,225Ac-RAYZ-8009;RYZ801,GPC3,225Ac标记的放射性药物;anti-GPC3多肽偶联核素,phase 1,1,2024-12-10,I期临床,2024-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,False,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),2
225Ac-RAYZ-8009,225Ac-RAYZ-8009,肝细胞癌,hepatocellular carcinoma,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 1,1,225Ac-RAYZ-8009;RYZ801,GPC3,225Ac标记的放射性药物;anti-GPC3多肽偶联核素,phase 1,1,2024-12-10,I期临床,2024-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,True,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),2
[68Ga]-RYZ-GPC3,[68Ga]-RYZ-GPC3,肝细胞癌,hepatocellular carcinoma,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,phase 1,1,[68Ga]-RYZ-GPC3;RYZ811,GPC3,anti-GPC3多肽偶联核素;68Ga标记的PET药物,phase 1,1,2024-12-10,I期临床,2024-12-10,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
[68Ga]-RYZ-GPC3,[68Ga]-RYZ-GPC3,PET显像,PET imaging,RayzeBio(Bristol-Myers Squibb),诊断试剂领域,Diagnostic Reagents,phase 1,1,[68Ga]-RYZ-GPC3;RYZ811,GPC3,anti-GPC3多肽偶联核素;68Ga标记的PET药物,phase 1,1,2024-12-10,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
68Ga-3BP-3940,68Ga-3BP-3940,实体瘤,solid tumors,3B Pharmaceuticals,肿瘤领域,Oncology,phase 1,1,68Ga-3BP-3940,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-04-24,I期临床,2025-04-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,3B Pharmaceuticals(原研),1
68Ga-3BP-3940,68Ga-3BP-3940,PET显像,PET imaging,3B Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-3BP-3940,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-04-24,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,3B Pharmaceuticals(原研),1
13N-oxytocin,13N-oxytocin,PET显像,PET imaging,Tonix Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,phase 1,1,13N-oxytocin,OXTR,13N标记的PET药物;anti-OXTR多肽偶联核素,phase 1,1,2025-05-02,I期临床,2025-05-02,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,13N标记的PET药物;多肽偶联核素,False,True,False,True,False,Tonix Pharmaceuticals(原研),1
FAP-2286,FAP-2286,实体瘤,solid tumors,Novartis,肿瘤领域,Oncology,phase 1,1,FAP-2286,FAP,FAP抑制剂,phase 1,1,2025-05-12,I期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
FAP-2286,FAP-2286,实体瘤,solid tumors,3B Pharmaceuticals,肿瘤领域,Oncology,phase 1,1,FAP-2286,FAP,FAP抑制剂,phase 1,1,2025-05-12,I期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
FAP-2286,FAP-2286,实体瘤,solid tumors,Clovis Oncology,肿瘤领域,Oncology,phase 1,1,FAP-2286,FAP,FAP抑制剂,phase 1,1,2025-05-12,I期临床,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
FAP-2286,FAP-2286,骨转移疼痛,bone metastasis pain,Novartis,肿瘤领域,Oncology,phase 1,1,FAP-2286,FAP,FAP抑制剂,phase 1,1,2025-05-12,I期临床,2025-05-12,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
FAP-2286,FAP-2286,骨转移疼痛,bone metastasis pain,3B Pharmaceuticals,肿瘤领域,Oncology,phase 1,1,FAP-2286,FAP,FAP抑制剂,phase 1,1,2025-05-12,I期临床,2025-05-12,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
FAP-2286,FAP-2286,骨转移疼痛,bone metastasis pain,Clovis Oncology,肿瘤领域,Oncology,phase 1,1,FAP-2286,FAP,FAP抑制剂,phase 1,1,2025-05-12,I期临床,2025-05-12,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
AUBE00,AUBE00,实体瘤,solid tumors,Chugai Pharmaceutical,肿瘤领域,Oncology,phase 1,1,AUBE00,KRAS,KRAS抑制剂,phase 1,1,2025-05-12,I期临床,2025-05-12,Active,创新药,化药,其他,环肽;难成药靶点,抑制剂,True,True,False,True,True,Chugai Pharmaceutical(Top20 MNC)(原研),1
68Ga-CCZ01048,68Ga-CCZ01048,黑色素瘤,melanoma,BC Cancer,肿瘤领域,Oncology,phase 1,1,68Ga-CCZ01048,MSH;MC1R,MSH类似物;anti-MC1R多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-05-22,I期临床,2025-05-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;中国无申报;Potential First-in-Class;Melanogenesis;瘦素-黑皮素通路,类似物;多肽偶联核素;68Ga标记的PET药物,False,True,True,True,False,BC Cancer(原研),1
68Ga-CCZ01048,68Ga-CCZ01048,诊断试剂,diagnostic reagents,BC Cancer,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-CCZ01048,MSH;MC1R,MSH类似物;anti-MC1R多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-05-22,I期临床,2025-05-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;中国无申报;Potential First-in-Class;Melanogenesis;瘦素-黑皮素通路,类似物;多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,BC Cancer(原研),1
MC-339,MC-339,实体瘤,solid tumors,Mariana Oncology(Novartis),肿瘤领域,Oncology,phase 1,1,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,phase 1,1,2025-06-05,I期临床,2025-06-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
MC-339,MC-339,小细胞肺癌,small cell lung cancer,Mariana Oncology(Novartis),肿瘤领域,Oncology,phase 1,1,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,phase 1,1,2025-06-05,I期临床,2025-06-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,True,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
MC-339,MC-339,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,Mariana Oncology(Novartis),肿瘤领域,Oncology,phase 1,1,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,phase 1,1,2025-06-05,I期临床,2025-06-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,True,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
MC-339,MC-339,大细胞神经内分泌癌,large cell neuroendocrine carcinoma,Mariana Oncology(Novartis),肿瘤领域,Oncology,phase 1,1,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,phase 1,1,2025-06-05,I期临床,2025-06-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,True,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
MC-339,MC-339,神经内分泌前列腺癌,neuroendocrine prostate cancer,Mariana Oncology(Novartis),肿瘤领域,Oncology,phase 1,1,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,phase 1,1,2025-06-05,I期临床,2025-06-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
MC-339,MC-339,肺神经内分泌肿瘤,Pulmonary neuroendocrine tumors,Mariana Oncology(Novartis),肿瘤领域,Oncology,phase 1,1,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,phase 1,1,2025-06-05,I期临床,2025-06-05,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,True,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
TT-P34,TT-P34,帕金森病,Parkinson's disease,Teitur Trophics,神经领域,Neurology,phase 1,1,TT-P34,CREB,CREB激活剂,phase 1,1,2025-06-13,I期临床,2025-06-13,Active,创新药,化药,多肽,环肽;Potential First-in-Class,激活剂,False,True,False,True,False,Teitur Trophics(原研),1
TT-P34,TT-P34,亨廷顿氏病,Huntington's disease,Teitur Trophics,神经领域,Neurology,pre-clinical,-1,TT-P34,CREB,CREB激活剂,phase 1,1,2025-06-13,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,激活剂,False,True,True,True,False,Teitur Trophics(原研),1
TT-P34,TT-P34,额颞叶痴呆,frontotemporal dementia,Teitur Trophics,神经领域,Neurology,pre-clinical,-1,TT-P34,CREB,CREB激活剂,phase 1,1,2025-06-13,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,激活剂,False,True,True,True,False,Teitur Trophics(原研),1
68Ga-nectin-4 bicyclic peptide,68Ga-nectin-4 bicyclic peptide,实体瘤,solid tumors,苏州大学附属第一医院,肿瘤领域,Oncology,phase 1,1,68Ga-nectin-4 bicyclic peptide,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-07-09,I期临床,2025-07-09,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,苏州大学附属第一医院(原研),1
68Ga-nectin-4 bicyclic peptide,68Ga-nectin-4 bicyclic peptide,PET显像,PET imaging,苏州大学附属第一医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-nectin-4 bicyclic peptide,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-07-09,I期临床,2025-07-09,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,苏州大学附属第一医院(原研),1
68Ga-DOTA-WL12,68Ga-DOTA-WL12,头颈癌,Head and neck cancer,复旦大学附属华山医院,肿瘤领域,Oncology,phase 1,1,68Ga-DOTA-WL12,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-07-30,I期临床,2025-07-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,复旦大学附属华山医院(原研),1
68Ga-DOTA-WL12,68Ga-DOTA-WL12,PET显像,PET imaging,复旦大学附属华山医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,68Ga-DOTA-WL12,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-07-30,I期临床,2025-07-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,复旦大学附属华山医院(原研),1
68Ga-DOTA-WL12,68Ga-DOTA-WL12,非小细胞肺癌,non-small cell lung cancer,复旦大学附属华山医院,肿瘤领域,Oncology,pre-clinical,-1,68Ga-DOTA-WL12,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,phase 1,1,2025-07-30,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,复旦大学附属华山医院(原研),1
[18F]DK222,[18F]DK222,尿路上皮癌,urothelial carcinoma,Johns Hopkins University,肿瘤领域,Oncology,phase 1,1,[18F]DK222;PMI06,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2025-08-24,I期临床,2025-08-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,False,True,False,False,False,Johns Hopkins University;Precision Molecular(原研),2
[18F]DK222,[18F]DK222,尿路上皮癌,urothelial carcinoma,Precision Molecular,肿瘤领域,Oncology,phase 1,1,[18F]DK222;PMI06,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,phase 1,1,2025-08-24,I期临床,2025-08-24,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,Johns Hopkins University;Precision Molecular(原研),2
18F-SiTATE,18F-SiTATE (LMU Munich),神经母细胞瘤,Neuroblastoma,Ludwig Maximilian University of Munich,肿瘤领域,Oncology,phase 1,1,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 1,1,2025-09-26,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,Ludwig Maximilian University of Munich(原研),1
18F-SiTATE,18F-SiTATE (LMU Munich),抑郁症,depression,Ludwig Maximilian University of Munich,精神领域,Psychiatry,phase 1,1,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 1,1,2025-09-26,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,Ludwig Maximilian University of Munich(原研),1
18F-SiTATE,18F-SiTATE (LMU Munich),不孕不育,Infertility,Ludwig Maximilian University of Munich,泌尿生殖领域,Genitourinary,phase 1,1,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 1,1,2025-09-26,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,Ludwig Maximilian University of Munich(原研),1
18F-SiTATE,18F-SiTATE (LMU Munich),嗜铬细胞瘤,Pheochromocytoma,Ludwig Maximilian University of Munich,肿瘤领域,Oncology,phase 1,1,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 1,1,2025-09-26,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,Ludwig Maximilian University of Munich(原研),1
18F-SiTATE,18F-SiTATE (LMU Munich),骨转移疼痛,bone metastasis pain,Ludwig Maximilian University of Munich,肿瘤领域,Oncology,phase 1,1,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 1,1,2025-09-26,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,Ludwig Maximilian University of Munich(原研),1
18F-SiTATE,18F-SiTATE (LMU Munich),副神经节瘤,paraganglioma,Ludwig Maximilian University of Munich,肿瘤领域,Oncology,phase 1,1,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 1,1,2025-09-26,I期临床,2025-09-26,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,True,True,False,Ludwig Maximilian University of Munich(原研),1
18F-SiTATE,18F-SiTATE (LMU Munich),PET显像,PET imaging,Ludwig Maximilian University of Munich,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 1,1,2025-09-26,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,Ludwig Maximilian University of Munich(原研),1
18F-SiTATE,18F-SiTATE (LMU Munich),脑膜瘤,Meningioma,Ludwig Maximilian University of Munich,肿瘤领域,Oncology,pre-clinical,-1,18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,phase 1,1,2025-09-26,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,Ludwig Maximilian University of Munich(原研),1
225Ac-DOTA-LM3,225Ac-DOTA-LM3,神经内分泌肿瘤,neuroendocrine tumors,Università Cattolica del Sacro Cuore,肿瘤领域,Oncology,phase 1,1,225Ac-DOTA-LM3,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,phase 1,1,,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,False,True,True,True,False,Università Cattolica del Sacro Cuore(原研),1
CAM4071,CAM4071 (pasireotide FluidCrystal® long-acting injection),肢端肥大症,acromegaly,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,CAM4071;CAM4071 (帕瑞肽FluidCrystal®长效注射剂）;CAM4071 (pasireotide FluidCrystal® long-acting injection),somatostatin,somatostatin类似物,phase 1,1,,I期临床,,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,Camurus(原研),1
CAM4071,CAM4071 (pasireotide FluidCrystal® long-acting injection),库欣综合征,Cushing's syndrome,Camurus,内分泌及代谢领域,Endocrinology & Metabolism,phase 1,1,CAM4071;CAM4071 (帕瑞肽FluidCrystal®长效注射剂）;CAM4071 (pasireotide FluidCrystal® long-acting injection),somatostatin,somatostatin类似物,phase 1,1,,I期临床,,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,Camurus(原研),1
CsA-SNU2001,CsA-SNU2001,干眼病,dry eye disease,CAMP Therapeutics,眼科领域,Ophthalmology,phase 1,1,CsA-SNU2001;SNU2101,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,phase 1,1,,I期临床,,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,False,True,False,True,False,CAMP Therapeutics(原研),1
NVI-100,NVI-100 (AXN-001),偏头痛,Migraine,Ferring Pharmaceuticals,麻醉镇痛领域,Anesthesia & Analgesia,phase 1,1,NVI-100;NVI-100 (AXN-001);FE205030,CGRP receptor,CGRP receptor拮抗剂,phase 1,1,,I期临床,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;中国无申报,拮抗剂,False,True,False,True,False,Ferring Pharmaceuticals(原研);Nuvie Bio,2
NVI-100,NVI-100 (AXN-001),偏头痛,Migraine,Nuvie Bio,麻醉镇痛领域,Anesthesia & Analgesia,phase 1,1,NVI-100;NVI-100 (AXN-001);FE205030,CGRP receptor,CGRP receptor拮抗剂,phase 1,1,,I期临床,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;中国无申报,拮抗剂,False,True,False,False,False,Ferring Pharmaceuticals(原研);Nuvie Bio,2
ZP BNP,ZP BNP (nesiritide patch),急性失代偿性心力衰竭,acute decompensated heart failure,Zosano Pharma,心脑血管领域,Cardiovascular & Cerebrovascular,phase 1,1,ZP BNP;ZP BNP (奈西立肽贴剂);ZP BNP (nesiritide patch),BNP,重组BNP,phase 1,1,,I期临床,,Active,微创新,生物,多肽,环肽,重组,False,True,False,True,False,Zosano Pharma(原研),1
[68Ga]-BCY25286,[68Ga]-BCY25286,PET显像,PET imaging,Bicycle Therapeutics,诊断试剂领域,Diagnostic Reagents,phase 1,1,[68Ga]-BCY25286,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,phase 1,1,,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
[68Ga]-BCY25286,[68Ga]-BCY25286,肺腺癌,lung adenocarcinoma,Bicycle Therapeutics,肿瘤领域,Oncology,phase 1,1,[68Ga]-BCY25286,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,phase 1,1,,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
[68Ga]Ga-C1-FAP-2286,[68Ga]Ga-C1-FAP-2286,肿瘤,tumor,南方医科大学南方医院,肿瘤领域,Oncology,phase 1,1,[68Ga]Ga-C1-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 1,1,,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,南方医科大学南方医院(原研),1
[68Ga]Ga-C1-FAP-2286,[68Ga]Ga-C1-FAP-2286,PET显像,PET imaging,南方医科大学南方医院,诊断试剂领域,Diagnostic Reagents,phase 1,1,[68Ga]Ga-C1-FAP-2286,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 1,1,,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,南方医科大学南方医院(原研),1
[68Ga]PSV377,[68Ga]PSV377,癌症,cancer,Perspective Therapeutics,肿瘤领域,Oncology,phase 1,1,[68Ga]PSV377;[68Ga]Ga-PSV377,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 1,1,,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Perspective Therapeutics(原研),1
[68Ga]PSV377,[68Ga]PSV377,PET显像,PET imaging,Perspective Therapeutics,诊断试剂领域,Diagnostic Reagents,phase 1,1,[68Ga]PSV377;[68Ga]Ga-PSV377,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,phase 1,1,,I期临床,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Perspective Therapeutics(原研),1
lanreotide acetate CRF,lanreotide acetate controlled release formulation,神经内分泌肿瘤,neuroendocrine tumors,ASCIL Biopharm,肿瘤领域,Oncology,phase 1,1,lanreotide acetate CRF;醋酸兰瑞肽控释注射剂;lanreotide acetate controlled release formulation,somatostatin,somatostatin类似物,phase 1,1,,I期临床,,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,True,True,False,ASCIL Biopharm(原研),1
octreotide acetate CR,octreotide acetate CR (octreotide controlled release formulation）,神经内分泌肿瘤,neuroendocrine tumors,ASCIL Biopharm,肿瘤领域,Oncology,phase 1,1,octreotide acetate CR;octreotide acetate CR (奥曲肽控释注射剂）;octreotide acetate CR (octreotide controlled release formulation）;octreotide acetate CRF,somatostatin,somatostatin类似物,phase 1,1,,I期临床,,Active,微创新,化药,多肽,环肽;中国无申报,类似物,False,True,True,True,False,ASCIL Biopharm(原研),1
GP-033,GP-033,炎症性肠病,inflammatory bowel disease,济群医药,免疫领域,Immunology,ind,0,GP-033,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,ind,0,2024-01-10,申报临床,2024-03-30,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,济群医药(原研),1
GP-033,GP-033,克罗恩病,Crohn's disease,济群医药,消化领域,Digestive System,ind,0,GP-033,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,ind,0,2024-01-10,申报临床,2024-03-30,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,济群医药(原研),1
GP-033,GP-033,溃疡性结肠炎,ulcerative colitis,济群医药,免疫领域,Immunology,ind,0,GP-033,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,ind,0,2024-01-10,申报临床,2024-01-10,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,济群医药(原研),1
[225Ac]Ac-DOTATOC,[225Ac]Ac-DOTATOC,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,Nantes University Hospital,肿瘤领域,Oncology,pre-clinical,-1,[225Ac]Ac-DOTATOC,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,2024-09-13,临床前,2024-09-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物;多肽偶联核素,False,True,True,True,False,Nantes University Hospital(原研);Angers University(原研),2
[225Ac]Ac-DOTATOC,[225Ac]Ac-DOTATOC,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,Angers University,肿瘤领域,Oncology,pre-clinical,-1,[225Ac]Ac-DOTATOC,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,2024-09-13,临床前,2024-09-13,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物;多肽偶联核素,False,True,True,True,False,Nantes University Hospital(原研);Angers University(原研),2
[18F]AlF-NOTA-A6P,[18F]AlF-NOTA-A6P,PET显像,PET imaging,江南大学附属医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[18F]AlF-NOTA-A6P,ITGA6,18F标记的PET药物;anti-ITGA6多肽偶联核素,pre-clinical,-1,2024-10-17,临床前,2024-10-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,江南大学附属医院(原研),1
[18F]AlF-NOTA-A6P,[18F]AlF-NOTA-A6P,结直肠癌,colorectal cancer,江南大学附属医院,肿瘤领域,Oncology,pre-clinical,-1,[18F]AlF-NOTA-A6P,ITGA6,18F标记的PET药物;anti-ITGA6多肽偶联核素,pre-clinical,-1,2024-10-17,临床前,2024-10-17,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,江南大学附属医院(原研),1
[225Ac]Ac-EBTATE,[225Ac]Ac-EBTATE,小细胞肺癌,small cell lung cancer,University of Saskatchewan,肿瘤领域,Oncology,pre-clinical,-1,[225Ac]Ac-EBTATE,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,pre-clinical,-1,2024-12-04,临床前,2024-12-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,多肽偶联核素;225Ac标记的放射性药物,False,True,True,True,False,University of Saskatchewan(原研),1
[225Ac]Ac-EBTATE,[225Ac]Ac-EBTATE,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,University of Saskatchewan,肿瘤领域,Oncology,pre-clinical,-1,[225Ac]Ac-EBTATE,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,pre-clinical,-1,2024-12-04,临床前,2024-12-04,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,多肽偶联核素;225Ac标记的放射性药物,False,True,True,True,False,University of Saskatchewan(原研),1
myostatin therapeutic peptide,myostatin therapeutic peptide (Kawasaki Medical School),肥胖,obesity,PeptiDream,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School),myostatin,myostatin抑制剂,pre-clinical,-1,2024-12-12,临床前,2024-12-12,Active,创新药,化药,多肽,环肽;TGF-β信号通路,抑制剂,False,True,False,True,False,PeptiDream(原研);Kawasaki Medical School(原研),2
myostatin therapeutic peptide,myostatin therapeutic peptide (Kawasaki Medical School),肥胖,obesity,Kawasaki Medical School,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School),myostatin,myostatin抑制剂,pre-clinical,-1,2024-12-12,临床前,2024-12-12,Active,创新药,化药,多肽,环肽;TGF-β信号通路,抑制剂,False,True,False,True,False,PeptiDream(原研);Kawasaki Medical School(原研),2
myostatin therapeutic peptide,myostatin therapeutic peptide (Kawasaki Medical School),假肥大性肌营养不良,Duchenne muscular dystrophy,PeptiDream,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School),myostatin,myostatin抑制剂,pre-clinical,-1,2024-12-12,临床前,,Active,创新药,化药,多肽,环肽;TGF-β信号通路,抑制剂,False,True,True,True,False,PeptiDream(原研);Kawasaki Medical School(原研),2
myostatin therapeutic peptide,myostatin therapeutic peptide (Kawasaki Medical School),假肥大性肌营养不良,Duchenne muscular dystrophy,Kawasaki Medical School,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School),myostatin,myostatin抑制剂,pre-clinical,-1,2024-12-12,临床前,,Active,创新药,化药,多肽,环肽;TGF-β信号通路,抑制剂,False,True,True,True,False,PeptiDream(原研);Kawasaki Medical School(原研),2
MCR环肽,MCR cyclic peptide (wepon),肥胖,obesity,万邦德制药,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,MCR环肽;MCR环肽 (wepon);MCR cyclic peptide (wepon),MC4R,MC4R激动剂,pre-clinical,-1,2025-03-29,临床前,2025-03-29,Active,创新药,化药,小分子,环肽;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,万邦德制药(原研),1
[149Tb]Tb-DOTA-LM3,[149Tb]Tb-DOTA-LM3,肿瘤,tumor,Paul Scherrer Institute,肿瘤领域,Oncology,pre-clinical,-1,[149Tb]Tb-DOTA-LM3,SSTR2,149Tb标记的放射性药物;anti-SSTR2多肽偶联核素,pre-clinical,-1,2025-03-31,临床前,2025-03-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;149Tb标记的放射性药物,False,True,False,True,False,Paul Scherrer Institute(原研),1
[149Tb]Tb-DOTATATE,[149Tb]Tb-DOTATATE,肿瘤,tumor,Paul Scherrer Institute,肿瘤领域,Oncology,pre-clinical,-1,[149Tb]Tb-DOTATATE,SSTR,anti-SSTR多肽偶联核素;149Tb标记的放射性药物,pre-clinical,-1,2025-03-31,临床前,2025-03-31,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;149Tb标记的放射性药物,False,True,False,True,False,Paul Scherrer Institute(原研),1
Al18F-NOTA-FAP-2286,Al18F-NOTA-FAP-2286,前列腺癌,prostate cancer,贵州医科大学,肿瘤领域,Oncology,pre-clinical,-1,Al18F-NOTA-FAP-2286,FAP,anti-FAP多肽偶联核素;18F标记的PET药物,pre-clinical,-1,2025-04-23,临床前,2025-04-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,贵州医科大学(原研),1
Al18F-NOTA-FAP-2286,Al18F-NOTA-FAP-2286,PET显像,PET imaging,贵州医科大学,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,Al18F-NOTA-FAP-2286,FAP,anti-FAP多肽偶联核素;18F标记的PET药物,pre-clinical,-1,2025-04-23,临床前,2025-04-23,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,贵州医科大学(原研),1
177Lu-PD-29875,177Lu-PD-29875,胰腺癌,pancreatic cancer,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,177Lu-PD-29875,CLDN18.2,177Lu标记的放射性药物;anti-CLDN18.2多肽偶联核素,pre-clinical,-1,2025-04-27,临床前,2025-04-27,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,True,True,False,PeptiDream(原研),1
[18F]AlF-NOTA-SC,[18F]AlF-NOTA-SC,肿瘤,tumor,Katholieke Universiteit Leuven,肿瘤领域,Oncology,pre-clinical,-1,[18F]AlF-NOTA-SC,CXCR4,18F标记的PET药物;anti-CXCR4多肽偶联核素,pre-clinical,-1,2025-04-30,临床前,2025-04-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,Katholieke Universiteit Leuven(原研),1
[18F]AlF-NOTA-SC,[18F]AlF-NOTA-SC,PET显像,PET imaging,Katholieke Universiteit Leuven,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[18F]AlF-NOTA-SC,CXCR4,18F标记的PET药物;anti-CXCR4多肽偶联核素,pre-clinical,-1,2025-04-30,临床前,2025-04-30,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,Katholieke Universiteit Leuven(原研),1
[64Cu]CARP-2,[64Cu]CARP-2,肿瘤,tumor,中国医学科学院&北京协和医学院,肿瘤领域,Oncology,pre-clinical,-1,[64Cu]CARP-2,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,pre-clinical,-1,2025-05-19,临床前,2025-05-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽,64Cu标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,中国医学科学院&北京协和医学院(原研),1
[64Cu]CARP-2,[64Cu]CARP-2,PET显像,PET imaging,中国医学科学院&北京协和医学院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[64Cu]CARP-2,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,pre-clinical,-1,2025-05-19,临床前,2025-05-19,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽,64Cu标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,中国医学科学院&北京协和医学院(原研),1
[18F]AlF-NOTA-(SDM17)2,[18F]AlF-NOTA-(SDM17)2,肿瘤,tumor,南方医科大学,肿瘤领域,Oncology,pre-clinical,-1,[18F]AlF-NOTA-(SDM17)2,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,pre-clinical,-1,2025-06-01,临床前,2025-06-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,南方医科大学(原研),1
[18F]AlF-NOTA-(SDM17)2,[18F]AlF-NOTA-(SDM17)2,PET显像,PET imaging,南方医科大学,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[18F]AlF-NOTA-(SDM17)2,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,pre-clinical,-1,2025-06-01,临床前,2025-06-01,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,南方医科大学(原研),1
[99mTc]Tc-HYNIC-cycOn,[99mTc]Tc-HYNIC-cycOn,放射性核素显像,radionuclide imaging,中国药科大学,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[99mTc]Tc-HYNIC-cycOn,c-Met,anti-c-Met多肽偶联核素;含锝放射性示踪剂,pre-clinical,-1,2025-06-22,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;Potential First-in-Class,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,中国药科大学(原研),1
[99mTc]Tc-HYNIC-cycOn,[99mTc]Tc-HYNIC-cycOn,结直肠癌,colorectal cancer,中国药科大学,肿瘤领域,Oncology,pre-clinical,-1,[99mTc]Tc-HYNIC-cycOn,c-Met,anti-c-Met多肽偶联核素;含锝放射性示踪剂,pre-clinical,-1,2025-06-22,临床前,2025-06-22,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;Potential First-in-Class,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,中国药科大学(原研),1
IL-17A and IL-17F Dual Inhibitor,IL-17A and IL-17F Dual Inhibitor (PeptiDream),自身免疫性疾病,autoimmune disease,PeptiDream,免疫领域,Immunology,pre-clinical,-1,IL-17A and IL-17F Dual Inhibitor;IL-17A and IL-17F Dual Inhibitor (PeptiDream),IL-17A;IL-17F,IL-17F抑制剂;IL-17A抑制剂,pre-clinical,-1,2025-12-17,临床前,2025-12-17,Active,创新药,化药,多肽,环肽;Th17通路,抑制剂,False,True,False,True,False,PeptiDream(原研),1
111In-DPI-4452,111In-DPI-4452,癌症,cancer,Debiopharm,肿瘤领域,Oncology,pre-clinical,-1,111In-DPI-4452,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,False,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4452,111In-DPI-4452,癌症,cancer,3B Pharmaceuticals,肿瘤领域,Oncology,pre-clinical,-1,111In-DPI-4452,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4452,111In-DPI-4452,SPECT显像,SPECT imaging,Debiopharm,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,111In-DPI-4452,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,False,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4452,111In-DPI-4452,SPECT显像,SPECT imaging,3B Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,111In-DPI-4452,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4501,111In-DPI-4501,肾细胞癌,renal cell carcinoma,Debiopharm,肿瘤领域,Oncology,pre-clinical,-1,111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,False,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4501,111In-DPI-4501,肾细胞癌,renal cell carcinoma,3B Pharmaceuticals,肿瘤领域,Oncology,pre-clinical,-1,111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4501,111In-DPI-4501,SPECT显像,SPECT imaging,Debiopharm,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,False,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4501,111In-DPI-4501,SPECT显像,SPECT imaging,3B Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4501,111In-DPI-4501,结直肠癌,colorectal cancer,Debiopharm,肿瘤领域,Oncology,pre-clinical,-1,111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,False,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-DPI-4501,111In-DPI-4501,结直肠癌,colorectal cancer,3B Pharmaceuticals,肿瘤领域,Oncology,pre-clinical,-1,111In-DPI-4501,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,Debiopharm;3B Pharmaceuticals(原研),2
111In-FAP-2286,111In-FAP-2286,实体瘤,solid tumors,Novartis,肿瘤领域,Oncology,pre-clinical,-1,111In-FAP-2286,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
111In-FAP-2286,111In-FAP-2286,实体瘤,solid tumors,3B Pharmaceuticals,肿瘤领域,Oncology,pre-clinical,-1,111In-FAP-2286,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
111In-FAP-2286,111In-FAP-2286,实体瘤,solid tumors,Clovis Oncology,肿瘤领域,Oncology,pre-clinical,-1,111In-FAP-2286,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
111In-FAP-2286,111In-FAP-2286,SPECT显像,SPECT imaging,Novartis,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,111In-FAP-2286,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,True,True,False,False,True,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
111In-FAP-2286,111In-FAP-2286,SPECT显像,SPECT imaging,3B Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,111In-FAP-2286,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,True,True,False,True,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
111In-FAP-2286,111In-FAP-2286,SPECT显像,SPECT imaging,Clovis Oncology,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,111In-FAP-2286,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,True,True,False,False,False,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),3
177 Lu-DOTA-EB-RGD,177 Lu-DOTA-EB-RGD,非小细胞肺癌,non-small cell lung cancer,Molecular Targeting Technologies,肿瘤领域,Oncology,pre-clinical,-1,177 Lu-DOTA-EB-RGD,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,Molecular Targeting Technologies(原研),1
177Lu-PD-32766,177Lu-PD-32766,PET显像,PET imaging,PeptiDream,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,177Lu-PD-32766,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,PeptiDream(原研),1
177Lu-PD-32766,177Lu-PD-32766,肾透明细胞癌,clear cell renal cell carcinoma,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,177Lu-PD-32766,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,PeptiDream(原研),1
177Lu-PTR-58,177Lu-PTR-58,肿瘤,tumor,Starget Pharma,肿瘤领域,Oncology,pre-clinical,-1,177Lu-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,False,True,False,True,False,Starget Pharma(原研),1
177Lu-PTR-58,177Lu-PTR-58,肉瘤,sarcoma,Starget Pharma,肿瘤领域,Oncology,pre-clinical,-1,177Lu-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,False,True,False,True,False,Starget Pharma(原研),1
177Lu-RAYZ-6114,177Lu-RAYZ-6114,实体瘤,solid tumors,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,177Lu-RAYZ-6114,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,False,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),2
177Lu-RAYZ-6114,177Lu-RAYZ-6114,实体瘤,solid tumors,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,177Lu-RAYZ-6114,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),2
177Lu-RAYZ-6283,177Lu-RAYZ-6283,实体瘤,solid tumors,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,177Lu-RAYZ-6283,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,False,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),2
177Lu-RAYZ-6283,177Lu-RAYZ-6283,实体瘤,solid tumors,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,177Lu-RAYZ-6283,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,True,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),2
225Ac-EBTATE,225Ac-EBTATE,小细胞肺癌,small cell lung cancer,Molecular Targeting Technologies,肿瘤领域,Oncology,pre-clinical,-1,225Ac-EBTATE,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,False,True,True,True,False,Molecular Targeting Technologies(原研),1
225Ac-EBTATE,225Ac-EBTATE,神经内分泌肿瘤,neuroendocrine tumors,Molecular Targeting Technologies,肿瘤领域,Oncology,pre-clinical,-1,225Ac-EBTATE,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,False,True,True,True,False,Molecular Targeting Technologies(原研),1
225Ac-PD-29875,225Ac-PD-29875,胃癌,stomach cancer,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,225Ac-PD-29875,CLDN18.2,anti-CLDN18.2多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,False,True,False,True,False,PeptiDream(原研),1
225Ac-PD-32766,225Ac-PD-32766,肾透明细胞癌,clear cell renal cell carcinoma,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,225Ac-PD-32766,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物;多肽偶联核素,False,True,False,True,False,PeptiDream(原研),1
225Ac-PTR-58,225Ac-PTR-58,肝细胞癌,hepatocellular carcinoma,Starget Pharma,肿瘤领域,Oncology,pre-clinical,-1,225Ac-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,False,True,False,True,False,Starget Pharma(原研),1
225Ac-PTR-58,225Ac-PTR-58,黑色素瘤,melanoma,Starget Pharma,肿瘤领域,Oncology,pre-clinical,-1,225Ac-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,False,True,True,True,False,Starget Pharma(原研),1
225Ac-PTR-58,225Ac-PTR-58,神经内分泌肿瘤,neuroendocrine tumors,Starget Pharma,肿瘤领域,Oncology,pre-clinical,-1,225Ac-PTR-58,SSTR3,anti-SSTR3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,False,True,True,True,False,Starget Pharma(原研),1
225Ac-RAYZ-6114,225Ac-RAYZ-6114,实体瘤,solid tumors,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,225Ac-RAYZ-6114,EphA2,225Ac标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,False,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),2
225Ac-RAYZ-6114,225Ac-RAYZ-6114,实体瘤,solid tumors,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,225Ac-RAYZ-6114,EphA2,225Ac标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,True,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),2
23-R09 (FAP),23-R09 (FAP),胰腺癌,pancreatic cancer,中晟全肽,肿瘤领域,Oncology,pre-clinical,-1,23-R09 (FAP),FAP,,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽,其他,False,True,True,True,False,中晟全肽(原研),1
23-R09 (FAP),23-R09 (FAP),消化道癌症,digestive tract cancer,中晟全肽,肿瘤领域,Oncology,pre-clinical,-1,23-R09 (FAP),FAP,,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽,其他,False,True,False,True,False,中晟全肽(原研),1
23-R09 (TROP2),23-R09 (TROP2),三阴性乳腺癌,triple negative breast cancer,中晟全肽,肿瘤领域,Oncology,pre-clinical,-1,23-R09 (TROP2),TROP2,anti-TROP2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素,False,True,False,True,False,中晟全肽(原研),1
23-R09 (TROP2/nectin-4),23-R09 (TROP2/nectin-4),未知/待定,unknown/pending,中晟全肽,其他领域,Others,pre-clinical,-1,23-R09 (TROP2/nectin-4),nectin-4;TROP2,anti-nectin-4×TROP2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素,False,True,False,True,False,中晟全肽(原研),1
36R-P138,36R-P138,自身免疫性疾病,autoimmune disease,Novartis,免疫领域,Immunology,pre-clinical,-1,36R-P138,IL-36R,IL-36R抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
36R-P192,36R-P192,自身免疫性疾病,autoimmune disease,Novartis,免疫领域,Immunology,pre-clinical,-1,36R-P192,IL-36R,IL-36R抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
64Cu-NOTA-TP-c(RGDfK),64Cu-NOTA-TP-c(RGDfK),胶质母细胞瘤,glioblastoma,Université de Sherbrooke,肿瘤领域,Oncology,pre-clinical,-1,64Cu-NOTA-TP-c(RGDfK),αvβ3,64Cu标记的放射性示踪剂;anti-αvβ3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,其他,放射性药物;多肽;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,False,True,True,True,False,Université de Sherbrooke(原研),1
64Cu-PD-29875,64Cu-PD-29875,胃癌,stomach cancer,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,64Cu-PD-29875,CLDN18.2,64Cu标记的放射性示踪剂;anti-CLDN18.2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,PeptiDream(原研),1
64Cu-PD-29875,64Cu-PD-29875,PET显像,PET imaging,PeptiDream,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,64Cu-PD-29875,CLDN18.2,64Cu标记的放射性示踪剂;anti-CLDN18.2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,PeptiDream(原研),1
68Ga-DOTA-CEND1,68Ga-DOTA-CEND1,肿瘤,tumor,复旦大学附属肿瘤医院,肿瘤领域,Oncology,pre-clinical,-1,68Ga-DOTA-CEND1,NRP1,anti-NRP1多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,复旦大学附属肿瘤医院(原研),1
68Ga-DOTA-CEND1,68Ga-DOTA-CEND1,PET显像,PET imaging,复旦大学附属肿瘤医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,68Ga-DOTA-CEND1,NRP1,anti-NRP1多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,复旦大学附属肿瘤医院(原研),1
68Ga-EMP-100,68Ga-EMP-100,实体瘤,solid tumors,Edinburgh Molecular Imaging,肿瘤领域,Oncology,pre-clinical,-1,68Ga-EMP-100;[Ga-68]EMP-100,c-Met,anti-c-Met多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Edinburgh Molecular Imaging(原研),1
68Ga-EMP-100,68Ga-EMP-100,PET显像,PET imaging,Edinburgh Molecular Imaging,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,68Ga-EMP-100;[Ga-68]EMP-100,c-Met,anti-c-Met多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Edinburgh Molecular Imaging(原研),1
68Ga-NOTA-XH05,68Ga-NOTA-XH05,黑色素瘤,melanoma,同济医学院,肿瘤领域,Oncology,pre-clinical,-1,68Ga-NOTA-XH05,LAG3,anti-LAG3多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,同济医学院(原研),1
68Ga-NOTA-XH05,68Ga-NOTA-XH05,PET显像,PET imaging,同济医学院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,68Ga-NOTA-XH05,LAG3,anti-LAG3多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,同济医学院(原研),1
90Y-CM600,90Y-CM600,肿瘤,tumor,Massachusetts General Hospital,肿瘤领域,Oncology,pre-clinical,-1,90Y-CM600,fibrin,90Y标记的放射性药物;anti-fibrin多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,90Y标记的放射性药物;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研);Collagen Medical(原研),2
90Y-CM600,90Y-CM600,肿瘤,tumor,Collagen Medical,肿瘤领域,Oncology,pre-clinical,-1,90Y-CM600,fibrin,90Y标记的放射性药物;anti-fibrin多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,90Y标记的放射性药物;多肽偶联核素,False,True,False,True,False,Massachusetts General Hospital(原研);Collagen Medical(原研),2
99mTc-PentixaTec,99mTc-PentixaTec,癌症,cancer,Technische Universität München,肿瘤领域,Oncology,pre-clinical,-1,99mTc-PentixaTec;[99mTc]Tc-PentixaTec,CXCR4,含锝放射性示踪剂;anti-CXCR4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;含锝放射性示踪剂,False,True,False,True,False,Technische Universität München(原研),1
99mTc-PentixaTec,99mTc-PentixaTec,SPECT显像,SPECT imaging,Technische Universität München,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,99mTc-PentixaTec;[99mTc]Tc-PentixaTec,CXCR4,含锝放射性示踪剂;anti-CXCR4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;含锝放射性示踪剂,False,True,False,True,False,Technische Universität München(原研),1
ABZ-706,ABZ-706,肝细胞癌,hepatocellular carcinoma,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,ABZ-706;177Lu-RAYZ-8009,GPC3,177Lu标记的放射性药物;anti-GPC3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研);PeptiDream(原研)(无权益);艾博兹医药(无权益),3
ABZ-706,ABZ-706,肝细胞癌,hepatocellular carcinoma,PeptiDream,肿瘤领域,Oncology,pre-clinical,-1,ABZ-706;177Lu-RAYZ-8009,GPC3,177Lu标记的放射性药物;anti-GPC3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,False,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研);PeptiDream(原研)(无权益);艾博兹医药(无权益),3
ABZ-706,ABZ-706,肝细胞癌,hepatocellular carcinoma,艾博兹医药,肿瘤领域,Oncology,pre-clinical,-1,ABZ-706;177Lu-RAYZ-8009,GPC3,177Lu标记的放射性药物;anti-GPC3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;177Lu标记的放射性药物,True,True,False,False,False,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研);PeptiDream(原研)(无权益);艾博兹医药(无权益),3
AP-01,AP-01 (Apmonia Therapeutics),实体瘤,solid tumors,Apmonia Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,AP-01;AP-01 (Apmonia Therapeutics);TAX2 peptide;TAX2,CD47;THBS1,CD47×THBS1蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽;肿瘤相关巨噬细胞;Potential First-in-Class;肿瘤免疫,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Apmonia Therapeutics(原研),1
ARAspheres,ARAspheres (225Ac-RGD-Alginate Nanospheres),胶质母细胞瘤,glioblastoma,Blue Wave Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,ARAspheres;ARAspheres (225Ac-RGD-Alginate Nanospheres),integrin,225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,False,True,True,True,False,Blue Wave Therapeutics(原研),1
Ano-3/3s,Ano-3/3s,黑色素瘤,melanoma,上海中医药大学,肿瘤领域,Oncology,pre-clinical,-1,Ano-3/3s,not available,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,True,True,False,上海中医药大学(原研),1
BE-43547A2,BE-43547A2,胰腺癌,pancreatic cancer,,肿瘤领域,Oncology,pre-clinical,-1,BE-43547A2,EEF1A1,EEF1A1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,True,False,False,--,0
BMN 333,BMN 333,骨骼肌肉疾病,musculoskeletal diseases,BioMarin Pharmaceutical,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,BMN 333,,,pre-clinical,-1,,临床前,,Active,微创新,其他,多肽,环肽,,False,True,False,True,False,BioMarin Pharmaceutical(原研),1
BT1769,BT1769,骨肉瘤,Osteosarcoma,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,BT1769,MMP14,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,True,True,False,Bicycle Therapeutics(原研),1
BT7455,BT7455,肿瘤,tumor,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,BT7455;BCY12491,EphA2;4-1BB,EphA2配体;4-1BB激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class;肿瘤免疫,配体;激动剂,False,True,False,True,False,Bicycle Therapeutics(原研),1
Bicycle 46,Bicycle 46,哮喘,asthma,Bicycle Therapeutics,呼吸领域,Respiratory,pre-clinical,-1,Bicycle 46,TSLP,TSLP抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th2通路;Potential First-in-Class,抑制剂,False,True,False,True,False,Bicycle Therapeutics(原研),1
C4m-3127,C4m-3127,未知/待定,unknown/pending,GeneFrontier,其他领域,Others,pre-clinical,-1,C4m-3127,CTLA4,CTLA4抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Treg细胞;Potential First-in-Class,抑制剂,False,True,False,True,False,GeneFrontier(原研),1
C5 Inhibitor,C5 Inhibitor (Nimble Therapeutics),重症肌无力,myasthenia gravis,Nimble Therapeutics(AbbVie),免疫领域,Immunology,pre-clinical,-1,C5 Inhibitor;C5 Inhibitor (Nimble Therapeutics),C5,C5抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,True,True,True,True,True,Nimble Therapeutics(AbbVie)(Top20 MNC)(原研),1
CAR Peptide,CAR Peptide (Vascular BioSciences),菌血症,bacteremia,Vascular Biosciences,感染领域,Infectious Diseases,pre-clinical,-1,CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Vascular Biosciences(原研),1
CAR Peptide,CAR Peptide (Vascular BioSciences),肺动脉高压,pulmonary hypertension,Vascular Biosciences,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,True,True,False,Vascular Biosciences(原研),1
CAR Peptide,CAR Peptide (Vascular BioSciences),新型冠状病毒感染,novel coronavirus infection,Vascular Biosciences,感染领域,Infectious Diseases,pre-clinical,-1,CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Vascular Biosciences(原研),1
CBT-005,CBT-005 (Cbiomex),软骨发育不全,Achondroplasia,C-BIOMEX,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,CBT-005;CBT-005 (Cbiomex),NPRB,NPRB激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,激动剂,False,True,True,True,False,C-BIOMEX(原研),1
CN119285702A,CN119285702A,癌症,cancer,禾泰健宇,肿瘤领域,Oncology,pre-clinical,-1,CN119285702A,EphA2,EphA2抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,抑制剂,False,True,False,True,False,禾泰健宇(原研),1
CN119303102A,CN119303102A,癌症,cancer,博瑞医药,肿瘤领域,Oncology,pre-clinical,-1,CN119303102A,EphA2;nectin-4,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;受体酪氨酸激酶;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,博瑞医药(原研),1
CN119390770A,CN119390770A,肿瘤,tumor,云南白药,肿瘤领域,Oncology,pre-clinical,-1,CN119390770A,nectin-4,18F标记的PET药物;anti-nectin-4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,云南白药(原研);北京大学第一医院(原研),2
CN119390770A,CN119390770A,肿瘤,tumor,北京大学第一医院,肿瘤领域,Oncology,pre-clinical,-1,CN119390770A,nectin-4,18F标记的PET药物;anti-nectin-4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,False,True,False,True,False,云南白药(原研);北京大学第一医院(原研),2
CN119390848A,CN119390848A,神经退行性疾病,neurodegenerative diseases,中晟全肽,神经领域,Neurology,pre-clinical,-1,CN119390848A,PSD95,PSD95抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,中晟全肽(原研),1
CN119390848A,CN119390848A,缺血性卒中,ischemic stroke,中晟全肽,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,CN119390848A,PSD95,PSD95抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,中晟全肽(原研),1
CN119552215A,CN119552215A,肿瘤,tumor,星洲生物,肿瘤领域,Oncology,pre-clinical,-1,CN119552215A,SSTR2,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,True,False,星洲生物(原研),1
CN119638783A,CN119638783A,细菌感染,bacterial infection,上海交通大学,感染领域,Infectious Diseases,pre-clinical,-1,CN119638783A,APHs,多肽类抗生素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,多肽类抗生素,False,True,False,True,False,上海交通大学(原研),1
CN119701000A,CN119701000A,葡萄球菌感染,Staph infection,第四军医大学,感染领域,Infectious Diseases,pre-clinical,-1,CN119701000A,S. aureus,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;payload [利福霉素类抗生素：dmDNA31];Potential First-in-Class,多肽偶联药物,False,True,False,True,False,第四军医大学(原研),1
CN119751581A,CN119751581A,癌症,cancer,上海交通大学,肿瘤领域,Oncology,pre-clinical,-1,CN119751581A,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,上海交通大学(原研);南京市第一医院(原研),2
CN119751581A,CN119751581A,癌症,cancer,南京市第一医院,肿瘤领域,Oncology,pre-clinical,-1,CN119751581A,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,上海交通大学(原研);南京市第一医院(原研),2
CN119874812A,CN119874812A,癌症,cancer,范恩柯尔,肿瘤领域,Oncology,pre-clinical,-1,CN119874812A,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,范恩柯尔(原研),1
CN119874812A,CN119874812A,PET显像,PET imaging,范恩柯尔,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,CN119874812A,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,范恩柯尔(原研),1
CN119874840A,CN119874840A,癌症,cancer,晶核生物,肿瘤领域,Oncology,pre-clinical,-1,CN119874840A,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,晶核生物(原研),1
CN119978071A,CN119978071A,疼痛,pain,中晟全肽,麻醉镇痛领域,Anesthesia & Analgesia,pre-clinical,-1,CN119978071A,NPFFR1,NPFFR1激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;Potential First-in-Class,激动剂,False,True,False,True,False,中晟全肽(原研),1
CN120004985A,CN120004985A,肿瘤,tumor,中国医学科学院药物研究所,肿瘤领域,Oncology,pre-clinical,-1,CN120004985A,uPA,64Cu标记的放射性示踪剂;anti-uPA多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,中国医学科学院药物研究所(原研),1
CN120004985A,CN120004985A,PET显像,PET imaging,中国医学科学院药物研究所,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,CN120004985A,uPA,64Cu标记的放射性示踪剂;anti-uPA多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,中国医学科学院药物研究所(原研),1
CN120058842A,CN120058842A,肿瘤,tumor,中国医学科学院药物研究所,肿瘤领域,Oncology,pre-clinical,-1,CN120058842A,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,中国医学科学院药物研究所(原研),1
CN120058842A,CN120058842A,PET显像,PET imaging,中国医学科学院药物研究所,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,CN120058842A,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,中国医学科学院药物研究所(原研),1
CN120136966A,CN120136966A,细菌感染,bacterial infection,上海交通大学,感染领域,Infectious Diseases,pre-clinical,-1,CN120136966A,not available,脂肽类抗生素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,脂肽类抗生素,False,True,False,True,False,上海交通大学(原研),1
CN120230182A,CN120230182A,肿瘤,tumor,北京大学肿瘤医院,肿瘤领域,Oncology,pre-clinical,-1,CN120230182A,CAIX,anti-CAIX多肽偶联核素;18F标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,北京大学肿瘤医院(原研),1
CN120230182A,CN120230182A,PET显像,PET imaging,北京大学肿瘤医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,CN120230182A,CAIX,anti-CAIX多肽偶联核素;18F标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,北京大学肿瘤医院(原研),1
CN120535589A,CN120535589A,肿瘤,tumor,北京大学肿瘤医院,肿瘤领域,Oncology,pre-clinical,-1,CN120535589A,ACE2;FAP,68Ga标记的PET药物;anti-ACE2×FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;肾素-血管紧张素-醛固酮系统;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学肿瘤医院(原研),1
CN120535589A,CN120535589A,PET显像,PET imaging,北京大学肿瘤医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,CN120535589A,ACE2;FAP,68Ga标记的PET药物;anti-ACE2×FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;肾素-血管紧张素-醛固酮系统;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学肿瘤医院(原研),1
CN120757611A,CN120757611A,肾细胞癌,renal cell carcinoma,南方医科大学南方医院,肿瘤领域,Oncology,pre-clinical,-1,CN120757611A,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,南方医科大学南方医院(原研),1
CN120757611A,CN120757611A,PET显像,PET imaging,南方医科大学南方医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,CN120757611A,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,南方医科大学南方医院(原研),1
CN120757611A,CN120757611A,肾透明细胞癌,clear cell renal cell carcinoma,南方医科大学南方医院,肿瘤领域,Oncology,pre-clinical,-1,CN120757611A,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,南方医科大学南方医院(原研),1
CN120818068A,CN120818068A,疼痛,pain,新乡医学院,麻醉镇痛领域,Anesthesia & Analgesia,pre-clinical,-1,CN120818068A,μ opioid receptor;Nav1.8,μ opioid receptor×Nav1.8-白蛋白融合蛋白;μ opioid receptor激动剂;Nav1.8抑制剂,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽;融合蛋白,环肽;G蛋白偶联受体;Potential First-in-Class,激动剂;抑制剂;白蛋白融合蛋白,False,True,False,True,False,新乡医学院(原研),1
CN120837693A,CN120837693A,PET显像,PET imaging,复旦大学附属肿瘤医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,CN120837693A,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,复旦大学附属肿瘤医院(原研),1
CN120865351A,CN120865351A,阵发性睡眠性血红蛋白尿症,paroxysmal nocturnal hemoglobinuria,普康唯新,血液领域,Hematology,pre-clinical,-1,CN120865351A,C5,C5抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,True,True,False,普康唯新(原研),1
CN120865351A,CN120865351A,非典型溶血尿毒综合征,atypical hemolytic uremic syndrome,普康唯新,泌尿生殖领域,Genitourinary,pre-clinical,-1,CN120865351A,C5,C5抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,True,True,False,普康唯新(原研),1
CN121005762A,CN121005762A,焦虑症,anxiety disorder,拜西欧斯,精神领域,Psychiatry,pre-clinical,-1,CN121005762A,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,拜西欧斯(原研),1
CN121005762A,CN121005762A,神经退行性疾病,neurodegenerative diseases,拜西欧斯,神经领域,Neurology,pre-clinical,-1,CN121005762A,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,拜西欧斯(原研),1
CN121005762A,CN121005762A,癫痫,epilepsy,拜西欧斯,神经领域,Neurology,pre-clinical,-1,CN121005762A,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,拜西欧斯(原研),1
CN121045338A,CN121045338A,肾透明细胞癌,clear cell renal cell carcinoma,原子高科,肿瘤领域,Oncology,pre-clinical,-1,CN121045338A,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,原子高科(原研),1
CN121045338A-1,CN121045338A-1,肾透明细胞癌,clear cell renal cell carcinoma,原子高科,肿瘤领域,Oncology,pre-clinical,-1,CN121045338A-1,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,原子高科(原研),1
CN2097,CN2097,快乐木偶综合症,happy puppet syndrome,Aingeal therapeutics,,,pre-clinical,-1,CN2097,PSD95,PSD95抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,True,True,False,Aingeal therapeutics(原研),1
CN2097,CN2097,外伤性脑损伤,traumatic brain injury,Aingeal therapeutics,神经领域,Neurology,pre-clinical,-1,CN2097,PSD95,PSD95抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,Aingeal therapeutics(原研),1
CN2097,CN2097,难治性抑郁症,treatment-resistant depression,Aingeal therapeutics,精神领域,Psychiatry,pre-clinical,-1,CN2097,PSD95,PSD95抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,Aingeal therapeutics(原研),1
CP7-FP13-2,CP7-FP13-2,葡萄球菌感染,Staph infection,南方医科大学,感染领域,Infectious Diseases,pre-clinical,-1,CP7-FP13-2,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,南方医科大学(原研),1
CPX-101,CPX-101,骨关节炎,osteoarthritis,Chondropeptix,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,CPX-101,BMP7,BMP7类似物,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽;TGF-β信号通路;Potential First-in-Class,类似物,False,True,False,True,False,Chondropeptix(原研),1
CRRL191,CRRL191,高血压,hypertension,Mayo Clinic,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,CRRL191,NPR1,NPR1激活剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,激活剂,False,True,False,True,False,Mayo Clinic(原研),1
CRRL269,CRRL269,急性肾损伤,acute kidney injury,Mayo Clinic,泌尿生殖领域,Genitourinary,pre-clinical,-1,CRRL269,NPR1,NPR1激活剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,激活剂,False,True,False,True,False,Mayo Clinic(原研),1
CRRL555,CRRL555,高血压,hypertension,Mayo Clinic,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,CRRL555,ANP,ANP类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,类似物,False,True,False,True,False,Mayo Clinic(原研),1
CXCR4-targeting radiopharmaceutical,CXCR4-targeting radiopharmaceutical (Alpha-9),肿瘤,tumor,Alpha-9,肿瘤领域,Oncology,pre-clinical,-1,CXCR4-targeting radiopharmaceutical;CXCR4-targeting radiopharmaceutical (Alpha-9),CXCR4,,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽;G蛋白偶联受体,其他,False,True,False,True,False,Alpha-9(原研),1
CXJ-2,CXJ-2,肝纤维化,liver fibrosis,中山大学,消化领域,Digestive System,pre-clinical,-1,CXJ-2,elastin-binding protein,elastin-binding protein抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,中山大学(原研),1
Colistin Cyclops,Colistin Cyclops (inhaled colistin),肺部感染,lung infection,PureIMS,感染领域,Infectious Diseases,pre-clinical,-1,Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),not available,多粘菌素类抗生素,pre-clinical,-1,,临床前,,Active,微创新,化药,其他,环肽,多粘菌素类抗生素,False,True,False,True,False,PureIMS(原研),1
Colistin Cyclops,Colistin Cyclops (inhaled colistin),囊性纤维化,cystic fibrosis,PureIMS,呼吸领域,Respiratory,pre-clinical,-1,Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),not available,多粘菌素类抗生素,pre-clinical,-1,,临床前,,Active,微创新,化药,其他,环肽,多粘菌素类抗生素,False,True,True,True,False,PureIMS(原研),1
Colistin Cyclops,Colistin Cyclops (inhaled colistin),绿脓杆菌感染,Pseudomonas aeruginosa infection,PureIMS,感染领域,Infectious Diseases,pre-clinical,-1,Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),not available,多粘菌素类抗生素,pre-clinical,-1,,临床前,,Active,微创新,化药,其他,环肽,多粘菌素类抗生素,False,True,False,True,False,PureIMS(原研),1
Cp1,Cp1 (Changhai Hospital),脓毒症,sepsis,上海长海医院,感染领域,Infectious Diseases,pre-clinical,-1,Cp1;Cp1 (长海医院);Cp1 (Changhai Hospital),C5a,C5a阻断剂,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽;差异化疾病;Potential First-in-Class,阻断剂,False,True,False,True,False,上海长海医院(原研),1
Cyclin A targeting macrocyclic compound,Cyclin A targeting macrocyclic compound (Circle Pharma),小细胞肺癌,small cell lung cancer,Circle Pharma,肿瘤领域,Oncology,pre-clinical,-1,Cyclin A targeting macrocyclic compound;Cyclin A targeting macrocyclic compound (Circle Pharma),cyclin A,cyclin A抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;细胞周期;Potential First-in-Class,抑制剂,False,True,True,True,False,Circle Pharma(原研),1
Cyclopeptides,Cyclopeptides (advanceCOR),格雷夫斯病,Graves' disease,advanceCOR,免疫领域,Immunology,pre-clinical,-1,Cyclopeptides;Cyclopeptides (advanceCOR),TSHR,,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽,其他,False,True,False,True,False,advanceCOR(原研),1
DYV024,DYV024 (cyclosporine transdermal delivery),银屑病,psoriasis,Dyve Biosciences,免疫领域,Immunology,pre-clinical,-1,DYV024;DYV024 (环孢素透皮递送);DYV024 (cyclosporine transdermal delivery),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,pre-clinical,-1,,临床前,,Active,微创新,化药,小分子,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Dyve Biosciences(原研),1
EGFR-targeted cyclic peptides project,EGFR-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,GeneFrontier,其他领域,Others,pre-clinical,-1,EGFR-targeted cyclic peptides project;EGFR-targeted cyclic peptides project (GeneFrontier),EGFR,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶,其他,False,True,False,True,False,GeneFrontier(原研),1
Enniatin A ,Enniatin A (Augusta University),三阴性乳腺癌,triple negative breast cancer,University of Notre Dame,肿瘤领域,Oncology,pre-clinical,-1,Enniatin A ;Enniatin A (Augusta University),not available,,pre-clinical,-1,,临床前,,Active,创新药,其他,其他,环肽,其他,False,True,False,True,False,University of Notre Dame(原研);Augusta University(原研),2
Enniatin A ,Enniatin A (Augusta University),三阴性乳腺癌,triple negative breast cancer,Augusta University,肿瘤领域,Oncology,pre-clinical,-1,Enniatin A ;Enniatin A (Augusta University),not available,,pre-clinical,-1,,临床前,,Active,创新药,其他,其他,环肽,其他,False,True,False,True,False,University of Notre Dame(原研);Augusta University(原研),2
EphA2-68Ga imaging agent,EphA2-68Ga imaging agent (Bicycle),PET显像,PET imaging,Bicycle Therapeutics,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,EphA2-68Ga imaging agent;EphA2-68Ga imaging agent (Bicycle),EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
Erk2-targeted cyclic peptides project,Erk2-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,GeneFrontier,其他领域,Others,pre-clinical,-1,Erk2-targeted cyclic peptides project;Erk2-targeted cyclic peptides project (GeneFrontier),ERK2,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;MAPK信号通路,其他,False,True,False,True,False,GeneFrontier(原研),1
FNDR-20364,FNDR-20364,非结核分枝杆菌肺病,non-tuberculous mycobacterial lung disease,FNDR,感染领域,Infectious Diseases,pre-clinical,-1,FNDR-20364;NF1001,not available,多肽类抗生素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,False,True,True,True,False,FNDR(原研);NCPOR(原研),2
FNDR-20364,FNDR-20364,非结核分枝杆菌肺病,non-tuberculous mycobacterial lung disease,NCPOR,感染领域,Infectious Diseases,pre-clinical,-1,FNDR-20364;NF1001,not available,多肽类抗生素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,False,True,True,True,False,FNDR(原研);NCPOR(原研),2
FOXA1 inhibitor,FOXA1 inhibitor (Curve Therapeutics),乳腺癌,breast cancer,Curve Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,FOXA1 inhibitor;FOXA1 inhibitor (Curve Therapeutics),FOXA1,FOXA1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,Curve Therapeutics(原研),1
FP-002,FP-002 (octreotide),肢端肥大症,acromegaly,逸达生物,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,FP-002;FP-002 (奥曲肽);FP-002 (octreotide);FP-008,somatostatin,somatostatin类似物,pre-clinical,-1,,临床前,,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,逸达生物(原研),1
FP-002,FP-002 (octreotide),糖尿病视网膜病变,diabetic retinopathy,逸达生物,眼科领域,Ophthalmology,pre-clinical,-1,FP-002;FP-002 (奥曲肽);FP-002 (octreotide);FP-008,somatostatin,somatostatin类似物,pre-clinical,-1,,临床前,,Active,微创新,化药,多肽,环肽,类似物,False,True,False,True,False,逸达生物(原研),1
FPP29,FPP29,肝癌,liver cancer,西南交通大学,肿瘤领域,Oncology,pre-clinical,-1,FPP29,FOXM1,FOXM1 PROTAC,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;降解类药物,环肽;E3 ligase [VHL];Potential First-in-Class,PROTAC,False,True,False,True,False,西南交通大学(原研),1
HER2-targeted cyclic peptides project,HER2-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,GeneFrontier,其他领域,Others,pre-clinical,-1,HER2-targeted cyclic peptides project;HER2-targeted cyclic peptides project (GeneFrontier),HER2,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶,其他,False,True,False,True,False,GeneFrontier(原研),1
IL-11/IL-11Rα inhibitor,IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),炎症(未指明),Inflammation (unspecified),Takeda Pharmaceuticals,免疫领域,Immunology,pre-clinical,-1,IL-11/IL-11Rα inhibitor;IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),IL-11;IL-11RA,IL-11×IL-11RA蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,True,True,False,True,True,Takeda Pharmaceuticals(Top20 MNC)(原研),1
IL-11/IL-11Rα inhibitor,IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),纤维化(未指明),Fibrosis (unspecified),Takeda Pharmaceuticals,其他领域,Others,pre-clinical,-1,IL-11/IL-11Rα inhibitor;IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),IL-11;IL-11RA,IL-11×IL-11RA蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,True,True,False,True,True,Takeda Pharmaceuticals(Top20 MNC)(原研),1
IL-23R Inhibitor,IL-23R Inhibitor (Nimble Therapeutics),银屑病,psoriasis,Nimble Therapeutics(AbbVie),免疫领域,Immunology,pre-clinical,-1,IL-23R Inhibitor;IL-23R Inhibitor (Nimble Therapeutics),IL-23R,IL-23R抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th17通路,抑制剂,True,True,False,True,True,Nimble Therapeutics(AbbVie)(Top20 MNC)(原研),1
IL-6-targeted cyclic peptides project,IL-6-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,GeneFrontier,其他领域,Others,pre-clinical,-1,IL-6-targeted cyclic peptides project;IL-6-targeted cyclic peptides project (GeneFrontier),IL-6,IL-6抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,GeneFrontier(原研),1
IL17 therapeutic MPC,IL17 therapeutic MPC (PeptiDream),自身免疫性疾病,autoimmune disease,PeptiDream,免疫领域,Immunology,pre-clinical,-1,IL17 therapeutic MPC;IL17 therapeutic MPC (PeptiDream),IL-17,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Th17通路;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,PeptiDream(原研),1
IT-01,IT-01,肿瘤,tumor,Interprotein,肿瘤领域,Oncology,pre-clinical,-1,IT-01,TIM3,TIM3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,Interprotein(原研),1
IT-201,IT-201,肿瘤,tumor,Interprotein,肿瘤领域,Oncology,pre-clinical,-1,IT-201,TIM3,TIM3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,Interprotein(原研),1
IT-202,IT-202,肿瘤,tumor,Interprotein,肿瘤领域,Oncology,pre-clinical,-1,IT-202,TIM3,TIM3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,Interprotein(原研),1
IT-203,IT-203,肿瘤,tumor,Interprotein,肿瘤领域,Oncology,pre-clinical,-1,IT-203,TIM3,TIM3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,Interprotein(原研),1
IT-205,IT-205,肿瘤,tumor,Interprotein,肿瘤领域,Oncology,pre-clinical,-1,IT-205,TIM3,TIM3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,Interprotein(原研),1
JMKX2301,JMKX2301,未知/待定,unknown/pending,济煜医药,其他领域,Others,pre-clinical,-1,JMKX2301,not available,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,True,False,济煜医药(原研),1
JVA-4001,JVA-4001,阿片成瘾,opiate addiction,University of Florida,精神领域,Psychiatry,pre-clinical,-1,JVA-4001,κ opioid receptor,κ opioid receptor拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体,拮抗剂,False,True,False,True,False,University of Florida(原研),1
JWP24,JWP24,癌症,cancer,University of North Carolina at Chapel Hill,肿瘤领域,Oncology,pre-clinical,-1,JWP24,MAGEA4,MAGEA4抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,University of North Carolina at Chapel Hill(原研),1
KROS-401,KROS-401,三阴性乳腺癌,triple negative breast cancer,Kairos Pharma,肿瘤领域,Oncology,pre-clinical,-1,KROS-401,IL-4Rα,IL-4Rα抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th2通路;差异化疾病;Potential First-in-Class,抑制剂,False,True,False,True,False,Kairos Pharma(原研),1
KROS-401,KROS-401,阿尔茨海默病,Alzheimer's disease,Kairos Pharma,神经领域,Neurology,pre-clinical,-1,KROS-401,IL-4Rα,IL-4Rα抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th2通路;差异化疾病;Potential First-in-Class,抑制剂,False,True,False,True,False,Kairos Pharma(原研),1
KS-133,KS-133,精神分裂症,Schizophrenia,Ichimaru Pharcos,精神领域,Psychiatry,pre-clinical,-1,KS-133,VIPR2,VIPR2拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;Potential First-in-Class,拮抗剂,False,True,False,True,False,Ichimaru Pharcos(原研),1
LAS200813,LAS200813,呼吸系统疾病,respiratory diseases,AstraZeneca,呼吸领域,Respiratory,pre-clinical,-1,LAS200813,Nrf2;Keap1,Nrf2×Keap1蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Keap1-Nrf2通路;Potential First-in-Class,蛋白蛋白相互作用抑制剂,True,True,False,False,True,AstraZeneca(Top20 MNC);Almirall(原研),2
LAS200813,LAS200813,呼吸系统疾病,respiratory diseases,Almirall,呼吸领域,Respiratory,pre-clinical,-1,LAS200813,Nrf2;Keap1,Nrf2×Keap1蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Keap1-Nrf2通路;Potential First-in-Class,蛋白蛋白相互作用抑制剂,True,True,False,True,False,AstraZeneca(Top20 MNC);Almirall(原研),2
LYTAP-001,LYTAP-001,炎症(未指明),Inflammation (unspecified),Filamon,免疫领域,Immunology,pre-clinical,-1,LYTAP-001,EGFR,EGFR降解剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;降解类药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,降解剂,False,True,False,True,False,Filamon(原研),1
MAI-516,MAI-516,结直肠癌,colorectal cancer,上海大学,肿瘤领域,Oncology,pre-clinical,-1,MAI-516,activated protein C;ARHGEF4,activated protein C×ARHGEF4蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,上海大学(原研),1
MCB_D2,MCB_D2 (University of Washington),未知/待定,unknown/pending,University of Washington,其他领域,Others,pre-clinical,-1,MCB_D2;MCB_D2 (University of Washington),Mcl-1,Mcl-1结合剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;细胞凋亡;Potential First-in-Class,结合剂,False,True,False,True,False,University of Washington(原研),1
MT1-MMP targeting BDC,MT1-MMP targeting BDC (BicycleTx),非小细胞肺癌,non-small cell lung cancer,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,MT1-MMP targeting BDC;MT1-MMP targeting BDC (BicycleTx),MMP14,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
MT1-MMP-68Ga imaging agent,MT1-MMP-68Ga imaging agent (Bicycle),PET显像,PET imaging,Bicycle Therapeutics,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,MT1-MMP-68Ga imaging agent;MT1-MMP-68Ga imaging agent (Bicycle),MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Bicycle Therapeutics(原研),1
NAI-112,NAI-112,疼痛,pain,Naicons,麻醉镇痛领域,Anesthesia & Analgesia,pre-clinical,-1,NAI-112,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Naicons(原研),1
NBP14,NBP14,阿尔茨海默病,Alzheimer's disease,Neuro-Bio,神经领域,Neurology,pre-clinical,-1,NBP14,α7 receptor,α7 receptor抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,抑制剂,False,True,False,True,False,Neuro-Bio(原研),1
NK-TICA,NK-TICA,肿瘤,tumor,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,NK-TICA;BCY17226,EphA2;NKp46,EphA2×NKp46结合剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;NK cell engager;NK细胞;受体酪氨酸激酶;Potential First-in-Class,结合剂,False,True,False,True,False,Bicycle Therapeutics(原研),1
NL301,NL301 (cyclosporine eye drop),干眼病,dry eye disease,诺思兰德,眼科领域,Ophthalmology,pre-clinical,-1,NL301;NL301 (环孢素滴眼液);NL301 (cyclosporine eye drop),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,pre-clinical,-1,,临床前,,Active,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,诺思兰德(原研),1
NPA7,NPA7,心血管疾病,cardiovascular disease,Mayo Clinic,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,NPA7,Mas receptor,Mas receptor激活剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;肾素-血管紧张素-醛固酮系统;G蛋白偶联受体,激活剂,False,True,False,True,False,Mayo Clinic(原研),1
NanoRomi,NanoRomi (romidepsin nanoparticle),T细胞淋巴瘤,T cell lymphoma,University of Virginia,肿瘤领域,Oncology,pre-clinical,-1,NanoRomi;NanoRomi (romidepsin nanoparticle),HDAC,HDAC抑制剂,pre-clinical,-1,,临床前,,Active,微创新,化药,小分子,环肽;表观遗传,抑制剂,False,True,True,True,False,University of Virginia(原研),1
OMN-51,OMN-51,细菌感染,bacterial infection,Omnix Medical,感染领域,Infectious Diseases,pre-clinical,-1,OMN-51,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报,其他,False,True,False,True,False,Omnix Medical(原研),1
ORYN 1051,ORYN 1051,克罗恩病,Crohn's disease,Oryn Therapeutics,消化领域,Digestive System,pre-clinical,-1,ORYN 1051,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Oryn Therapeutics(原研),1
ORYN 1051,ORYN 1051,溃疡性结肠炎,ulcerative colitis,Oryn Therapeutics,免疫领域,Immunology,pre-clinical,-1,ORYN 1051,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Oryn Therapeutics(原研),1
ORYN 1053,ORYN 1053,肿瘤,tumor,Oryn Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,ORYN 1053,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Oryn Therapeutics(原研),1
ORYN 1064,ORYN 1064,细菌感染,bacterial infection,Oryn Therapeutics,感染领域,Infectious Diseases,pre-clinical,-1,ORYN 1064,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Oryn Therapeutics(原研),1
P1-1,P1-1,肝纤维化,liver fibrosis,中山大学,消化领域,Digestive System,pre-clinical,-1,P1-1,GPR55,GPR55拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,拮抗剂,False,True,False,True,False,中山大学(原研);图微安创(原研),2
P1-1,P1-1,肝纤维化,liver fibrosis,图微安创,消化领域,Digestive System,pre-clinical,-1,P1-1,GPR55,GPR55拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,拮抗剂,False,True,False,True,False,中山大学(原研);图微安创(原研),2
PBP3s inhibitor,PBP3s inhibitor (Bicycle Therapeutics),细菌感染,bacterial infection,Bicycle Therapeutics,感染领域,Infectious Diseases,pre-clinical,-1,PBP3s inhibitor;PBP3s inhibitor (Bicycle Therapeutics),PBP3,PBP3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,Bicycle Therapeutics(原研),1
PD-K(111In-DOTA)-RGD,PD-K(111In-DOTA)-RGD,胰腺导管癌,pancreatic ductal carcinoma,National Cancer Center Japan,肿瘤领域,Oncology,pre-clinical,-1,PD-K(111In-DOTA)-RGD,αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;含铟放射性示踪剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,National Cancer Center Japan(原研),1
PD-K(177Lu-DOTA)-c(RGDfK),PD-K(177Lu-DOTA)-c(RGDfK),胰腺导管癌,pancreatic ductal carcinoma,National Cancer Center Japan,肿瘤领域,Oncology,pre-clinical,-1,PD-K(177Lu-DOTA)-c(RGDfK),αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;177Lu标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,National Cancer Center Japan(原研),1
PD-K(225Ac-DOTA)-c(RGDfK),PD-K(225Ac-DOTA)-c(RGDfK),胰腺导管癌,pancreatic ductal carcinoma,National Cancer Center Japan,肿瘤领域,Oncology,pre-clinical,-1,PD-K(225Ac-DOTA)-c(RGDfK),αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,False,True,False,True,False,National Cancer Center Japan(原研),1
PG-004,PG-004,未知/待定,unknown/pending,PeptiGrowth,其他领域,Others,pre-clinical,-1,PG-004,BMP7;BMP4,BMP4抑制剂;BMP7抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;TGF-β信号通路;Potential First-in-Class,抑制剂,False,True,False,True,False,PeptiGrowth(原研),1
PG-005,PG-005,未知/待定,unknown/pending,PeptiGrowth,其他领域,Others,pre-clinical,-1,PG-005,BMP7,BMP7抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;TGF-β信号通路;Potential First-in-Class,抑制剂,False,True,False,True,False,PeptiGrowth(原研),1
PG-006,PG-006,未知/待定,unknown/pending,PeptiGrowth,其他领域,Others,pre-clinical,-1,PG-006,BMP4,BMP4抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,PeptiGrowth(原研),1
PG-007,PG-007,未知/待定,unknown/pending,PeptiGrowth,其他领域,Others,pre-clinical,-1,PG-007,VEGFR2,VEGFR2激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,激动剂,False,True,False,True,False,PeptiGrowth(原研),1
PG-008,PG-008,未知/待定,unknown/pending,PeptiGrowth,其他领域,Others,pre-clinical,-1,PG-008,WNT3A,WNT3A类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,类似物,False,True,False,True,False,PeptiGrowth(原研),1
PG-010,PG-010,未知/待定,unknown/pending,PeptiGrowth,其他领域,Others,pre-clinical,-1,PG-010,TPO receptor,TPO receptor激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,激动剂,False,True,False,True,False,PeptiGrowth(原研),1
PG-012,PG-012,未知/待定,unknown/pending,PeptiGrowth,其他领域,Others,pre-clinical,-1,PG-012,FGFR2,FGFR2激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,激动剂,False,True,False,True,False,PeptiGrowth(原研),1
PHIN-1314,PHIN-1314,实体瘤,solid tumors,PharmaIN,肿瘤领域,Oncology,pre-clinical,-1,PHIN-1314,CNP,CNP类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,类似物,False,True,False,True,False,PharmaIN(原研),1
PHIN-1314,PHIN-1314,纤维化(未指明),Fibrosis (unspecified),PharmaIN,其他领域,Others,pre-clinical,-1,PHIN-1314,CNP,CNP类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,类似物,False,True,False,True,False,PharmaIN(原研),1
PLX138,PLX138,软骨发育不全,Achondroplasia,ProLynx,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,"PLX138;[Gln6,14]CNP-38",CNP,CNP类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,类似物,False,True,True,True,False,ProLynx(原研),1
PN23114,PN23114,遗传性血色素沉着病,hereditary hemochromatosis,Protagonist Therapeutics,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,PN23114,Hepc,Hepc模拟物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;铁代谢,模拟物,False,True,True,True,False,Protagonist Therapeutics(原研),1
POL7306,POL7306,细菌感染,bacterial infection,Polyphor(Spexis),感染领域,Infectious Diseases,pre-clinical,-1,POL7306,BamA,BamA抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,Polyphor(Spexis)(原研),1
PT-2,PT-2 (oral octreotide),类癌,carcinoid,Imagine Pharma,肿瘤领域,Oncology,pre-clinical,-1,PT-2;PT-2 (口服奥曲肽);PT-2 (oral octreotide),somatostatin,somatostatin类似物,pre-clinical,-1,,临床前,,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,Imagine Pharma(原研),1
PT-2,PT-2 (oral octreotide),类癌综合征,carcinoid syndrome,Imagine Pharma,肿瘤领域,Oncology,pre-clinical,-1,PT-2;PT-2 (口服奥曲肽);PT-2 (oral octreotide),somatostatin,somatostatin类似物,pre-clinical,-1,,临床前,,Active,微创新,化药,多肽,环肽,类似物,False,True,True,True,False,Imagine Pharma(原研),1
Pb-BCY20603,Pb-BCY20603,癌症,cancer,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,Pb-BCY20603,MMP14,212Pb标记的放射性药物;anti-MMP14多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,False,True,False,Bicycle Therapeutics(原研);Orano Med,2
Pb-BCY20603,Pb-BCY20603,癌症,cancer,Orano Med,肿瘤领域,Oncology,pre-clinical,-1,Pb-BCY20603,MMP14,212Pb标记的放射性药物;anti-MMP14多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,False,True,False,False,False,Bicycle Therapeutics(原研);Orano Med,2
RAY0221,RAY0221,糖尿病,diabetes,众生睿创,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,RAY0221,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,True,False,众生睿创(原研),1
RAY0221,RAY0221,肥胖,obesity,众生睿创,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,RAY0221,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,True,False,众生睿创(原研),1
RAY0221,RAY0221,代谢相关脂肪性肝炎,Metabolic related steatohepatitis,众生睿创,消化领域,Digestive System,pre-clinical,-1,RAY0221,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,False,True,False,True,False,众生睿创(原研),1
RGD-VC-CA,RGD-VC-CA,癌症,cancer,中国科学院深圳先进技术研究院,肿瘤领域,Oncology,pre-clinical,-1,RGD-VC-CA,not available,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,True,False,中国科学院深圳先进技术研究院(原研),1
SAG602,SAG602,癌症,cancer,羿肽生物,肿瘤领域,Oncology,pre-clinical,-1,SAG602,Muc1,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,羿肽生物(原研),1
SAG602,SAG602,光学成像剂,optical imaging agent,羿肽生物,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,SAG602,Muc1,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,羿肽生物(原研),1
SBL-PX1-206,SBL-PX1-206,心血管疾病,cardiovascular disease,Vrije Universiteit Brussel,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,SBL-PX1-206,PANX1,PANX1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,Vrije Universiteit Brussel(原研),1
SBL-PX1-42,SBL-PX1-42,心血管疾病,cardiovascular disease,Vrije Universiteit Brussel,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,SBL-PX1-42,PANX1,PANX1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,Vrije Universiteit Brussel(原研),1
SBL-PX1-44,SBL-PX1-44,心血管疾病,cardiovascular disease,Vrije Universiteit Brussel,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,SBL-PX1-44,PANX1,PANX1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,Vrije Universiteit Brussel(原研),1
SG5035,SG5035,侵袭性念珠菌病,Invasive candidiasis,祥根生物,感染领域,Infectious Diseases,pre-clinical,-1,SG5035,glucan synthase,glucan synthase抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,祥根生物(原研),1
SP-002,SP-002 (cyclosporin nanoparticles),肢体缺血性疾病,limb ischemic disease,Sentan Pharma,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,SP-002;SP-002 (环孢素纳米粒);SP-002 (cyclosporin nanoparticles),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,pre-clinical,-1,,临床前,,Active,微创新,化药,小分子,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,False,True,False,True,False,Sentan Pharma(原研),1
SVC112,SVC112,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,SuviCa,肿瘤领域,Oncology,pre-clinical,-1,SVC112,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,SuviCa(原研),1
SYNB011128,SYNB011128,癌症,cancer,元思生肽,肿瘤领域,Oncology,pre-clinical,-1,SYNB011128,CAIX;EGFR,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,False,True,False,True,False,元思生肽(原研),1
SYNB021225,SYNB021225,肿瘤,tumor,元思生肽,肿瘤领域,Oncology,pre-clinical,-1,SYNB021225,KRAS,KRAS抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;难成药靶点,抑制剂,False,True,False,True,False,元思生肽(原研),1
ShK-235,ShK-235,类风湿性关节炎,rheumatoid arthritis,Baylor College of Medicine,免疫领域,Immunology,pre-clinical,-1,ShK-235;LrS235,Kv1.3,Kv1.3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,Baylor College of Medicine(原研),1
Syn3,Syn3,快乐木偶综合症,happy puppet syndrome,Aingeal therapeutics,,,pre-clinical,-1,Syn3,BDNF,BDNF增强剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,增强剂,False,True,True,True,False,Aingeal therapeutics(原研),1
Syn3,Syn3,外伤性脑损伤,traumatic brain injury,Aingeal therapeutics,神经领域,Neurology,pre-clinical,-1,Syn3,BDNF,BDNF增强剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,增强剂,False,True,False,True,False,Aingeal therapeutics(原研),1
Syn3,Syn3,难治性抑郁症,treatment-resistant depression,Aingeal therapeutics,精神领域,Psychiatry,pre-clinical,-1,Syn3,BDNF,BDNF增强剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,增强剂,False,True,False,True,False,Aingeal therapeutics(原研),1
Synova macrocyclic peptide,Synova macrocyclic peptide (Syneron Bio),自身免疫性疾病,autoimmune disease,AstraZeneca,免疫领域,Immunology,pre-clinical,-1,Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio),not available,,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽;中国无申报,其他,True,True,False,False,True,AstraZeneca(Top20 MNC);元思生肽(原研),2
Synova macrocyclic peptide,Synova macrocyclic peptide (Syneron Bio),自身免疫性疾病,autoimmune disease,元思生肽,免疫领域,Immunology,pre-clinical,-1,Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio),not available,,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽;中国无申报,其他,True,True,False,True,False,AstraZeneca(Top20 MNC);元思生肽(原研),2
Synova macrocyclic peptide,Synova macrocyclic peptide (Syneron Bio),代谢疾病,Metabolic diseases,AstraZeneca,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio),not available,,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽;中国无申报,其他,True,True,False,False,True,AstraZeneca(Top20 MNC);元思生肽(原研),2
Synova macrocyclic peptide,Synova macrocyclic peptide (Syneron Bio),代谢疾病,Metabolic diseases,元思生肽,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio),not available,,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽;中国无申报,其他,True,True,False,True,False,AstraZeneca(Top20 MNC);元思生肽(原研),2
T20K,T20K,多发性硬化症相关视神经炎,Multiple sclerosis-related optic neuritis,Cyxone,神经领域,Neurology,pre-clinical,-1,T20K,IL-2,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,True,True,False,Cyxone(原研),1
TB513,TB513,肿瘤,tumor,Twinpig Biolab,肿瘤领域,Oncology,pre-clinical,-1,TB513,SIRPα,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;肿瘤相关巨噬细胞;中国无申报;Potential First-in-Class;肿瘤免疫,多肽偶联药物,False,True,False,True,False,Twinpig Biolab(原研),1
TB551,TB551,胰腺癌,pancreatic cancer,Twinpig Biolab,肿瘤领域,Oncology,pre-clinical,-1,TB551;TB522,not available,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;中国无申报,多肽偶联药物,False,True,True,True,False,Twinpig Biolab(原研),1
TB712,TB712,肿瘤,tumor,Twinpig Biolab,肿瘤领域,Oncology,pre-clinical,-1,TB712;TB711,CD18;STAT6,多肽偶联药物;反义疗法,pre-clinical,-1,,临床前,,Active,创新药,化药,核酸;多肽;偶联药物,环肽;JAK-STAT信号通路;小核酸;中国无申报;Potential First-in-Class,反义疗法;多肽偶联药物,False,True,False,True,False,Twinpig Biolab(原研),1
TBR521,TBR521,癌症,cancer,Twinpig Biolab,肿瘤领域,Oncology,pre-clinical,-1,TBR521,FAP,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;中国无申报,多肽偶联药物,False,True,False,True,False,Twinpig Biolab(原研),1
TBR551,TBR551,癌症,cancer,Twinpig Biolab,肿瘤领域,Oncology,pre-clinical,-1,TBR551,nectin-4,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;中国无申报,多肽偶联药物,False,True,False,True,False,Twinpig Biolab(原研),1
TBR552,TBR552,癌症,cancer,Twinpig Biolab,肿瘤领域,Oncology,pre-clinical,-1,TBR552,TROP2,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;中国无申报;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,Twinpig Biolab(原研),1
TBR553,TBR553,癌症,cancer,Twinpig Biolab,肿瘤领域,Oncology,pre-clinical,-1,TBR553,ROR1,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联药物,False,True,False,True,False,Twinpig Biolab(原研),1
TLR3 targeted Bicycle,TLR3 targeted Bicycle (Bicycle Therapeutics),实体瘤,solid tumors,Genentech(Roche),肿瘤领域,Oncology,pre-clinical,-1,TLR3 targeted Bicycle;TLR3 targeted Bicycle (Bicycle Therapeutics),TLR3,TLR3调节剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Toll样受体信号通路;中国无申报;Potential First-in-Class;肿瘤免疫,调节剂,True,True,False,False,True,Genentech(Roche)(Top20 MNC);Bicycle Therapeutics(原研),2
TLR3 targeted Bicycle,TLR3 targeted Bicycle (Bicycle Therapeutics),实体瘤,solid tumors,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,TLR3 targeted Bicycle;TLR3 targeted Bicycle (Bicycle Therapeutics),TLR3,TLR3调节剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Toll样受体信号通路;中国无申报;Potential First-in-Class;肿瘤免疫,调节剂,True,True,False,True,False,Genentech(Roche)(Top20 MNC);Bicycle Therapeutics(原研),2
TNF-α-targeted cyclic peptides project,TNF-α-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,GeneFrontier,其他领域,Others,pre-clinical,-1,TNF-α-targeted cyclic peptides project;TNF-α-targeted cyclic peptides project (GeneFrontier),TNF-α,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,GeneFrontier(原研),1
TT-241X,TT-241X,神经痛,neuralgia,Teitur Trophics,麻醉镇痛领域,Anesthesia & Analgesia,pre-clinical,-1,TT-241X,not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Teitur Trophics(原研),1
Tye-1002,Tye-1002,小细胞肺癌,small cell lung cancer,泰尔康生物,肿瘤领域,Oncology,pre-clinical,-1,Tye-1002,SSTR2,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;差异化疾病,多肽偶联药物,False,True,True,True,False,泰尔康生物(原研),1
Tye-1002,Tye-1002,鼻咽癌,Nasopharyngeal cancer,泰尔康生物,肿瘤领域,Oncology,pre-clinical,-1,Tye-1002,SSTR2,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;差异化疾病,多肽偶联药物,False,True,True,True,False,泰尔康生物(原研),1
Tye-1002,Tye-1002,神经内分泌肿瘤,neuroendocrine tumors,泰尔康生物,肿瘤领域,Oncology,pre-clinical,-1,Tye-1002,SSTR2,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;差异化疾病,多肽偶联药物,False,True,True,True,False,泰尔康生物(原研),1
Tye-2001,Tye-2001,器官移植,organ transplant,泰尔康生物,其他领域,Others,pre-clinical,-1,Tye-2001;Tye2001,CaN;SSTR2;FKBP12,多肽偶联药物;CaN×FKBP12分子胶,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物;分子胶,False,True,False,True,False,泰尔康生物(原研),1
ULT3,ULT3,细菌感染,bacterial infection,Ultupharma,感染领域,Infectious Diseases,pre-clinical,-1,ULT3,P. aeruginosa;S. aureus;E. coli;K. pneumoniae;A. baumannii,多肽类抗生素,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;Potential First-in-Class,多肽类抗生素,False,True,False,True,False,Ultupharma(原研),1
UNP-6457,UNP-6457,未知/待定,unknown/pending,Unnatural Products,其他领域,Others,pre-clinical,-1,UNP-6457,MDM2;p53,MDM2×p53蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;细胞凋亡;泛素-蛋白酶体系统;合成致死;难成药靶点;p53信号通路,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Unnatural Products(原研),1
US2025122242A1,US2025122242A1,阿尔茨海默病,Alzheimer's disease,WARF,神经领域,Neurology,pre-clinical,-1,US2025122242A1,Aβ,Aβ聚集抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Amyloid beta通路,聚集抑制剂,False,True,False,True,False,WARF(原研),1
US2025145665A1,US2025145665A1,自身免疫性疾病,autoimmune disease,Bristol-Myers Squibb,免疫领域,Immunology,pre-clinical,-1,US2025145665A1,TNF-α,TNF-α抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC)(原研),1
US2025145665A1,US2025145665A1,炎症(未指明),Inflammation (unspecified),Bristol-Myers Squibb,免疫领域,Immunology,pre-clinical,-1,US2025145665A1,TNF-α,TNF-α抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC)(原研),1
VIAN-c4551,VIAN-c4551,湿性年龄相关性黄斑变性,Wet age-related macular degeneration,ViAn Therapeutics,眼科领域,Ophthalmology,pre-clinical,-1,VIAN-c4551,Ang2;VEGF,Ang2×VEGF抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,ViAn Therapeutics(原研),1
VIAN-c4551,VIAN-c4551,糖尿病黄斑水肿,diabetic macular edema,ViAn Therapeutics,眼科领域,Ophthalmology,pre-clinical,-1,VIAN-c4551,Ang2;VEGF,Ang2×VEGF抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,ViAn Therapeutics(原研),1
VIAN-c4551,VIAN-c4551,糖尿病视网膜病变,diabetic retinopathy,ViAn Therapeutics,眼科领域,Ophthalmology,pre-clinical,-1,VIAN-c4551,Ang2;VEGF,Ang2×VEGF抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,ViAn Therapeutics(原研),1
VRP-034,VRP-034,细菌感染,bacterial infection,Venus Remedies,感染领域,Infectious Diseases,pre-clinical,-1,VRP-034;VRP-034 (Polymyxin B),not available,多粘菌素类抗生素,pre-clinical,-1,,临床前,,Active,微创新,化药,其他,环肽;中国无申报,多粘菌素类抗生素,False,True,False,True,False,Venus Remedies(原研),1
WN561,WN561,心血管疾病,cardiovascular disease,浙江大学医学院附属邵逸夫医院,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WN561,APLNR,APLNR激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体,激动剂,False,True,False,True,False,浙江大学医学院附属邵逸夫医院(原研),1
WO2021007436A1,WO2021007436A1,癌症,cancer,拓创生物,肿瘤领域,Oncology,pre-clinical,-1,WO2021007436A1,Bcl-2;PD1;TNF-α,Bcl-2抑制剂;TNF-α抑制剂;PD1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;细胞凋亡;Potential First-in-Class;难成药靶点;肿瘤免疫,抑制剂,False,True,False,True,False,拓创生物(原研),1
WO2022034057A1,WO2022034057A1,糖尿病,diabetes,Bayer,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2022034057A1,RARRES2,RARRES2类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,类似物,True,True,False,True,True,Bayer(Top20 MNC)(原研),1
WO2022096394A1,WO2022096394A1,心肌再灌注损伤,myocardial reperfusion injury,Bayer,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2022096394A1,MASP,MASP抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,True,True,False,True,True,Bayer(Top20 MNC)(原研),1
WO2022096394A1,WO2022096394A1,肾脏缺血再灌注损伤,renal ischemia-reperfusion injury,Bayer,泌尿生殖领域,Genitourinary,pre-clinical,-1,WO2022096394A1,MASP,MASP抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,True,True,False,True,True,Bayer(Top20 MNC)(原研),1
WO2022115799A1,WO2022115799A1,结直肠癌,colorectal cancer,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,WO2022115799A1,GC-C,anti-GC-C多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
WO2022129254A1,WO2022129254A1,糖尿病,diabetes,MedImmune(AstraZeneca),内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2022129254A1,amylin,amylin类似物,pre-clinical,-1,,临床前,,Active,微创新,化药,多肽,环肽,类似物,True,True,False,True,True,MedImmune(AstraZeneca)(Top20 MNC)(原研),1
WO2022129254A1,WO2022129254A1,肥胖,obesity,MedImmune(AstraZeneca),内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2022129254A1,amylin,amylin类似物,pre-clinical,-1,,临床前,,Active,微创新,化药,多肽,环肽,类似物,True,True,False,True,True,MedImmune(AstraZeneca)(Top20 MNC)(原研),1
WO2022212947A1,WO2022212947A1,癌症,cancer,Indi Molecular,肿瘤领域,Oncology,pre-clinical,-1,WO2022212947A1,KRAS G12D,KRAS G12D抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;难成药靶点;Ras-Raf信号通路,抑制剂,False,True,False,True,False,Indi Molecular(原研),1
WO2022223969A1,WO2022223969A1,癌症,cancer,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,WO2022223969A1,P-sel,P-sel抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;CLR信号通路,抑制剂,False,True,False,True,False,Bicycle Therapeutics(原研),1
WO2022223969A1,WO2022223969A1,镰状细胞病,sickle cell disease,Bicycle Therapeutics,血液领域,Hematology,pre-clinical,-1,WO2022223969A1,P-sel,P-sel抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;CLR信号通路,抑制剂,False,True,True,True,False,Bicycle Therapeutics(原研),1
WO2022223969A1,WO2022223969A1,新型冠状病毒感染,novel coronavirus infection,Bicycle Therapeutics,感染领域,Infectious Diseases,pre-clinical,-1,WO2022223969A1,P-sel,P-sel抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;CLR信号通路,抑制剂,False,True,False,True,False,Bicycle Therapeutics(原研),1
WO2022253051A1,WO2022253051A1,肿瘤,tumor,药明康德,肿瘤领域,Oncology,pre-clinical,-1,WO2022253051A1,nectin-4,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,True,False,药明康德(原研),1
WO2023020485A1,WO2023020485A1,实体瘤,solid tumors,药明康德,肿瘤领域,Oncology,pre-clinical,-1,WO2023020485A1,EphA2,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];受体酪氨酸激酶,多肽偶联药物,False,True,False,True,False,药明康德(原研),1
WO2023026994A1,WO2023026994A1,假肥大性肌营养不良,Duchenne muscular dystrophy,Takeda Pharmaceuticals,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,WO2023026994A1,dystrophin;TfR,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,核酸;多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,True,True,True,True,True,Takeda Pharmaceuticals(Top20 MNC)(原研),1
WO2023048151A1,WO2023048151A1,新型冠状病毒感染,novel coronavirus infection,Shionogi,感染领域,Infectious Diseases,pre-clinical,-1,WO2023048151A1,SARS-CoV-2 S protein,SARS-CoV-2 S protein抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,Shionogi(原研);Hokkaido University(原研),2
WO2023048151A1,WO2023048151A1,新型冠状病毒感染,novel coronavirus infection,Hokkaido University,感染领域,Infectious Diseases,pre-clinical,-1,WO2023048151A1,SARS-CoV-2 S protein,SARS-CoV-2 S protein抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,Shionogi(原研);Hokkaido University(原研),2
WO2023056368A1,WO2023056368A1,男性避孕,male contraception,Department of Health and Human Services,泌尿生殖领域,Genitourinary,pre-clinical,-1,WO2023056368A1,DDX25,DDX25抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,Department of Health and Human Services(原研),1
WO2023061482A1,WO2023061482A1,肿瘤,tumor,海思科,肿瘤领域,Oncology,pre-clinical,-1,WO2023061482A1,EphA2,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;受体酪氨酸激酶,多肽偶联药物,False,True,False,True,False,海思科(原研),1
WO2023066314A1,WO2023066314A1,肿瘤,tumor,海思科,肿瘤领域,Oncology,pre-clinical,-1,WO2023066314A1,nectin-4,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,True,False,海思科(原研),1
WO2023069332A1,WO2023069332A1,癌症,cancer,Merck & Co.,肿瘤领域,Oncology,pre-clinical,-1,WO2023069332A1,eIF4E,eIF4E抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
WO2023084234A1,WO2023084234A1,新型冠状病毒感染,novel coronavirus infection,Bicycle Therapeutics,感染领域,Infectious Diseases,pre-clinical,-1,WO2023084234A1,ACE2,ACE2结合剂,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;肾素-血管紧张素-醛固酮系统,结合剂,False,True,False,True,False,Bicycle Therapeutics(原研),1
WO2023088236A1,WO2023088236A1,癌症,cancer,海思科,肿瘤领域,Oncology,pre-clinical,-1,WO2023088236A1,MMP14,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,海思科(原研),1
WO2023098072A1,WO2023098072A1,肿瘤,tumor,北京大学第一医院,肿瘤领域,Oncology,pre-clinical,-1,WO2023098072A1,nectin-4,177Lu标记的放射性药物;anti-nectin-4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,北京大学第一医院(原研),1
WO2023111350A2,WO2023111350A2,癌症,cancer,3B Pharmaceuticals,肿瘤领域,Oncology,pre-clinical,-1,WO2023111350A2,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,False,True,False,True,False,3B Pharmaceuticals(原研),1
WO2023111350A2,WO2023111350A2,SPECT显像,SPECT imaging,3B Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2023111350A2,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,False,True,False,True,False,3B Pharmaceuticals(原研),1
WO2023121699A1,WO2023121699A1,癌症,cancer,KSURF,肿瘤领域,Oncology,pre-clinical,-1,WO2023121699A1,CTLA4,CTLA4抑制剂,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;Treg细胞;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,KSURF(原研),1
WO2023136342A1,WO2023136342A1,外周动脉疾病,peripheral arterial disease,Daiichi Sankyo,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2023136342A1,THBS1,THBS1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,Daiichi Sankyo(原研);PeptiDream(原研),2
WO2023136342A1,WO2023136342A1,外周动脉疾病,peripheral arterial disease,PeptiDream,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2023136342A1,THBS1,THBS1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,Daiichi Sankyo(原研);PeptiDream(原研),2
WO2023136342A1,WO2023136342A1,严重肢体缺血,critical limb ischemia,Daiichi Sankyo,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2023136342A1,THBS1,THBS1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,Daiichi Sankyo(原研);PeptiDream(原研),2
WO2023136342A1,WO2023136342A1,严重肢体缺血,critical limb ischemia,PeptiDream,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2023136342A1,THBS1,THBS1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,Daiichi Sankyo(原研);PeptiDream(原研),2
WO2023145860A1,WO2023145860A1,肿瘤,tumor,Ajinomoto,肿瘤领域,Oncology,pre-clinical,-1,WO2023145860A1,c-Kit,c-Kit激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,激动剂,False,True,False,True,False,Ajinomoto(原研),1
WO2023165476A1,WO2023165476A1,肿瘤,tumor,智肽生物,肿瘤领域,Oncology,pre-clinical,-1,WO2023165476A1,Sortilin,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,True,False,智肽生物(原研),1
WO2023169584A1,WO2023169584A1,癌症,cancer,智肽生物,肿瘤领域,Oncology,pre-clinical,-1,WO2023169584A1,nectin-4,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE],多肽偶联药物,False,True,False,True,False,智肽生物(原研),1
WO2023220634A2,WO2023220634A2,癌症,cancer,University of Pennsylvania,肿瘤领域,Oncology,pre-clinical,-1,WO2023220634A2,EGFR,EGFR类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,类似物,False,True,False,True,False,University of Pennsylvania(原研);Elicio Therapeutics(原研),2
WO2023220634A2,WO2023220634A2,癌症,cancer,Elicio Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,WO2023220634A2,EGFR,EGFR类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,类似物,False,True,False,True,False,University of Pennsylvania(原研);Elicio Therapeutics(原研),2
WO2023220836A1,WO2023220836A1,PET显像,PET imaging,University of Alberta,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2023220836A1,SSTR2,125I标记的放射性示踪剂;anti-SSTR2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;中国无申报;Potential First-in-Class,多肽偶联核素;125I标记的放射性示踪剂,False,True,False,True,False,University of Alberta(原研),1
WO2023225661A1,WO2023225661A1,癌症,cancer,Bristol-Myers Squibb,肿瘤领域,Oncology,pre-clinical,-1,WO2023225661A1,PD1;PDL1,PD1×PDL1蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;肿瘤免疫,蛋白蛋白相互作用抑制剂,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC)(原研),1
WO2023228186A1,WO2023228186A1,癌症,cancer,Ariel Precision Medicine,肿瘤领域,Oncology,pre-clinical,-1,WO2023228186A1,EGFR,EGFR结合剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,结合剂,False,True,False,True,False,Ariel Precision Medicine(原研),1
WO2023244554A1,WO2023244554A1,动脉粥样硬化,atherosclerosis,Merck & Co.,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2023244554A1,IL-1β,IL-1β抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
WO2023245016A1,WO2023245016A1,皮肤病,skin disease,B.A.I. Biosciences,皮肤领域,Dermatology,pre-clinical,-1,WO2023245016A1,IL-13,IL-13抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th2通路;Potential First-in-Class,抑制剂,False,True,False,True,False,B.A.I. Biosciences(原研),1
WO2024003313A1,WO2024003313A1,炎症性肠病,inflammatory bowel disease,Sanofi,免疫领域,Immunology,pre-clinical,-1,WO2024003313A1,IL-23R,IL-23R拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th17通路,拮抗剂,True,True,False,True,True,Sanofi(Top20 MNC)(原研),1
WO2024010957A2,WO2024010957A2,肿瘤,tumor,Aktis Oncology,肿瘤领域,Oncology,pre-clinical,-1,WO2024010957A2,nectin-4,含铟放射性示踪剂;anti-nectin-4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,Aktis Oncology(原研),1
WO2024010957A2,WO2024010957A2,SPECT显像,SPECT imaging,Aktis Oncology,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2024010957A2,nectin-4,含铟放射性示踪剂;anti-nectin-4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,Aktis Oncology(原研),1
WO2024015958A1,WO2024015958A1,自身免疫性疾病,autoimmune disease,Janssen Biotech(Johnson & Johnson),免疫领域,Immunology,pre-clinical,-1,WO2024015958A1,IL-23R,IL-23R拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th17通路,拮抗剂,True,True,False,True,True,Janssen Biotech(Johnson & Johnson)(Top20 MNC)(原研),1
WO2024020159A1,WO2024020159A1,癌症,cancer,Merck & Co.,肿瘤领域,Oncology,pre-clinical,-1,WO2024020159A1,KRAS G12D,KRAS G12D抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;难成药靶点;Ras-Raf信号通路,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
WO2024043250A1,WO2024043250A1,癌症,cancer,Fujifilm,肿瘤领域,Oncology,pre-clinical,-1,WO2024043250A1,MDMX,MDMX抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;p53信号通路,抑制剂,False,True,False,True,False,Fujifilm(原研),1
WO2024052431A1,WO2024052431A1,前列腺癌,prostate cancer,3B Pharmaceuticals,肿瘤领域,Oncology,pre-clinical,-1,WO2024052431A1,PSMA,anti-PSMA多肽偶联核素;含铟放射性示踪剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,3B Pharmaceuticals(原研),1
WO2024052431A1,WO2024052431A1,SPECT显像,SPECT imaging,3B Pharmaceuticals,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2024052431A1,PSMA,anti-PSMA多肽偶联核素;含铟放射性示踪剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,False,True,False,True,False,3B Pharmaceuticals(原研),1
WO2024083224A1,WO2024083224A1,癌症,cancer,辐联科技,肿瘤领域,Oncology,pre-clinical,-1,WO2024083224A1,CCKBR;SSTR2,177Lu标记的放射性药物;anti-CCKBR×SSTR2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,辐联科技(原研),1
WO2024094747A1,WO2024094747A1,心力衰竭,heart failure,Novo Nordisk,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2024094747A1,CNP,CNP类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,类似物,True,True,False,True,True,Novo Nordisk(Top20 MNC)(原研),1
WO2024101386A1,WO2024101386A1,癌症,cancer,Chugai Pharmaceutical,肿瘤领域,Oncology,pre-clinical,-1,WO2024101386A1,KRAS,KRAS抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;难成药靶点,抑制剂,True,True,False,True,True,Chugai Pharmaceutical(Top20 MNC)(原研),1
WO2024114762A1,WO2024114762A1,自身免疫性疾病,autoimmune disease,翰森制药,免疫领域,Immunology,pre-clinical,-1,WO2024114762A1,IL-23R,IL-23R抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th17通路,抑制剂,False,True,False,True,False,翰森制药(原研),1
WO2024163691A1,WO2024163691A1,自身免疫性疾病,autoimmune disease,Merck & Co.,免疫领域,Immunology,pre-clinical,-1,WO2024163691A1,TNFR1,TNFR1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;细胞凋亡;差异化疾病,抑制剂,True,True,False,True,True,Merck & Co.(Top20 MNC)(原研),1
WO2024163691A1,WO2024163691A1,自身炎症性疾病,autoinflammatory disease,Merck & Co.,免疫领域,Immunology,pre-clinical,-1,WO2024163691A1,TNFR1,TNFR1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;细胞凋亡;差异化疾病,抑制剂,True,True,True,True,True,Merck & Co.(Top20 MNC)(原研),1
WO2024182044A1,WO2024182044A1,炎症(未指明),Inflammation (unspecified),Mayo Clinic,免疫领域,Immunology,pre-clinical,-1,WO2024182044A1,Nrf2,Nrf2激活剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Keap1-Nrf2通路,激活剂,False,True,False,True,False,Mayo Clinic(原研),1
WO2024188291A1,WO2024188291A1,卵巢癌,ovarian cancer,上海药物研究所,肿瘤领域,Oncology,pre-clinical,-1,WO2024188291A1,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;受体酪氨酸激酶;中国无申报,多肽偶联核素;68Ga标记的PET药物,False,True,True,True,False,上海药物研究所(原研);Northeastern University(原研),2
WO2024188291A1,WO2024188291A1,卵巢癌,ovarian cancer,Northeastern University,肿瘤领域,Oncology,pre-clinical,-1,WO2024188291A1,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;受体酪氨酸激酶;中国无申报,多肽偶联核素;68Ga标记的PET药物,False,True,True,True,False,上海药物研究所(原研);Northeastern University(原研),2
WO2024188291A1,WO2024188291A1,PET显像,PET imaging,上海药物研究所,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2024188291A1,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;受体酪氨酸激酶;中国无申报,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,上海药物研究所(原研);Northeastern University(原研),2
WO2024188291A1,WO2024188291A1,PET显像,PET imaging,Northeastern University,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2024188291A1,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;受体酪氨酸激酶;中国无申报,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,上海药物研究所(原研);Northeastern University(原研),2
WO2024189611A1,WO2024189611A1,骨质疏松症,osteoporosis,Yissum,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,WO2024189611A1,calcitonin,calcitonin类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报,类似物,False,True,False,True,False,Yissum(原研),1
WO2024195709A1,WO2024195709A1,癌症,cancer,Fujifilm,肿瘤领域,Oncology,pre-clinical,-1,WO2024195709A1,FGFR,FGFR抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶,抑制剂,False,True,False,True,False,Fujifilm(原研),1
WO2024199103A1,WO2024199103A1,骨质疏松症,osteoporosis,奥达生物,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,WO2024199103A1,calcitonin,calcitonin类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,类似物,False,True,False,True,False,奥达生物(原研),1
WO2024199103A1,WO2024199103A1,骨病,bone disease,奥达生物,骨骼肌肉领域,Musculoskeletal,pre-clinical,-1,WO2024199103A1,calcitonin,calcitonin类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,类似物,False,True,False,True,False,奥达生物(原研),1
WO2024227437A1,WO2024227437A1,银屑病,psoriasis,海思科,免疫领域,Immunology,pre-clinical,-1,WO2024227437A1,IL-23R,IL-23R抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th17通路,抑制剂,False,True,False,True,False,海思科(原研),1
WO2024227437A1,WO2024227437A1,炎症性肠病,inflammatory bowel disease,海思科,免疫领域,Immunology,pre-clinical,-1,WO2024227437A1,IL-23R,IL-23R抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th17通路,抑制剂,False,True,False,True,False,海思科(原研),1
WO2024227437A1,WO2024227437A1,克罗恩病,Crohn's disease,海思科,消化领域,Digestive System,pre-clinical,-1,WO2024227437A1,IL-23R,IL-23R抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Th17通路,抑制剂,False,True,False,True,False,海思科(原研),1
WO2024230246A1,WO2024230246A1,肿瘤,tumor,纽瑞特医疗,肿瘤领域,Oncology,pre-clinical,-1,WO2024230246A1,FAP,anti-FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素,False,True,False,True,False,纽瑞特医疗(原研),1
WO2024235273A1,WO2024235273A1,癌症,cancer,远大医药,肿瘤领域,Oncology,pre-clinical,-1,WO2024235273A1,CXCR4;FAP,anti-CXCR4×FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素,False,True,False,True,False,远大医药(原研),1
WO2024238623A1,WO2024238623A1,阿尔茨海默病,Alzheimer's disease,University of Georgia,神经领域,Neurology,pre-clinical,-1,WO2024238623A1,LRRK2,LRRK2变构抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,False,True,False,True,False,University of Georgia(原研),1
WO2024238623A1,WO2024238623A1,帕金森病,Parkinson's disease,University of Georgia,神经领域,Neurology,pre-clinical,-1,WO2024238623A1,LRRK2,LRRK2变构抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,False,True,False,True,False,University of Georgia(原研),1
WO2024238623A1,WO2024238623A1,亨廷顿氏病,Huntington's disease,University of Georgia,神经领域,Neurology,pre-clinical,-1,WO2024238623A1,LRRK2,LRRK2变构抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,False,True,True,True,False,University of Georgia(原研),1
WO2024238623A1,WO2024238623A1,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,University of Georgia,神经领域,Neurology,pre-clinical,-1,WO2024238623A1,LRRK2,LRRK2变构抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,False,True,True,True,False,University of Georgia(原研),1
WO2024238623A1,WO2024238623A1,神经系统疾病,neurological disease,University of Georgia,神经领域,Neurology,pre-clinical,-1,WO2024238623A1,LRRK2,LRRK2变构抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,False,True,False,True,False,University of Georgia(原研),1
WO2024243509A1,WO2024243509A1,神经退行性疾病,neurodegenerative diseases,UGARF,神经领域,Neurology,pre-clinical,-1,WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,UGARF(原研),1
WO2024243509A1,WO2024243509A1,阿尔茨海默病,Alzheimer's disease,UGARF,神经领域,Neurology,pre-clinical,-1,WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,UGARF(原研),1
WO2024243509A1,WO2024243509A1,帕金森病,Parkinson's disease,UGARF,神经领域,Neurology,pre-clinical,-1,WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,UGARF(原研),1
WO2024243509A1,WO2024243509A1,亨廷顿氏病,Huntington's disease,UGARF,神经领域,Neurology,pre-clinical,-1,WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,True,True,False,UGARF(原研),1
WO2024243509A1,WO2024243509A1,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,UGARF,神经领域,Neurology,pre-clinical,-1,WO2024243509A1,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,True,True,False,UGARF(原研),1
WO2024248042A1,WO2024248042A1,重症肌无力,myasthenia gravis,National Hospital Organization,免疫领域,Immunology,pre-clinical,-1,WO2024248042A1,MuSK,MuSK激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class;Wnt信号通路,激动剂,False,True,True,True,False,National Hospital Organization(原研),1
WO2024259132A1,WO2024259132A1,癌症,cancer,Mariana Oncology(Novartis),肿瘤领域,Oncology,pre-clinical,-1,WO2024259132A1,DLL3,anti-DLL3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Notch信号通路;Potential First-in-Class,多肽偶联核素,True,True,False,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
WO2025007839A1,WO2025007839A1,肿瘤,tumor,韦恩生物,肿瘤领域,Oncology,pre-clinical,-1,WO2025007839A1,nectin-4,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,True,False,韦恩生物(原研),1
WO2025011611A1,WO2025011611A1,癌症,cancer,恒瑞医药,肿瘤领域,Oncology,pre-clinical,-1,WO2025011611A1,FAP,anti-FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素,False,True,False,True,False,恒瑞医药(原研),1
WO2025067477A1,WO2025067477A1,鲍曼不动杆菌感染,Acinetobacter baumannii infection,人福医药,感染领域,Infectious Diseases,pre-clinical,-1,WO2025067477A1,A. baumannii,抗生素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,抗生素,False,True,False,True,False,人福医药(原研),1
WO2025068348A1,WO2025068348A1,癌症,cancer,University of Michigan,肿瘤领域,Oncology,pre-clinical,-1,WO2025068348A1,PD1;CXCR4,CXCR4抑制剂;PD1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;中国无申报;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,University of Michigan(原研);Johns Hopkins University(原研);Cedars-Sinai(原研);Spexis(原研),4
WO2025068348A1,WO2025068348A1,癌症,cancer,Johns Hopkins University,肿瘤领域,Oncology,pre-clinical,-1,WO2025068348A1,PD1;CXCR4,CXCR4抑制剂;PD1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;中国无申报;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,University of Michigan(原研);Johns Hopkins University(原研);Cedars-Sinai(原研);Spexis(原研),4
WO2025068348A1,WO2025068348A1,癌症,cancer,Cedars-Sinai,肿瘤领域,Oncology,pre-clinical,-1,WO2025068348A1,PD1;CXCR4,CXCR4抑制剂;PD1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;中国无申报;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,University of Michigan(原研);Johns Hopkins University(原研);Cedars-Sinai(原研);Spexis(原研),4
WO2025068348A1,WO2025068348A1,癌症,cancer,Spexis,肿瘤领域,Oncology,pre-clinical,-1,WO2025068348A1,PD1;CXCR4,CXCR4抑制剂;PD1抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;中国无申报;Potential First-in-Class;肿瘤免疫,抑制剂,False,True,False,True,False,University of Michigan(原研);Johns Hopkins University(原研);Cedars-Sinai(原研);Spexis(原研),4
WO2025073871A1,WO2025073871A1,癌症,cancer,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,WO2025073871A1,TfR1,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
WO2025073871A1,WO2025073871A1,癫痫,epilepsy,Bicycle Therapeutics,神经领域,Neurology,pre-clinical,-1,WO2025073871A1,TfR1,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
WO2025073871A1,WO2025073871A1,眼科疾病,Eye diseases,Bicycle Therapeutics,眼科领域,Ophthalmology,pre-clinical,-1,WO2025073871A1,TfR1,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
WO2025073871A1,WO2025073871A1,神经系统疾病,neurological disease,Bicycle Therapeutics,神经领域,Neurology,pre-clinical,-1,WO2025073871A1,TfR1,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,Bicycle Therapeutics(原研),1
WO2025077823A1,WO2025077823A1,癌症,cancer,海思科,肿瘤领域,Oncology,pre-clinical,-1,WO2025077823A1,αvβ3,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,海思科(原研),1
WO2025079064A1,WO2025079064A1,类风湿性关节炎,rheumatoid arthritis,Pepticom,免疫领域,Immunology,pre-clinical,-1,WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Pepticom(原研),1
WO2025079064A1,WO2025079064A1,多发性硬化症,multiple sclerosis,Pepticom,神经领域,Neurology,pre-clinical,-1,WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,True,True,False,Pepticom(原研),1
WO2025079064A1,WO2025079064A1,银屑病,psoriasis,Pepticom,免疫领域,Immunology,pre-clinical,-1,WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Pepticom(原研),1
WO2025079064A1,WO2025079064A1,斑块状银屑病,plaque psoriasis,Pepticom,免疫领域,Immunology,pre-clinical,-1,WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Pepticom(原研),1
WO2025079064A1,WO2025079064A1,系统性红斑狼疮,systemic lupus erythematosus,Pepticom,免疫领域,Immunology,pre-clinical,-1,WO2025079064A1,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,Pepticom(原研),1
WO2025082283A1,WO2025082283A1,肿瘤,tumor,科伦博泰,肿瘤领域,Oncology,pre-clinical,-1,WO2025082283A1,FAP,FAP抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,科伦博泰(原研),1
WO2025082283A1,WO2025082283A1,诊断试剂,diagnostic reagents,科伦博泰,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2025082283A1,FAP,FAP抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病,抑制剂,False,True,False,True,False,科伦博泰(原研),1
WO2025105948A1,WO2025105948A1,肿瘤,tumor,Instituto Nacional de Investigaciones Nucleares,肿瘤领域,Oncology,pre-clinical,-1,WO2025105948A1,PDL1,含锝放射性示踪剂;anti-PDL1多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;中国无申报;Potential First-in-Class;肿瘤免疫,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,Instituto Nacional de Investigaciones Nucleares(原研),1
WO2025105948A1,WO2025105948A1,SPECT显像,SPECT imaging,Instituto Nacional de Investigaciones Nucleares,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2025105948A1,PDL1,含锝放射性示踪剂;anti-PDL1多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;中国无申报;Potential First-in-Class;肿瘤免疫,含锝放射性示踪剂;多肽偶联核素,False,True,False,True,False,Instituto Nacional de Investigaciones Nucleares(原研),1
WO2025106567A1,WO2025106567A1,心力衰竭,heart failure,Antlia Bioscience,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2025106567A1,BNP,BNP类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,类似物,False,True,False,True,False,Antlia Bioscience(原研),1
WO2025106567A1,WO2025106567A1,代谢疾病,Metabolic diseases,Antlia Bioscience,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2025106567A1,BNP,BNP类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,类似物,False,True,False,True,False,Antlia Bioscience(原研),1
WO2025106567A1,WO2025106567A1,肺病,pulmonary disease,Antlia Bioscience,呼吸领域,Respiratory,pre-clinical,-1,WO2025106567A1,BNP,BNP类似物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,类似物,False,True,False,True,False,Antlia Bioscience(原研),1
WO2025112214A1,WO2025112214A1,癌症,cancer,碳云智能,肿瘤领域,Oncology,pre-clinical,-1,WO2025112214A1,αvβ3,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,碳云智能(原研),1
WO2025113628A1,WO2025113628A1,癌症,cancer,辐联科技,肿瘤领域,Oncology,pre-clinical,-1,WO2025113628A1,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,辐联科技(原研),1
WO2025113628A1,WO2025113628A1,PET显像,PET imaging,辐联科技,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2025113628A1,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,辐联科技(原研),1
WO2025117586A1,WO2025117586A1,癌症,cancer,Mariana Oncology(Novartis),肿瘤领域,Oncology,pre-clinical,-1,WO2025117586A1,DLL3,anti-DLL3多肽偶联核素;177Lu标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Notch信号通路;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
WO2025121943A1,WO2025121943A1,结肠癌,colon cancer,Soonchunhyang University,肿瘤领域,Oncology,pre-clinical,-1,WO2025121943A1,CD51,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;差异化疾病;中国无申报;Potential First-in-Class,多肽偶联药物,False,True,False,True,False,Soonchunhyang University(原研),1
WO2025122525A1,WO2025122525A1,心力衰竭,heart failure,Biohaven Pharmaceuticals(Pfizer),心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2025122525A1,IgG,IgG降解剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;降解类药物,环肽;差异化疾病,降解剂,True,True,False,True,True,Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研),1
WO2025122525A1,WO2025122525A1,扩张型心肌病,dilated cardiomyopathy,Biohaven Pharmaceuticals(Pfizer),心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2025122525A1,IgG,IgG降解剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;降解类药物,环肽;差异化疾病,降解剂,True,True,True,True,True,Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研),1
WO2025137441A,WO2025137441A,肿瘤,tumor,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,WO2025137441A,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽,多肽偶联核素;64Cu标记的放射性示踪剂,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
WO2025137441A1,WO2025137441A1,肿瘤,tumor,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,WO2025137441A1,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
WO2025151982A1,WO2025151982A1,前列腺癌,prostate cancer,北京协和医院,肿瘤领域,Oncology,pre-clinical,-1,WO2025151982A1,PSMA;SSTR2,anti-PSMA×SSTR2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京协和医院(原研);北京师范大学(原研),2
WO2025151982A1,WO2025151982A1,前列腺癌,prostate cancer,北京师范大学,肿瘤领域,Oncology,pre-clinical,-1,WO2025151982A1,PSMA;SSTR2,anti-PSMA×SSTR2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京协和医院(原研);北京师范大学(原研),2
WO2025151982A1,WO2025151982A1,PET显像,PET imaging,北京协和医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2025151982A1,PSMA;SSTR2,anti-PSMA×SSTR2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京协和医院(原研);北京师范大学(原研),2
WO2025151982A1,WO2025151982A1,PET显像,PET imaging,北京师范大学,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2025151982A1,PSMA;SSTR2,anti-PSMA×SSTR2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京协和医院(原研);北京师范大学(原研),2
WO2025153102A1,WO2025153102A1,肿瘤,tumor,深景医药,肿瘤领域,Oncology,pre-clinical,-1,WO2025153102A1,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽,多肽偶联核素;177Lu标记的放射性药物,False,True,False,True,False,深景医药(原研),1
WO2025160448A1,WO2025160448A1,癌症,cancer,Mariana Oncology(Novartis),肿瘤领域,Oncology,pre-clinical,-1,WO2025160448A1,B7-H3,anti-B7-H3多肽偶联核素;225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,True,True,False,True,True,Mariana Oncology(Novartis)(Top20 MNC)(原研),1
WO2025191093A1,WO2025191093A1,癌症,cancer,University of Glasgow,肿瘤领域,Oncology,pre-clinical,-1,WO2025191093A1,CRAF,CRAF抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class;Ras-Raf信号通路,抑制剂,False,True,False,True,False,University of Glasgow(原研),1
WO2025191093A1,WO2025191093A1,自身免疫性疾病,autoimmune disease,University of Glasgow,免疫领域,Immunology,pre-clinical,-1,WO2025191093A1,CRAF,CRAF抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class;Ras-Raf信号通路,抑制剂,False,True,False,True,False,University of Glasgow(原研),1
WO2025193569A1,WO2025193569A1,癌症,cancer,Bristol-Myers Squibb,肿瘤领域,Oncology,pre-clinical,-1,WO2025193569A1,LAG3;MHC-II,LAG3×MHC-II蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,蛋白蛋白相互作用抑制剂,True,True,False,True,True,Bristol-Myers Squibb(Top20 MNC)(原研),1
WO2025199179A2,WO2025199179A2,饮食障碍,eating disorder,Tonix Pharmaceuticals,精神领域,Psychiatry,pre-clinical,-1,WO2025199179A2,oxytocin,oxytocin类似物,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Tonix Pharmaceuticals(原研),1
WO2025199179A2,WO2025199179A2,头痛,Headache,Tonix Pharmaceuticals,麻醉镇痛领域,Anesthesia & Analgesia,pre-clinical,-1,WO2025199179A2,oxytocin,oxytocin类似物,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;差异化疾病,类似物,False,True,False,True,False,Tonix Pharmaceuticals(原研),1
WO2025214417A1,WO2025214417A1,癌症,cancer,元思生肽,肿瘤领域,Oncology,pre-clinical,-1,WO2025214417A1,EGFR,EGFR抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;受体酪氨酸激酶,抑制剂,False,True,False,True,False,元思生肽(原研),1
WO2025218677A1,WO2025218677A1,肿瘤,tumor,范恩柯尔,肿瘤领域,Oncology,pre-clinical,-1,WO2025218677A1,αvβ6;αvβ3;FAP,anti-αvβ6×αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,范恩柯尔(原研),1
WO2025218677A1,WO2025218677A1,PET显像,PET imaging,范恩柯尔,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,WO2025218677A1,αvβ6;αvβ3;FAP,anti-αvβ6×αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,范恩柯尔(原研),1
WO2025218677A1-1,WO2025218677A1-1,肿瘤,tumor,范恩柯尔,肿瘤领域,Oncology,pre-clinical,-1,WO2025218677A1-1,αvβ6;αvβ3;FAP,177Lu标记的放射性药物;anti-αvβ6×αvβ3×FAP多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,放射性药物;多肽;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,范恩柯尔(原研),1
WO2025224598A1,WO2025224598A1,癌症,cancer,Novartis,肿瘤领域,Oncology,pre-clinical,-1,WO2025224598A1,HER2,anti-HER2多肽偶联核素;177Lu标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,True,True,False,True,True,Novartis(Top20 MNC)(原研),1
WO2025228156A1,WO2025228156A1,高尿酸血症,hyperuricemia,炫景生物,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2025228156A1,URAT1,多肽偶联药物;siRNA疗法,pre-clinical,-1,,临床前,,Active,创新药,化药,核酸;多肽;偶联药物,环肽;小核酸;Potential First-in-Class;尿酸代谢通路,siRNA疗法;多肽偶联药物,False,True,False,True,False,炫景生物(原研),1
WO2025232577A1,WO2025232577A1,早产,premature birth,羚诺生物,泌尿生殖领域,Genitourinary,pre-clinical,-1,WO2025232577A1,OXTR,OXTR拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体,拮抗剂,False,True,False,True,False,羚诺生物(原研),1
WO2025236772A1,WO2025236772A1,糖尿病,diabetes,万邦德制药,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2025236772A1,melanocortin receptor,melanocortin receptor激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,False,True,False,True,False,万邦德制药(原研),1
WO2025236772A1,WO2025236772A1,肥胖,obesity,万邦德制药,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2025236772A1,melanocortin receptor,melanocortin receptor激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,False,True,False,True,False,万邦德制药(原研),1
WO2025236772A1,WO2025236772A1,血脂异常,dyslipidemia,万邦德制药,心脑血管领域,Cardiovascular & Cerebrovascular,pre-clinical,-1,WO2025236772A1,melanocortin receptor,melanocortin receptor激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,False,True,False,True,False,万邦德制药(原研),1
WO2025245483A1,WO2025245483A1,肥胖,obesity,Flagship Pioneering,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2025245483A1,MC4R,MC4R激动剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,False,True,False,True,False,Flagship Pioneering(原研),1
WO2025246257A1,WO2025246257A1,癌症,cancer,睿诺医疗科技,肿瘤领域,Oncology,pre-clinical,-1,WO2025246257A1,PPID;PPIA,PPIA抑制剂;PPID抑制剂,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,睿诺医疗科技(原研),1
WO2025249754A1,WO2025249754A1,炎症(未指明),Inflammation (unspecified),EyebioKorea,免疫领域,Immunology,pre-clinical,-1,WO2025249754A1,IL-1β,IL-1β抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子,环肽;中国无申报;Potential First-in-Class,抑制剂,False,True,False,True,False,EyebioKorea(原研),1
WO2025255635A1,WO2025255635A1,糖尿病,diabetes,Monash University,内分泌及代谢领域,Endocrinology & Metabolism,pre-clinical,-1,WO2025255635A1,MC5R,MC5R激动剂,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;G蛋白偶联受体;中国无申报,激动剂,False,True,False,True,False,Monash University(原研),1
WP-101,WP-101,尿路感染,urinary tract infection,WellPep,感染领域,Infectious Diseases,pre-clinical,-1,WP-101,not available,多肽类抗生素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,False,True,False,True,False,WellPep(原研),1
WP-101,WP-101,脓毒症,sepsis,WellPep,感染领域,Infectious Diseases,pre-clinical,-1,WP-101,not available,多肽类抗生素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,False,True,False,True,False,WellPep(原研),1
WP-101,WP-101,肺炎,pneumonia,WellPep,呼吸领域,Respiratory,pre-clinical,-1,WP-101,not available,多肽类抗生素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,False,True,False,True,False,WellPep(原研),1
XTR024,XTR024,小细胞肺癌,small cell lung cancer,先通医药,肿瘤领域,Oncology,pre-clinical,-1,XTR024,SSTR,225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,其他,放射性药物;其他,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,False,True,True,True,False,先通医药(原研),1
XTR024,XTR024,神经内分泌肿瘤,neuroendocrine tumors,先通医药,肿瘤领域,Oncology,pre-clinical,-1,XTR024,SSTR,225Ac标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,其他,放射性药物;其他,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,False,True,True,True,False,先通医药(原研),1
ZP10068,ZP10068,炎症(未指明),Inflammation (unspecified),Alexion Pharmaceuticals(AstraZeneca),免疫领域,Immunology,pre-clinical,-1,ZP10068,C3,C3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报,抑制剂,True,True,False,False,True,Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC);Zealand Pharma(原研),2
ZP10068,ZP10068,炎症(未指明),Inflammation (unspecified),Zealand Pharma,免疫领域,Immunology,pre-clinical,-1,ZP10068,C3,C3抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报,抑制剂,True,True,False,True,False,Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC);Zealand Pharma(原研),2
[111In]In-BCY18469,[111In]In-BCY18469,肿瘤,tumor,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,[111In]In-BCY18469,EphA2,含铟放射性示踪剂;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含铟放射性示踪剂;多肽偶联核素,False,True,False,True,False,Bicycle Therapeutics(原研),1
[111In]In-BCY18469,[111In]In-BCY18469,SPECT显像,SPECT imaging,Bicycle Therapeutics,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[111In]In-BCY18469,EphA2,含铟放射性示踪剂;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含铟放射性示踪剂;多肽偶联核素,False,True,False,True,False,Bicycle Therapeutics(原研),1
[161Tb]Tb-DOTATATE,[161Tb]Tb-DOTATATE,神经母细胞瘤,Neuroblastoma,Uppsala University,肿瘤领域,Oncology,pre-clinical,-1,[161Tb]Tb-DOTATATE,SSTR2,161Tb标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物,环肽;治疗用放射性药物;Potential First-in-Class,161Tb标记的放射性药物,False,True,True,True,False,Uppsala University(原研),1
[161Tb]Tb-DPI-4452,[161Tb]Tb-DPI-4452,胰腺导管癌,pancreatic ductal carcinoma,Katholieke Universiteit Leuven,肿瘤领域,Oncology,pre-clinical,-1,[161Tb]Tb-DPI-4452,CAIX,161Tb标记的放射性药物;anti-CAIX多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;161Tb标记的放射性药物,False,True,False,True,False,Katholieke Universiteit Leuven(原研),1
[177Lu]Lu-BCY18469,[177Lu]Lu-BCY18469,肿瘤,tumor,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,[177Lu]Lu-BCY18469,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,False,True,False,True,False,Bicycle Therapeutics(原研),1
[177Lu]Lu-RYZ-GPC3,[177Lu]Lu-RYZ-GPC3,神经内分泌前列腺癌,neuroendocrine prostate cancer,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,[177Lu]Lu-RYZ-GPC3,GPC3,177Lu标记的放射性药物;anti-GPC3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class;Wnt信号通路,177Lu标记的放射性药物;多肽偶联核素,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
[18F]AlF-NOTA-IMB,[18F]AlF-NOTA-IMB,癌症,cancer,南京医科大学,肿瘤领域,Oncology,pre-clinical,-1,[18F]AlF-NOTA-IMB,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;肿瘤免疫,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,南京医科大学(原研),1
[18F]AlF-NOTA-IMB,[18F]AlF-NOTA-IMB,PET显像,PET imaging,南京医科大学,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[18F]AlF-NOTA-IMB,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;肿瘤免疫,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,南京医科大学(原研),1
[18F]AlF-NOTA-IPB-GPC3P,[18F]AlF-NOTA-IPB-GPC3P,肿瘤,tumor,南方医科大学南方医院,肿瘤领域,Oncology,pre-clinical,-1,[18F]AlF-NOTA-IPB-GPC3P,GPC3,18F标记的PET药物;anti-GPC3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,南方医科大学南方医院(原研),1
[18F]AlF-NOTA-IPB-GPC3P,[18F]AlF-NOTA-IPB-GPC3P,PET显像,PET imaging,南方医科大学南方医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[18F]AlF-NOTA-IPB-GPC3P,GPC3,18F标记的PET药物;anti-GPC3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;18F标记的PET药物,False,True,False,True,False,南方医科大学南方医院(原研),1
[225Ac]Ac-RYZ-GPC3,[225Ac]Ac-RYZ-GPC3,神经内分泌前列腺癌,neuroendocrine prostate cancer,RayzeBio(Bristol-Myers Squibb),肿瘤领域,Oncology,pre-clinical,-1,[225Ac]Ac-RYZ-GPC3,GPC3,225Ac标记的放射性药物;anti-GPC3多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Wnt信号通路,225Ac标记的放射性药物;多肽偶联核素,True,True,False,True,True,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),1
[64Cu]Cu-NECT-224,[64Cu]Cu-NECT-224,尿路上皮癌,urothelial carcinoma,Helmholtz-Zentrum Dresden-Rossendorf,肿瘤领域,Oncology,pre-clinical,-1,[64Cu]Cu-NECT-224;[64Cu]Cu-TKR2-24,nectin-4,64Cu标记的放射性示踪剂;anti-nectin-4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Helmholtz-Zentrum Dresden-Rossendorf(原研),1
[64Cu]Cu-NECT-224,[64Cu]Cu-NECT-224,PET显像,PET imaging,Helmholtz-Zentrum Dresden-Rossendorf,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[64Cu]Cu-NECT-224;[64Cu]Cu-TKR2-24,nectin-4,64Cu标记的放射性示踪剂;anti-nectin-4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,False,True,False,True,False,Helmholtz-Zentrum Dresden-Rossendorf(原研),1
[64Cu]Cu-NODAGA-BL34,[64Cu]Cu-NODAGA-BL34,肿瘤,tumor,University of British Columbia,肿瘤领域,Oncology,pre-clinical,-1,[64Cu]Cu-NODAGA-BL34,CXCR4,64Cu标记的放射性示踪剂;anti-CXCR4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,University of British Columbia(原研),1
[64Cu]Cu-NODAGA-BL34,[64Cu]Cu-NODAGA-BL34,PET显像,PET imaging,University of British Columbia,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[64Cu]Cu-NODAGA-BL34,CXCR4,64Cu标记的放射性示踪剂;anti-CXCR4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,False,True,False,True,False,University of British Columbia(原研),1
[67Cu]Cu-NODAGA-BL34,[67Cu]Cu-NODAGA-BL34,肿瘤,tumor,University of British Columbia,肿瘤领域,Oncology,pre-clinical,-1,[67Cu]Cu-NODAGA-BL34,CXCR4,67Cu标记的放射性药物;anti-CXCR4多肽偶联核素,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,False,True,False,True,False,University of British Columbia(原研),1
[67Cu]Cu-SAR-bisRGD,[67Cu]Cu-SAR-bisRGD,肿瘤,tumor,Memorial Sloan Kettering Cancer Center (MSKCC),肿瘤领域,Oncology,pre-clinical,-1,[67Cu]Cu-SAR-bisRGD,αvβ3,anti-αvβ3多肽偶联核素;67Cu标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;67Cu标记的放射性药物,False,True,False,True,False,Memorial Sloan Kettering Cancer Center (MSKCC)(原研);Clarity Pharmaceuticals(原研),2
[67Cu]Cu-SAR-bisRGD,[67Cu]Cu-SAR-bisRGD,肿瘤,tumor,Clarity Pharmaceuticals,肿瘤领域,Oncology,pre-clinical,-1,[67Cu]Cu-SAR-bisRGD,αvβ3,anti-αvβ3多肽偶联核素;67Cu标记的放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;67Cu标记的放射性药物,False,True,False,True,False,Memorial Sloan Kettering Cancer Center (MSKCC)(原研);Clarity Pharmaceuticals(原研),2
[68Ga]Ga-B6FA-01,[68Ga]Ga-B6FA-01,肿瘤,tumor,武汉大学中南医院,肿瘤领域,Oncology,pre-clinical,-1,[68Ga]Ga-B6FA-01,αvβ6;FAP,68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物,False,True,False,True,False,武汉大学中南医院(原研),1
[68Ga]Ga-B6FA-01,[68Ga]Ga-B6FA-01,PET显像,PET imaging,武汉大学中南医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[68Ga]Ga-B6FA-01,αvβ6;FAP,68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物,False,True,False,True,False,武汉大学中南医院(原研),1
[68Ga]Ga-BCY18469,[68Ga]Ga-BCY18469,肿瘤,tumor,Bicycle Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,[68Ga]Ga-BCY18469,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Bicycle Therapeutics(原研),1
[68Ga]Ga-BCY18469,[68Ga]Ga-BCY18469,PET显像,PET imaging,Bicycle Therapeutics,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[68Ga]Ga-BCY18469,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,Bicycle Therapeutics(原研),1
[68Ga]Ga-DOTA-Ahx-VGB3,[68Ga]Ga-DOTA-Ahx-VGB3,乳腺癌,breast cancer,Tehran University of Medical Sciences,肿瘤领域,Oncology,pre-clinical,-1,[68Ga]Ga-DOTA-Ahx-VGB3,VEGFR1;VEGFR2,anti-VEGFR1×VEGFR2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Tehran University of Medical Sciences(原研),1
[68Ga]Ga-DOTA-Ahx-VGB3,[68Ga]Ga-DOTA-Ahx-VGB3,PET显像,PET imaging,Tehran University of Medical Sciences,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[68Ga]Ga-DOTA-Ahx-VGB3,VEGFR1;VEGFR2,anti-VEGFR1×VEGFR2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,Tehran University of Medical Sciences(原研),1
[68Ga]Ga-DOTA-BP1,[68Ga]Ga-DOTA-BP1,多发性骨髓瘤,multiple myeloma,北京大学第一医院,肿瘤领域,Oncology,pre-clinical,-1,[68Ga]Ga-DOTA-BP1,BCMA,anti-BCMA多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,True,True,False,北京大学第一医院(原研),1
[68Ga]Ga-DOTA-BP1,[68Ga]Ga-DOTA-BP1,PET显像,PET imaging,北京大学第一医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[68Ga]Ga-DOTA-BP1,BCMA,anti-BCMA多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,False,True,False,True,False,北京大学第一医院(原研),1
[68Ga]Ga-ES-02,[68Ga]Ga-ES-02,PET显像,PET imaging,山东大学齐鲁医院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[68Ga]Ga-ES-02,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,山东大学齐鲁医院(原研),1
[68Ga]Ga-ES-02,[68Ga]Ga-ES-02,结直肠癌,colorectal cancer,山东大学齐鲁医院,肿瘤领域,Oncology,pre-clinical,-1,[68Ga]Ga-ES-02,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,山东大学齐鲁医院(原研),1
[68Ga]Ga-RCC78,[68Ga]Ga-RCC78,肾细胞癌,renal cell carcinoma,同济医学院,肿瘤领域,Oncology,pre-clinical,-1,[68Ga]Ga-RCC78;[68Ga] Ga-RCC78,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,同济医学院(原研),1
[68Ga]Ga-RCC78,[68Ga]Ga-RCC78,PET显像,PET imaging,同济医学院,诊断试剂领域,Diagnostic Reagents,pre-clinical,-1,[68Ga]Ga-RCC78;[68Ga] Ga-RCC78,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,False,True,False,True,False,同济医学院(原研),1
[αTH]EMP-100,[αTH]EMP-100,实体瘤,solid tumors,Edinburgh Molecular Imaging,肿瘤领域,Oncology,pre-clinical,-1,[αTH]EMP-100,c-Met,anti-c-Met多肽偶联核素;含钍放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含钍放射性药物;多肽偶联核素,False,True,False,True,False,Edinburgh Molecular Imaging(原研),1
[βTH]EMP-100,[βTH]EMP-100,实体瘤,solid tumors,Edinburgh Molecular Imaging,肿瘤领域,Oncology,pre-clinical,-1,[βTH]EMP-100;[βTH]EMP-100 ,c-Met,anti-c-Met多肽偶联核素;含钍放射性药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含钍放射性药物;多肽偶联核素,False,True,False,True,False,Edinburgh Molecular Imaging(原研),1
alzheimer disease treatment,alzheimer disease treatment (Interprotein),阿尔茨海默病,Alzheimer's disease,Interprotein,神经领域,Neurology,pre-clinical,-1,alzheimer disease treatment;alzheimer disease treatment (Interprotein),Aβ,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Amyloid beta通路,其他,False,True,False,True,False,Interprotein(原研),1
anti-TBC peptide,anti-TBC peptide (tuberculosis plectasin),肺结核,tuberculosis,Hamlet Pharma,感染领域,Infectious Diseases,pre-clinical,-1,anti-TBC peptide;anti-TBC peptide (tuberculosis plectasin),M.tb,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Hamlet Pharma(原研),1
bleeding disorders program,bleeding disorders program (Gubra),出血,Bleeding,Hemab,其他领域,Others,pre-clinical,-1,bleeding disorders program;bleeding disorders program (Gubra),not available,,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽,其他,False,True,False,True,False,Hemab(原研);Gubra(原研),2
bleeding disorders program,bleeding disorders program (Gubra),出血,Bleeding,Gubra,其他领域,Others,pre-clinical,-1,bleeding disorders program;bleeding disorders program (Gubra),not available,,pre-clinical,-1,,临床前,,Active,创新药,其他,多肽,环肽,其他,False,True,False,True,False,Hemab(原研);Gubra(原研),2
certepetide-drug conjugate,certepetide-drug conjugate (Catalent),实体瘤,solid tumors,Catalent(Novo Nordisk),肿瘤领域,Oncology,pre-clinical,-1,certepetide-drug conjugate;certepetide-drug conjugate (Catalent),CD51,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,True,True,False,True,True,Catalent(Novo Nordisk)(Top20 MNC)(原研);Lisata Therapeutics(无权益),2
certepetide-drug conjugate,certepetide-drug conjugate (Catalent),实体瘤,solid tumors,Lisata Therapeutics,肿瘤领域,Oncology,pre-clinical,-1,certepetide-drug conjugate;certepetide-drug conjugate (Catalent),CD51,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,True,True,False,False,False,Catalent(Novo Nordisk)(Top20 MNC)(原研);Lisata Therapeutics(无权益),2
compsorbin,compsorbin,自身免疫性疾病,autoimmune disease,Amyndas Pharmaceuticals,免疫领域,Immunology,pre-clinical,-1,compsorbin;AMY-301,CFH,CFH抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,Amyndas Pharmaceuticals(原研),1
compsorbin,compsorbin,炎症(未指明),Inflammation (unspecified),Amyndas Pharmaceuticals,免疫领域,Immunology,pre-clinical,-1,compsorbin;AMY-301,CFH,CFH抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,Amyndas Pharmaceuticals(原研),1
cyclic peptide PSD-95 Inhibitors,cyclic peptide PSD-95 Inhibitors (Avilex Pharm),未知/待定,unknown/pending,Avilex Pharma,其他领域,Others,pre-clinical,-1,cyclic peptide PSD-95 Inhibitors;cyclic peptide PSD-95 Inhibitors (Avilex Pharm),PSD95,PSD95抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,抑制剂,False,True,False,True,False,Avilex Pharma(原研),1
cyclic peptide project 40,cyclic peptide project 40 (InnoCare Pharma),自身免疫性疾病,autoimmune disease,诺诚健华,免疫领域,Immunology,pre-clinical,-1,cyclic peptide project 40;cyclic peptide project 40 (诺诚健华);cyclic peptide project 40 (InnoCare Pharma),not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,诺诚健华(原研),1
cyclo-CRLLIF,cyclo-CRLLIF,癌症,cancer,University of Southampton,肿瘤领域,Oncology,pre-clinical,-1,cyclo-CRLLIF,HIF-1α;HIF-2α;ARNT,HIF-2α×ARNT蛋白蛋白相互作用抑制剂;HIF-1α×ARNT蛋白蛋白相互作用抑制剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;HIF信号通路;Potential First-in-Class,蛋白蛋白相互作用抑制剂,False,True,False,True,False,University of Southampton(原研),1
integrin α4β7 program,integrin α4β7 program (Quantum Intelligence),炎症性肠病,inflammatory bowel disease,Quantum Intelligence,免疫领域,Immunology,pre-clinical,-1,integrin α4β7 program;integrin α4β7 program (Quantum Intelligence),α4β7,α4β7拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报,拮抗剂,False,True,False,True,False,Quantum Intelligence(原研),1
macrocyclic peptide 5L1,macrocyclic peptide 5L1 (Shandong University),癌症,cancer,山东大学,肿瘤领域,Oncology,pre-clinical,-1,macrocyclic peptide 5L1;macrocyclic peptide 5L1 (山东大学);macrocyclic peptide 5L1 (Shandong University),Mcl-1,Mcl-1抑制剂;Mcl-1分子胶,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;细胞凋亡;非降解型分子胶;Potential First-in-Class,抑制剂;分子胶,False,True,False,True,False,山东大学(原研);智峪生科,2
macrocyclic peptide 5L1,macrocyclic peptide 5L1 (Shandong University),癌症,cancer,智峪生科,肿瘤领域,Oncology,pre-clinical,-1,macrocyclic peptide 5L1;macrocyclic peptide 5L1 (山东大学);macrocyclic peptide 5L1 (Shandong University),Mcl-1,Mcl-1抑制剂;Mcl-1分子胶,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;细胞凋亡;非降解型分子胶;Potential First-in-Class,抑制剂;分子胶,False,True,False,False,False,山东大学(原研);智峪生科,2
macrocyclic peptide antagonist of IL-11,macrocyclic peptide antagonist of IL-11 (Xuzhou Medical University),肾纤维化,renal fibrosis,徐州医科大学,泌尿生殖领域,Genitourinary,pre-clinical,-1,macrocyclic peptide antagonist of IL-11;macrocyclic peptide antagonist of IL-11 (Xuzhou Medical University),IL-11,IL-11拮抗剂,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,拮抗剂,False,True,False,True,False,徐州医科大学(原研),1
macrocyclic peptide therapeutics,macrocyclic peptide therapeutics (Pfizer),未知/待定,unknown/pending,Pfizer,其他领域,Others,pre-clinical,-1,macrocyclic peptide therapeutics;macrocyclic peptide therapeutics (Pfizer),not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,True,True,False,False,True,Pfizer(Top20 MNC);Circle Pharma(原研),2
macrocyclic peptide therapeutics,macrocyclic peptide therapeutics (Pfizer),未知/待定,unknown/pending,Circle Pharma,其他领域,Others,pre-clinical,-1,macrocyclic peptide therapeutics;macrocyclic peptide therapeutics (Pfizer),not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,True,True,False,True,False,Pfizer(Top20 MNC);Circle Pharma(原研),2
neurodegenerative disease program,neurodegenerative disease program (Histide),神经退行性疾病,neurodegenerative diseases,Histide,神经领域,Neurology,pre-clinical,-1,neurodegenerative disease program;neurodegenerative disease program (Histide),not available,,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽,其他,False,True,False,True,False,Histide(原研),1
non-addictive analgesic peptide,non-addictive analgesic peptide (PreveCeutical),疼痛,pain,PreveCeutical Medical,麻醉镇痛领域,Anesthesia & Analgesia,pre-clinical,-1,non-addictive analgesic peptide;non-addictive analgesic peptide (PreveCeutical),not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报,其他,False,True,False,True,False,PreveCeutical Medical(原研),1
oral macrocyclic peptide drugs,oral macrocyclic peptide drugs (Unnatural Products),未知/待定,unknown/pending,Argenx,其他领域,Others,pre-clinical,-1,oral macrocyclic peptide drugs;oral macrocyclic peptide drugs (Unnatural Products),not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报,其他,False,True,False,True,False,Argenx(原研);Unnatural Products(原研),2
oral macrocyclic peptide drugs,oral macrocyclic peptide drugs (Unnatural Products),未知/待定,unknown/pending,Unnatural Products,其他领域,Others,pre-clinical,-1,oral macrocyclic peptide drugs;oral macrocyclic peptide drugs (Unnatural Products),not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽;中国无申报,其他,False,True,False,True,False,Argenx(原研);Unnatural Products(原研),2
oral macrocyclic peptides,oral macrocyclic peptides (Dayra Therapeutics),免疫相关疾病,immune related diseases,Biogen,免疫领域,Immunology,pre-clinical,-1,oral macrocyclic peptides;oral macrocyclic peptides (Dayra Therapeutics),not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Biogen(原研);Dayra Therapeutics(原研),2
oral macrocyclic peptides,oral macrocyclic peptides (Dayra Therapeutics),免疫相关疾病,immune related diseases,Dayra Therapeutics,免疫领域,Immunology,pre-clinical,-1,oral macrocyclic peptides;oral macrocyclic peptides (Dayra Therapeutics),not available,,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽,环肽,其他,False,True,False,True,False,Biogen(原研);Dayra Therapeutics(原研),2
αvβ6 inhibitor,αvβ6 inhibitor (Lassogen),肿瘤,tumor,Lassogen,肿瘤领域,Oncology,pre-clinical,-1,αvβ6 inhibitor;αvβ6 inhibitor (Lassogen),αvβ6,αvβ6抑制剂,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽;Potential First-in-Class,抑制剂,False,True,False,True,False,Lassogen(原研),1
αvβ8 inhibitor,αvβ8 inhibitor (Lassogen),肿瘤,tumor,Lassogen,肿瘤领域,Oncology,pre-clinical,-1,αvβ8 inhibitor;αvβ8 inhibitor (Lassogen),αvβ8,αvβ8抑制剂,pre-clinical,-1,,临床前,,Active,创新药,生物,多肽,环肽,抑制剂,False,True,False,True,False,Lassogen(原研),1
多肽偶联核素创新药物,peptide-conjugated nuclide innovations (Anji Biotechnology),未知/待定,unknown/pending,安吉生物,其他领域,Others,pre-clinical,-1,多肽偶联核素创新药物;多肽偶联核素创新药物 (安吉生物);peptide-conjugated nuclide innovations (Anji Biotechnology),not available,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,True,False,安吉生物(原研);纽瑞特医疗,2
多肽偶联核素创新药物,peptide-conjugated nuclide innovations (Anji Biotechnology),未知/待定,unknown/pending,纽瑞特医疗,其他领域,Others,pre-clinical,-1,多肽偶联核素创新药物;多肽偶联核素创新药物 (安吉生物);peptide-conjugated nuclide innovations (Anji Biotechnology),not available,多肽偶联药物,pre-clinical,-1,,临床前,,Active,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,False,True,False,False,False,安吉生物(原研);纽瑞特医疗,2
